id	sid	tid	token	lemma	pos
dpc-1075	1	1	dermatology	dermatology	NOUN
dpc-1075	1	2	:	:	PUNCT
dpc-1075	1	3	practical	practical	ADJ
dpc-1075	1	4	and	and	CCONJ
dpc-1075	1	5	conceptual	conceptual	ADJ
dpc-1075	1	6	research	research	NOUN
dpc-1075	1	7	|	|	ADV
dpc-1075	1	8	dermatol	dermatol	ADJ
dpc-1075	1	9	pract	pract	NOUN
dpc-1075	1	10	concept	concept	NOUN
dpc-1075	1	11	2020;10(2):e2020039	2020;10(2):e2020039	NUM
dpc-1075	1	12	1	1	NUM
dpc-1075	1	13	dermatology	dermatology	NOUN
dpc-1075	1	14	practical	practical	ADJ
dpc-1075	1	15	&	&	CCONJ
dpc-1075	1	16	conceptual	conceptual	ADJ
dpc-1075	1	17	efficacy	efficacy	NOUN
dpc-1075	1	18	of	of	ADP
dpc-1075	1	19	topical	topical	ADJ
dpc-1075	1	20	finasteride	finasteride	ADJ
dpc-1075	1	21	0.5	0.5	NUM
dpc-1075	1	22	%	%	NOUN
dpc-1075	1	23	vs	vs	ADP
dpc-1075	1	24	17α	17α	NOUN
dpc-1075	1	25	-	-	PUNCT
dpc-1075	1	26	estradiol	estradiol	NOUN
dpc-1075	1	27	0.05	0.05	NUM
dpc-1075	1	28	%	%	NOUN
dpc-1075	1	29	in	in	ADP
dpc-1075	1	30	the	the	DET
dpc-1075	1	31	treatment	treatment	NOUN
dpc-1075	1	32	of	of	ADP
dpc-1075	1	33	postmenopausal	postmenopausal	ADJ
dpc-1075	1	34	female	female	ADJ
dpc-1075	1	35	pattern	pattern	NOUN
dpc-1075	1	36	hair	hair	NOUN
dpc-1075	1	37	loss	loss	NOUN
dpc-1075	1	38	:	:	PUNCT
dpc-1075	1	39	a	a	DET
dpc-1075	1	40	retrospective	retrospective	ADJ
dpc-1075	1	41	,	,	PUNCT
dpc-1075	1	42	single	single	ADJ
dpc-1075	1	43	-	-	PUNCT
dpc-1075	1	44	blind	blind	ADJ
dpc-1075	1	45	study	study	NOUN
dpc-1075	1	46	of	of	ADP
dpc-1075	1	47	119	119	NUM
dpc-1075	1	48	patients	patient	NOUN
dpc-1075	1	49	alfredo	alfredo	X
dpc-1075	1	50	rossi,1	rossi,1	X
dpc-1075	1	51	francesca	francesca	PROPN
dpc-1075	1	52	magri,1	magri,1	PROPN
dpc-1075	1	53	andrea	andrea	PROPN
dpc-1075	1	54	d’arino,1	d’arino,1	PROPN
dpc-1075	1	55	flavia	flavia	PROPN
dpc-1075	1	56	pigliacelli,1	pigliacelli,1	PROPN
dpc-1075	1	57	marta	marta	PROPN
dpc-1075	1	58	muscianese,1	muscianese,1	PROPN
dpc-1075	1	59	pierpaolo	pierpaolo	PROPN
dpc-1075	1	60	leoncini,2	leoncini,2	VERB
dpc-1075	1	61	gemma	gemma	PROPN
dpc-1075	1	62	caro,1	caro,1	PROPN
dpc-1075	1	63	alessandro	alessandro	PROPN
dpc-1075	1	64	federico,1	federico,1	PROPN
dpc-1075	1	65	maria	maria	PROPN
dpc-1075	1	66	caterina	caterina	PROPN
dpc-1075	1	67	fortuna,1	fortuna,1	PROPN
dpc-1075	1	68	marta	marta	PROPN
dpc-1075	1	69	carlesimo1	carlesimo1	PROPN
dpc-1075	1	70	1	1	NUM
dpc-1075	1	71	division	division	NOUN
dpc-1075	1	72	of	of	ADP
dpc-1075	1	73	dermatology	dermatology	NOUN
dpc-1075	1	74	,	,	PUNCT
dpc-1075	1	75	department	department	NOUN
dpc-1075	1	76	of	of	ADP
dpc-1075	1	77	internal	internal	ADJ
dpc-1075	1	78	medicine	medicine	NOUN
dpc-1075	1	79	and	and	CCONJ
dpc-1075	1	80	medical	medical	ADJ
dpc-1075	1	81	specialties	specialty	NOUN
dpc-1075	1	82	,	,	PUNCT
dpc-1075	1	83	sapienza	sapienza	PROPN
dpc-1075	1	84	university	university	PROPN
dpc-1075	1	85	,	,	PUNCT
dpc-1075	1	86	rome	rome	PROPN
dpc-1075	1	87	,	,	PUNCT
dpc-1075	1	88	italy	italy	PROPN
dpc-1075	1	89	2	2	NUM
dpc-1075	1	90	department	department	NOUN
dpc-1075	1	91	of	of	ADP
dpc-1075	1	92	pediatric	pediatric	ADJ
dpc-1075	1	93	hematology	hematology	NOUN
dpc-1075	1	94	and	and	CCONJ
dpc-1075	1	95	oncology	oncology	NOUN
dpc-1075	1	96	,	,	PUNCT
dpc-1075	1	97	istituto	istituto	X
dpc-1075	1	98	di	di	X
dpc-1075	1	99	ricovero	ricovero	PROPN
dpc-1075	1	100	e	e	PROPN
dpc-1075	1	101	cura	cura	PROPN
dpc-1075	1	102	a	a	PROPN
dpc-1075	1	103	carattere	carattere	PROPN
dpc-1075	1	104	scientifico	scientifico	PROPN
dpc-1075	1	105	(	(	PUNCT
dpc-1075	1	106	irccs	irccs	PROPN
dpc-1075	1	107	)	)	PUNCT
dpc-1075	1	108	,	,	PUNCT
dpc-1075	1	109	bambino	bambino	PROPN
dpc-1075	1	110	gesù	gesù	PROPN
dpc-1075	1	111	children	child	NOUN
dpc-1075	1	112	’s	’s	PART
dpc-1075	1	113	hospital	hospital	NOUN
dpc-1075	1	114	,	,	PUNCT
dpc-1075	1	115	rome	rome	PROPN
dpc-1075	1	116	,	,	PUNCT
dpc-1075	1	117	italy	italy	PROPN
dpc-1075	1	118	key	key	ADJ
dpc-1075	1	119	words	word	NOUN
dpc-1075	1	120	:	:	PUNCT
dpc-1075	1	121	female	female	ADJ
dpc-1075	1	122	pattern	pattern	NOUN
dpc-1075	1	123	hair	hair	NOUN
dpc-1075	1	124	loss	loss	NOUN
dpc-1075	1	125	,	,	PUNCT
dpc-1075	1	126	topical	topical	ADJ
dpc-1075	1	127	finasteride	finasteride	ADJ
dpc-1075	1	128	,	,	PUNCT
dpc-1075	1	129	17α	17α	NOUN
dpc-1075	1	130	-	-	PUNCT
dpc-1075	1	131	estriadol	estriadol	NOUN
dpc-1075	1	132	,	,	PUNCT
dpc-1075	1	133	minoxidil	minoxidil	ADJ
dpc-1075	1	134	citation	citation	NOUN
dpc-1075	1	135	:	:	PUNCT
dpc-1075	1	136	rossi	rossi	PROPN
dpc-1075	1	137	a	a	X
dpc-1075	1	138	,	,	PUNCT
dpc-1075	1	139	magri	magri	NOUN
dpc-1075	1	140	f	f	NOUN
dpc-1075	1	141	,	,	PUNCT
dpc-1075	1	142	d’arino	d’arino	PROPN
dpc-1075	1	143	a	a	PRON
dpc-1075	1	144	,	,	PUNCT
dpc-1075	1	145	pigliacelli	pigliacelli	PROPN
dpc-1075	1	146	f	f	NOUN
dpc-1075	1	147	,	,	PUNCT
dpc-1075	1	148	muscianese	muscianese	PROPN
dpc-1075	1	149	m	m	PROPN
dpc-1075	1	150	,	,	PUNCT
dpc-1075	1	151	leoncini	leoncini	VERB
dpc-1075	1	152	p	p	NOUN
dpc-1075	1	153	,	,	PUNCT
dpc-1075	1	154	caro	caro	NOUN
dpc-1075	1	155	g	g	PROPN
dpc-1075	1	156	,	,	PUNCT
dpc-1075	1	157	federico	federico	PROPN
dpc-1075	1	158	a	a	PROPN
dpc-1075	1	159	,	,	PUNCT
dpc-1075	1	160	fortuna	fortuna	PROPN
dpc-1075	1	161	mc	mc	PROPN
dpc-1075	1	162	,	,	PUNCT
dpc-1075	1	163	carlesimo	carlesimo	PROPN
dpc-1075	1	164	m.	m.	PROPN
dpc-1075	1	165	efficacy	efficacy	PROPN
dpc-1075	1	166	of	of	ADP
dpc-1075	1	167	topical	topical	ADJ
dpc-1075	1	168	finasteride	finasteride	ADJ
dpc-1075	1	169	0.5	0.5	NUM
dpc-1075	1	170	%	%	NOUN
dpc-1075	1	171	vs	vs	ADP
dpc-1075	1	172	17α	17α	NOUN
dpc-1075	1	173	-	-	PUNCT
dpc-1075	1	174	estradiol	estradiol	NOUN
dpc-1075	1	175	0.05	0.05	NUM
dpc-1075	1	176	%	%	NOUN
dpc-1075	1	177	in	in	ADP
dpc-1075	1	178	the	the	DET
dpc-1075	1	179	treatment	treatment	NOUN
dpc-1075	1	180	of	of	ADP
dpc-1075	1	181	postmenopausal	postmenopausal	ADJ
dpc-1075	1	182	female	female	ADJ
dpc-1075	1	183	pattern	pattern	NOUN
dpc-1075	1	184	hair	hair	NOUN
dpc-1075	1	185	loss	loss	NOUN
dpc-1075	1	186	:	:	PUNCT
dpc-1075	1	187	a	a	DET
dpc-1075	1	188	retrospective	retrospective	ADJ
dpc-1075	1	189	,	,	PUNCT
dpc-1075	1	190	single	single	ADJ
dpc-1075	1	191	-	-	PUNCT
dpc-1075	1	192	blind	blind	ADJ
dpc-1075	1	193	study	study	NOUN
dpc-1075	1	194	of	of	ADP
dpc-1075	1	195	119	119	NUM
dpc-1075	1	196	patients	patient	NOUN
dpc-1075	1	197	.	.	PUNCT
dpc-1075	2	1	dermatol	dermatol	NOUN
dpc-1075	2	2	pract	pract	PROPN
dpc-1075	2	3	concept	concept	NOUN
dpc-1075	2	4	.	.	PUNCT
dpc-1075	3	1	2020;10(2):e2020039	2020;10(2):e2020039	NUM
dpc-1075	3	2	.	.	PUNCT
dpc-1075	4	1	doi	doi	PROPN
dpc-1075	4	2	:	:	PUNCT
dpc-1075	4	3	https://doi.org/10.5826/dpc.1002a39	https://doi.org/10.5826/dpc.1002a39	PROPN
dpc-1075	4	4	accepted	accept	VERB
dpc-1075	4	5	:	:	PUNCT
dpc-1075	4	6	november	november	PROPN
dpc-1075	4	7	3	3	NUM
dpc-1075	4	8	,	,	PUNCT
dpc-1075	4	9	2019	2019	NUM
dpc-1075	4	10	;	;	PUNCT
dpc-1075	4	11	published	publish	VERB
dpc-1075	4	12	:	:	PUNCT
dpc-1075	4	13	april	april	PROPN
dpc-1075	4	14	20	20	NUM
dpc-1075	4	15	,	,	PUNCT
dpc-1075	4	16	2020	2020	NUM
dpc-1075	4	17	copyright	copyright	NOUN
dpc-1075	4	18	:	:	PUNCT
dpc-1075	4	19	©	©	PROPN
dpc-1075	4	20	2020	2020	NUM
dpc-1075	4	21	rossi	rossi	PROPN
dpc-1075	4	22	et	et	PROPN
dpc-1075	4	23	al	al	PROPN
dpc-1075	4	24	.	.	PUNCT
dpc-1075	5	1	this	this	PRON
dpc-1075	5	2	is	be	AUX
dpc-1075	5	3	an	an	DET
dpc-1075	5	4	open	open	ADJ
dpc-1075	5	5	-	-	PUNCT
dpc-1075	5	6	access	access	NOUN
dpc-1075	5	7	article	article	NOUN
dpc-1075	5	8	distributed	distribute	VERB
dpc-1075	5	9	under	under	ADP
dpc-1075	5	10	the	the	DET
dpc-1075	5	11	terms	term	NOUN
dpc-1075	5	12	of	of	ADP
dpc-1075	5	13	the	the	DET
dpc-1075	5	14	creative	creative	ADJ
dpc-1075	5	15	commons	common	NOUN
dpc-1075	5	16	attribution	attribution	NOUN
dpc-1075	5	17	license	license	NOUN
dpc-1075	5	18	,	,	PUNCT
dpc-1075	5	19	which	which	PRON
dpc-1075	5	20	permits	permit	VERB
dpc-1075	5	21	unrestricted	unrestricted	ADJ
dpc-1075	5	22	use	use	NOUN
dpc-1075	5	23	,	,	PUNCT
dpc-1075	5	24	distribution	distribution	NOUN
dpc-1075	5	25	,	,	PUNCT
dpc-1075	5	26	and	and	CCONJ
dpc-1075	5	27	reproduction	reproduction	NOUN
dpc-1075	5	28	in	in	ADP
dpc-1075	5	29	any	any	DET
dpc-1075	5	30	medium	medium	NOUN
dpc-1075	5	31	,	,	PUNCT
dpc-1075	5	32	provided	provide	VERB
dpc-1075	5	33	the	the	DET
dpc-1075	5	34	original	original	ADJ
dpc-1075	5	35	author	author	NOUN
dpc-1075	5	36	and	and	CCONJ
dpc-1075	5	37	source	source	NOUN
dpc-1075	5	38	are	be	AUX
dpc-1075	5	39	credited	credit	VERB
dpc-1075	5	40	.	.	PUNCT
dpc-1075	6	1	funding	funding	NOUN
dpc-1075	6	2	:	:	PUNCT
dpc-1075	6	3	none	none	NOUN
dpc-1075	6	4	.	.	PUNCT
dpc-1075	7	1	competing	compete	VERB
dpc-1075	7	2	interests	interest	NOUN
dpc-1075	7	3	:	:	PUNCT
dpc-1075	7	4	the	the	DET
dpc-1075	7	5	authors	author	NOUN
dpc-1075	7	6	have	have	VERB
dpc-1075	7	7	no	no	DET
dpc-1075	7	8	conflicts	conflict	NOUN
dpc-1075	7	9	of	of	ADP
dpc-1075	7	10	interest	interest	NOUN
dpc-1075	7	11	to	to	PART
dpc-1075	7	12	disclose	disclose	VERB
dpc-1075	7	13	.	.	PUNCT
dpc-1075	8	1	authorship	authorship	NOUN
dpc-1075	8	2	:	:	PUNCT
dpc-1075	8	3	all	all	DET
dpc-1075	8	4	authors	author	NOUN
dpc-1075	8	5	have	have	AUX
dpc-1075	8	6	contributed	contribute	VERB
dpc-1075	8	7	significantly	significantly	ADV
dpc-1075	8	8	to	to	ADP
dpc-1075	8	9	this	this	DET
dpc-1075	8	10	publication	publication	NOUN
dpc-1075	8	11	.	.	PUNCT
dpc-1075	9	1	corresponding	correspond	VERB
dpc-1075	9	2	author	author	NOUN
dpc-1075	9	3	:	:	PUNCT
dpc-1075	9	4	alfredo	alfredo	PROPN
dpc-1075	9	5	rossi	rossi	PROPN
dpc-1075	9	6	,	,	PUNCT
dpc-1075	9	7	md	md	PROPN
dpc-1075	9	8	,	,	PUNCT
dpc-1075	9	9	division	division	NOUN
dpc-1075	9	10	of	of	ADP
dpc-1075	9	11	dermatology	dermatology	NOUN
dpc-1075	9	12	,	,	PUNCT
dpc-1075	9	13	department	department	NOUN
dpc-1075	9	14	of	of	ADP
dpc-1075	9	15	internal	internal	ADJ
dpc-1075	9	16	medicine	medicine	NOUN
dpc-1075	9	17	and	and	CCONJ
dpc-1075	9	18	medical	medical	ADJ
dpc-1075	9	19	specialties	specialty	NOUN
dpc-1075	9	20	,	,	PUNCT
dpc-1075	9	21	sapienza	sapienza	PROPN
dpc-1075	9	22	university	university	NOUN
dpc-1075	9	23	,	,	PUNCT
dpc-1075	9	24	viale	viale	NOUN
dpc-1075	9	25	del	del	PROPN
dpc-1075	9	26	policlinico	policlinico	NOUN
dpc-1075	9	27	155	155	NUM
dpc-1075	9	28	,	,	PUNCT
dpc-1075	9	29	00100	00100	NUM
dpc-1075	9	30	,	,	PUNCT
dpc-1075	9	31	rome	rome	PROPN
dpc-1075	9	32	,	,	PUNCT
dpc-1075	9	33	italy	italy	PROPN
dpc-1075	9	34	.	.	PUNCT
dpc-1075	9	35	email	email	NOUN
dpc-1075	9	36	:	:	PUNCT
dpc-1075	9	37	alfredo.rossi@uniroma1.it	alfredo.rossi@uniroma1.it	PRON
dpc-1075	9	38	background	background	NOUN
dpc-1075	9	39	and	and	CCONJ
dpc-1075	9	40	objectives	objective	NOUN
dpc-1075	9	41	:	:	PUNCT
dpc-1075	9	42	female	female	ADJ
dpc-1075	9	43	pattern	pattern	NOUN
dpc-1075	9	44	hair	hair	NOUN
dpc-1075	9	45	loss	loss	NOUN
dpc-1075	9	46	(	(	PUNCT
dpc-1075	9	47	fphl	fphl	PROPN
dpc-1075	9	48	)	)	PUNCT
dpc-1075	9	49	is	be	AUX
dpc-1075	9	50	a	a	DET
dpc-1075	9	51	common	common	ADJ
dpc-1075	9	52	form	form	NOUN
dpc-1075	9	53	of	of	ADP
dpc-1075	9	54	scalp	scalp	NOUN
dpc-1075	9	55	hair	hair	NOUN
dpc-1075	9	56	loss	loss	NOUN
dpc-1075	9	57	that	that	PRON
dpc-1075	9	58	occurs	occur	VERB
dpc-1075	9	59	in	in	ADP
dpc-1075	9	60	38	38	NUM
dpc-1075	9	61	%	%	NOUN
dpc-1075	9	62	of	of	ADP
dpc-1075	9	63	females	female	NOUN
dpc-1075	9	64	.	.	PUNCT
dpc-1075	10	1	currently	currently	ADV
dpc-1075	10	2	,	,	PUNCT
dpc-1075	10	3	minoxidil	minoxidil	ADJ
dpc-1075	10	4	solution	solution	NOUN
dpc-1075	10	5	is	be	AUX
dpc-1075	10	6	the	the	DET
dpc-1075	10	7	only	only	ADJ
dpc-1075	10	8	therapy	therapy	NOUN
dpc-1075	10	9	approved	approve	VERB
dpc-1075	10	10	by	by	ADP
dpc-1075	10	11	the	the	DET
dpc-1075	10	12	us	us	PROPN
dpc-1075	10	13	food	food	NOUN
dpc-1075	10	14	and	and	CCONJ
dpc-1075	10	15	drug	drug	NOUN
dpc-1075	10	16	administration	administration	NOUN
dpc-1075	10	17	,	,	PUNCT
dpc-1075	10	18	but	but	CCONJ
dpc-1075	10	19	many	many	ADJ
dpc-1075	10	20	other	other	ADJ
dpc-1075	10	21	treatments	treatment	NOUN
dpc-1075	10	22	are	be	AUX
dpc-1075	10	23	used	use	VERB
dpc-1075	10	24	,	,	PUNCT
dpc-1075	10	25	including	include	VERB
dpc-1075	10	26	cyproterone	cyproterone	NOUN
dpc-1075	10	27	acetate	acetate	NOUN
dpc-1075	10	28	,	,	PUNCT
dpc-1075	10	29	spironolactone	spironolactone	NOUN
dpc-1075	10	30	,	,	PUNCT
dpc-1075	10	31	topical	topical	ADJ
dpc-1075	10	32	17α	17α	NOUN
dpc-1075	10	33	-	-	PUNCT
dpc-1075	10	34	estradiol	estradiol	NOUN
dpc-1075	10	35	,	,	PUNCT
dpc-1075	10	36	and	and	CCONJ
dpc-1075	10	37	prostaglandin	prostaglandin	NOUN
dpc-1075	10	38	analogs	analog	NOUN
dpc-1075	10	39	.	.	PUNCT
dpc-1075	11	1	systemic	systemic	ADJ
dpc-1075	11	2	finasteride	finasteride	NOUN
dpc-1075	11	3	has	have	AUX
dpc-1075	11	4	been	be	AUX
dpc-1075	11	5	considered	consider	VERB
dpc-1075	11	6	a	a	DET
dpc-1075	11	7	treatment	treatment	NOUN
dpc-1075	11	8	option	option	NOUN
dpc-1075	11	9	in	in	ADP
dpc-1075	11	10	women	woman	NOUN
dpc-1075	11	11	even	even	ADV
dpc-1075	11	12	though	though	SCONJ
dpc-1075	11	13	its	its	PRON
dpc-1075	11	14	teratogenic	teratogenic	ADJ
dpc-1075	11	15	effects	effect	NOUN
dpc-1075	11	16	tend	tend	VERB
dpc-1075	11	17	to	to	PART
dpc-1075	11	18	limit	limit	VERB
dpc-1075	11	19	its	its	PRON
dpc-1075	11	20	prescription	prescription	NOUN
dpc-1075	11	21	.	.	PUNCT
dpc-1075	12	1	recently	recently	ADV
dpc-1075	12	2	,	,	PUNCT
dpc-1075	12	3	topical	topical	ADJ
dpc-1075	12	4	finasteride	finasteride	NOUN
dpc-1075	12	5	has	have	AUX
dpc-1075	12	6	been	be	AUX
dpc-1075	12	7	evaluated	evaluate	VERB
dpc-1075	12	8	to	to	PART
dpc-1075	12	9	limit	limit	VERB
dpc-1075	12	10	the	the	DET
dpc-1075	12	11	side	side	ADJ
dpc-1075	12	12	effect	effect	NOUN
dpc-1075	12	13	profile	profile	NOUN
dpc-1075	12	14	of	of	ADP
dpc-1075	12	15	the	the	DET
dpc-1075	12	16	drug	drug	NOUN
dpc-1075	12	17	.	.	PUNCT
dpc-1075	13	1	the	the	DET
dpc-1075	13	2	objective	objective	NOUN
dpc-1075	13	3	of	of	ADP
dpc-1075	13	4	the	the	DET
dpc-1075	13	5	present	present	ADJ
dpc-1075	13	6	study	study	NOUN
dpc-1075	13	7	is	be	AUX
dpc-1075	13	8	to	to	PART
dpc-1075	13	9	compare	compare	VERB
dpc-1075	13	10	retrospectively	retrospectively	ADV
dpc-1075	13	11	the	the	DET
dpc-1075	13	12	efficacy	efficacy	NOUN
dpc-1075	13	13	of	of	ADP
dpc-1075	13	14	topical	topical	ADJ
dpc-1075	13	15	0.05	0.05	NUM
dpc-1075	13	16	%	%	NOUN
dpc-1075	13	17	17α	17α	NOUN
dpc-1075	13	18	-	-	PUNCT
dpc-1075	13	19	estradiol	estradiol	PROPN
dpc-1075	13	20	solution	solution	NOUN
dpc-1075	13	21	and	and	CCONJ
dpc-1075	13	22	a	a	DET
dpc-1075	13	23	0.5	0.5	NUM
dpc-1075	13	24	%	%	NOUN
dpc-1075	13	25	finasteride	finasteride	ADJ
dpc-1075	13	26	lotion	lotion	NOUN
dpc-1075	13	27	in	in	ADP
dpc-1075	13	28	the	the	DET
dpc-1075	13	29	treatment	treatment	NOUN
dpc-1075	13	30	of	of	ADP
dpc-1075	13	31	fphl	fphl	NOUN
dpc-1075	13	32	.	.	PUNCT
dpc-1075	14	1	patients	patient	NOUN
dpc-1075	14	2	and	and	CCONJ
dpc-1075	14	3	methods	method	NOUN
dpc-1075	14	4	:	:	PUNCT
dpc-1075	14	5	we	we	PRON
dpc-1075	14	6	enrolled	enrol	VERB
dpc-1075	14	7	119	119	NUM
dpc-1075	14	8	postmenopausal	postmenopausal	ADJ
dpc-1075	14	9	female	female	ADJ
dpc-1075	14	10	patients	patient	NOUN
dpc-1075	14	11	.	.	PUNCT
dpc-1075	15	1	the	the	DET
dpc-1075	15	2	first	first	ADJ
dpc-1075	15	3	group	group	NOUN
dpc-1075	15	4	comprised	comprise	VERB
dpc-1075	15	5	69	69	NUM
dpc-1075	15	6	women	woman	NOUN
dpc-1075	15	7	treated	treat	VERB
dpc-1075	15	8	with	with	ADP
dpc-1075	15	9	finasteride	finasteride	ADJ
dpc-1075	15	10	0.5	0.5	NUM
dpc-1075	15	11	%	%	NOUN
dpc-1075	15	12	and	and	CCONJ
dpc-1075	15	13	minoxidil	minoxidil	ADJ
dpc-1075	15	14	2	2	NUM
dpc-1075	15	15	%	%	NOUN
dpc-1075	15	16	.	.	PUNCT
dpc-1075	16	1	the	the	DET
dpc-1075	16	2	second	second	ADJ
dpc-1075	16	3	group	group	NOUN
dpc-1075	16	4	included	include	VERB
dpc-1075	16	5	50	50	NUM
dpc-1075	16	6	women	woman	NOUN
dpc-1075	16	7	treated	treat	VERB
dpc-1075	16	8	with	with	ADP
dpc-1075	16	9	17α	17α	NOUN
dpc-1075	16	10	-	-	PUNCT
dpc-1075	16	11	estradiol	estradiol	NOUN
dpc-1075	16	12	0.05	0.05	NUM
dpc-1075	16	13	%	%	NOUN
dpc-1075	16	14	and	and	CCONJ
dpc-1075	16	15	minoxidil	minoxidil	ADJ
dpc-1075	16	16	2	2	NUM
dpc-1075	16	17	%	%	NOUN
dpc-1075	16	18	.	.	PUNCT
dpc-1075	17	1	at	at	ADP
dpc-1075	17	2	baseline	baseline	NOUN
dpc-1075	17	3	and	and	CCONJ
dpc-1075	17	4	at	at	ADP
dpc-1075	17	5	6and	6and	NUM
dpc-1075	17	6	12to	12to	ADJ
dpc-1075	17	7	18	18	NUM
dpc-1075	17	8	-	-	PUNCT
dpc-1075	17	9	month	month	NOUN
dpc-1075	17	10	follow	follow	NOUN
dpc-1075	17	11	-	-	PUNCT
dpc-1075	17	12	up	up	NOUN
dpc-1075	17	13	,	,	PUNCT
dpc-1075	17	14	global	global	ADJ
dpc-1075	17	15	photographs	photograph	NOUN
dpc-1075	17	16	were	be	AUX
dpc-1075	17	17	systematically	systematically	ADV
dpc-1075	17	18	taken	take	VERB
dpc-1075	17	19	.	.	PUNCT
dpc-1075	18	1	three	three	NUM
dpc-1075	18	2	operators	operator	NOUN
dpc-1075	18	3	blind	blind	ADJ
dpc-1075	18	4	to	to	ADP
dpc-1075	18	5	the	the	DET
dpc-1075	18	6	prescribed	prescribed	ADJ
dpc-1075	18	7	treatment	treatment	NOUN
dpc-1075	18	8	evaluated	evaluate	VERB
dpc-1075	18	9	photographs	photograph	NOUN
dpc-1075	18	10	using	use	VERB
dpc-1075	18	11	a	a	DET
dpc-1075	18	12	7	7	NUM
dpc-1075	18	13	-	-	PUNCT
dpc-1075	18	14	point	point	NOUN
dpc-1075	18	15	scale	scale	NOUN
dpc-1075	18	16	.	.	PUNCT
dpc-1075	19	1	one	one	NUM
dpc-1075	19	2	-	-	PUNCT
dpc-1075	19	3	way	way	NOUN
dpc-1075	19	4	analysis	analysis	NOUN
dpc-1075	19	5	of	of	ADP
dpc-1075	19	6	variance	variance	NOUN
dpc-1075	19	7	and	and	CCONJ
dpc-1075	19	8	unpaired	unpaired	ADJ
dpc-1075	19	9	student	student	NOUN
dpc-1075	19	10	t	t	NOUN
dpc-1075	19	11	tests	test	NOUN
dpc-1075	19	12	were	be	AUX
dpc-1075	19	13	performed	perform	VERB
dpc-1075	19	14	to	to	PART
dpc-1075	19	15	analyze	analyze	VERB
dpc-1075	19	16	7	7	NUM
dpc-1075	19	17	-	-	PUNCT
dpc-1075	19	18	point	point	NOUN
dpc-1075	19	19	scale	scale	NOUN
dpc-1075	19	20	scores	score	NOUN
dpc-1075	19	21	.	.	PUNCT
dpc-1075	20	1	results	result	NOUN
dpc-1075	20	2	:	:	PUNCT
dpc-1075	20	3	the	the	DET
dpc-1075	20	4	improvement	improvement	NOUN
dpc-1075	20	5	was	be	AUX
dpc-1075	20	6	statistically	statistically	ADV
dpc-1075	20	7	significant	significant	ADJ
dpc-1075	20	8	from	from	ADP
dpc-1075	20	9	6	6	NUM
dpc-1075	20	10	months	month	NOUN
dpc-1075	20	11	to	to	ADP
dpc-1075	20	12	12	12	NUM
dpc-1075	20	13	-	-	SYM
dpc-1075	20	14	18	18	NUM
dpc-1075	20	15	months	month	NOUN
dpc-1075	20	16	,	,	PUNCT
dpc-1075	20	17	both	both	PRON
dpc-1075	20	18	for	for	ADP
dpc-1075	20	19	finasteride	finasteride	ADJ
dpc-1075	20	20	(	(	PUNCT
dpc-1075	20	21	p	p	X
dpc-1075	20	22	<	<	X
dpc-1075	20	23	0.005	0.005	NUM
dpc-1075	20	24	)	)	PUNCT
dpc-1075	20	25	and	and	CCONJ
dpc-1075	20	26	17α	17α	NOUN
dpc-1075	20	27	-	-	PUNCT
dpc-1075	20	28	estradiol	estradiol	PROPN
dpc-1075	20	29	(	(	PUNCT
dpc-1075	20	30	p	p	X
dpc-1075	20	31	<	<	X
dpc-1075	20	32	0.05	0.05	NUM
dpc-1075	20	33	)	)	PUNCT
dpc-1075	20	34	.	.	PUNCT
dpc-1075	21	1	the	the	DET
dpc-1075	21	2	efficacy	efficacy	NOUN
dpc-1075	21	3	of	of	ADP
dpc-1075	21	4	topical	topical	ADJ
dpc-1075	21	5	finasteride	finasteride	NOUN
dpc-1075	21	6	was	be	AUX
dpc-1075	21	7	significantly	significantly	ADV
dpc-1075	21	8	abstract	abstract	ADJ
dpc-1075	21	9	https://doi.org/10.5826/dpc.1002a39	https://doi.org/10.5826/dpc.1002a39	NOUN
dpc-1075	21	10	mailto:alfredo.rossi@uniroma1.it	mailto:alfredo.rossi@uniroma1.it	ADP
dpc-1075	21	11	2	2	NUM
dpc-1075	21	12	research	research	NOUN
dpc-1075	21	13	|	|	ADV
dpc-1075	21	14	dermatol	dermatol	NOUN
dpc-1075	21	15	pract	pract	NOUN
dpc-1075	21	16	concept	concept	NOUN
dpc-1075	21	17	2020;10(2):e2020039	2020;10(2):e2020039	NUM
dpc-1075	21	18	the	the	DET
dpc-1075	21	19	sample	sample	NOUN
dpc-1075	21	20	included	include	VERB
dpc-1075	21	21	119	119	NUM
dpc-1075	21	22	female	female	ADJ
dpc-1075	21	23	patients	patient	NOUN
dpc-1075	21	24	affected	affect	VERB
dpc-1075	21	25	by	by	ADP
dpc-1075	21	26	fphl	fphl	PROPN
dpc-1075	21	27	(	(	PUNCT
dpc-1075	21	28	i	i	PROPN
dpc-1075	21	29	-	-	PUNCT
dpc-1075	21	30	ii	ii	PROPN
dpc-1075	21	31	-	-	PUNCT
dpc-1075	21	32	iii	iii	NOUN
dpc-1075	21	33	type	type	NOUN
dpc-1075	21	34	of	of	ADP
dpc-1075	21	35	ludwig	ludwig	PROPN
dpc-1075	21	36	classification	classification	NOUN
dpc-1075	21	37	)	)	PUNCT
dpc-1075	21	38	followed	follow	VERB
dpc-1075	21	39	in	in	ADP
dpc-1075	21	40	our	our	PRON
dpc-1075	21	41	department	department	NOUN
dpc-1075	21	42	of	of	ADP
dpc-1075	21	43	dermatology	dermatology	NOUN
dpc-1075	21	44	.	.	PUNCT
dpc-1075	22	1	inclusion	inclusion	NOUN
dpc-1075	22	2	criteria	criterion	NOUN
dpc-1075	22	3	and	and	CCONJ
dpc-1075	22	4	exclusion	exclusion	NOUN
dpc-1075	22	5	criteria	criterion	NOUN
dpc-1075	22	6	for	for	ADP
dpc-1075	22	7	the	the	DET
dpc-1075	22	8	study	study	NOUN
dpc-1075	22	9	are	be	AUX
dpc-1075	22	10	summarized	summarize	VERB
dpc-1075	22	11	in	in	ADP
dpc-1075	22	12	table	table	NOUN
dpc-1075	22	13	1	1	NUM
dpc-1075	22	14	.	.	PUNCT
dpc-1075	23	1	patients	patient	NOUN
dpc-1075	23	2	undergoing	undergo	VERB
dpc-1075	23	3	treatment	treatment	NOUN
dpc-1075	23	4	1	1	NUM
dpc-1075	23	5	comprised	comprise	VERB
dpc-1075	23	6	50	50	NUM
dpc-1075	23	7	female	female	ADJ
dpc-1075	23	8	patients	patient	NOUN
dpc-1075	23	9	,	,	PUNCT
dpc-1075	23	10	topically	topically	ADV
dpc-1075	23	11	treated	treat	VERB
dpc-1075	23	12	with	with	ADP
dpc-1075	23	13	a	a	DET
dpc-1075	23	14	galenic	galenic	ADJ
dpc-1075	23	15	100	100	NUM
dpc-1075	23	16	-	-	PUNCT
dpc-1075	23	17	ml	ml	NOUN
dpc-1075	23	18	solution	solution	NOUN
dpc-1075	23	19	containing	contain	VERB
dpc-1075	23	20	finasteride	finasteride	ADJ
dpc-1075	23	21	0.5	0.5	NUM
dpc-1075	23	22	%	%	NOUN
dpc-1075	23	23	,	,	PUNCT
dpc-1075	23	24	minoxidil	minoxidil	NOUN
dpc-1075	23	25	2	2	NUM
dpc-1075	23	26	%	%	NOUN
dpc-1075	23	27	,	,	PUNCT
dpc-1075	23	28	hydrocortisone	hydrocortisone	PROPN
dpc-1075	23	29	butyrate	butyrate	NOUN
dpc-1075	23	30	0.08	0.08	NUM
dpc-1075	23	31	%	%	NOUN
dpc-1075	23	32	,	,	PUNCT
dpc-1075	23	33	and	and	CCONJ
dpc-1075	24	1	cyclosilicone	cyclosilicone	NOUN
dpc-1075	24	2	pentamer	pentamer	NOUN
dpc-1075	24	3	16	16	NUM
dpc-1075	24	4	%	%	NOUN
dpc-1075	24	5	in	in	ADP
dpc-1075	24	6	alcohol	alcohol	NOUN
dpc-1075	24	7	96	96	NUM
dpc-1075	24	8	°	°	NUM
dpc-1075	24	9	81.4	81.4	NUM
dpc-1075	24	10	%	%	NOUN
dpc-1075	24	11	.	.	PUNCT
dpc-1075	25	1	patients	patient	NOUN
dpc-1075	25	2	were	be	AUX
dpc-1075	25	3	between	between	ADP
dpc-1075	25	4	46	46	NUM
dpc-1075	25	5	and	and	CCONJ
dpc-1075	25	6	74	74	NUM
dpc-1075	25	7	years	year	NOUN
dpc-1075	25	8	old	old	ADJ
dpc-1075	25	9	and	and	CCONJ
dpc-1075	25	10	were	be	AUX
dpc-1075	25	11	observed	observe	VERB
dpc-1075	25	12	between	between	ADP
dpc-1075	25	13	2016	2016	NUM
dpc-1075	25	14	and	and	CCONJ
dpc-1075	25	15	2019	2019	NUM
dpc-1075	25	16	.	.	PUNCT
dpc-1075	26	1	patients	patient	NOUN
dpc-1075	26	2	undergoing	undergo	VERB
dpc-1075	26	3	treatment	treatment	NOUN
dpc-1075	26	4	2	2	NUM
dpc-1075	26	5	comprised	comprise	VERB
dpc-1075	26	6	69	69	NUM
dpc-1075	26	7	female	female	ADJ
dpc-1075	26	8	patients	patient	NOUN
dpc-1075	26	9	who	who	PRON
dpc-1075	26	10	were	be	AUX
dpc-1075	26	11	prescribed	prescribe	VERB
dpc-1075	26	12	a	a	DET
dpc-1075	26	13	100	100	NUM
dpc-1075	26	14	-	-	PUNCT
dpc-1075	26	15	ml	ml	ADV
dpc-1075	26	16	galenic	galenic	ADJ
dpc-1075	26	17	formulation	formulation	NOUN
dpc-1075	26	18	containing	contain	VERB
dpc-1075	26	19	17α	17α	NOUN
dpc-1075	26	20	-	-	PUNCT
dpc-1075	26	21	estradiol	estradiol	PROPN
dpc-1075	26	22	0.05	0.05	NUM
dpc-1075	26	23	%	%	NOUN
dpc-1075	26	24	,	,	PUNCT
dpc-1075	26	25	minoxidil	minoxidil	NOUN
dpc-1075	26	26	2	2	NUM
dpc-1075	26	27	%	%	NOUN
dpc-1075	26	28	,	,	PUNCT
dpc-1075	26	29	hydrocortisone	hydrocortisone	PROPN
dpc-1075	26	30	butyrate	butyrate	NOUN
dpc-1075	26	31	0.08	0.08	NUM
dpc-1075	26	32	%	%	NOUN
dpc-1075	26	33	,	,	PUNCT
dpc-1075	26	34	and	and	CCONJ
dpc-1075	26	35	cyclosilicone	cyclosilicone	NOUN
dpc-1075	26	36	pentamer	pentamer	NOUN
dpc-1075	26	37	16	16	NUM
dpc-1075	26	38	%	%	NOUN
dpc-1075	26	39	in	in	ADP
dpc-1075	26	40	alcohol	alcohol	NOUN
dpc-1075	26	41	96	96	NUM
dpc-1075	26	42	°	°	NOUN
dpc-1075	26	43	81.87	81.87	NUM
dpc-1075	26	44	%	%	NOUN
dpc-1075	26	45	.	.	PUNCT
dpc-1075	27	1	patients	patient	NOUN
dpc-1075	27	2	were	be	AUX
dpc-1075	27	3	observed	observe	VERB
dpc-1075	27	4	within	within	ADP
dpc-1075	27	5	a	a	DET
dpc-1075	27	6	10	10	NUM
dpc-1075	27	7	-	-	PUNCT
dpc-1075	27	8	year	year	NOUN
dpc-1075	27	9	time	time	NOUN
dpc-1075	27	10	range	range	NOUN
dpc-1075	27	11	,	,	PUNCT
dpc-1075	27	12	from	from	ADP
dpc-1075	27	13	2009	2009	NUM
dpc-1075	27	14	to	to	ADP
dpc-1075	27	15	2019	2019	NUM
dpc-1075	27	16	.	.	PUNCT
dpc-1075	28	1	the	the	DET
dpc-1075	28	2	patients	patient	NOUN
dpc-1075	28	3	’	’	PART
dpc-1075	28	4	ages	age	NOUN
dpc-1075	28	5	ranged	range	VERB
dpc-1075	28	6	from	from	ADP
dpc-1075	28	7	45	45	NUM
dpc-1075	28	8	to	to	PART
dpc-1075	28	9	79	79	NUM
dpc-1075	28	10	years	year	NOUN
dpc-1075	28	11	.	.	PUNCT
dpc-1075	29	1	all	all	DET
dpc-1075	29	2	patients	patient	NOUN
dpc-1075	29	3	were	be	AUX
dpc-1075	29	4	instructed	instruct	VERB
dpc-1075	29	5	to	to	PART
dpc-1075	29	6	apply	apply	VERB
dpc-1075	29	7	1	1	NUM
dpc-1075	29	8	ml	ml	NOUN
dpc-1075	29	9	of	of	ADP
dpc-1075	29	10	the	the	DET
dpc-1075	29	11	assigned	assign	VERB
dpc-1075	29	12	topical	topical	ADJ
dpc-1075	29	13	solution	solution	NOUN
dpc-1075	29	14	every	every	DET
dpc-1075	29	15	night	night	NOUN
dpc-1075	29	16	,	,	PUNCT
dpc-1075	29	17	on	on	ADP
dpc-1075	29	18	the	the	DET
dpc-1075	29	19	vertex	vertex	NOUN
dpc-1075	29	20	and	and	CCONJ
dpc-1075	29	21	frontal	frontal	ADJ
dpc-1075	29	22	mineral	mineral	NOUN
dpc-1075	29	23	supplements	supplement	NOUN
dpc-1075	29	24	,	,	PUNCT
dpc-1075	29	25	and	and	CCONJ
dpc-1075	29	26	prostaglandin	prostaglandin	NOUN
dpc-1075	29	27	analogs	analog	NOUN
dpc-1075	29	28	,	,	PUNCT
dpc-1075	29	29	as	as	ADV
dpc-1075	29	30	well	well	ADV
dpc-1075	29	31	as	as	ADP
dpc-1075	29	32	surgical	surgical	ADJ
dpc-1075	29	33	therapy	therapy	NOUN
dpc-1075	29	34	and	and	CCONJ
dpc-1075	29	35	light	light	NOUN
dpc-1075	29	36	therapy	therapy	NOUN
dpc-1075	29	37	[	[	X
dpc-1075	29	38	10	10	NUM
dpc-1075	29	39	]	]	PUNCT
dpc-1075	29	40	.	.	PUNCT
dpc-1075	30	1	the	the	DET
dpc-1075	30	2	weak	weak	ADJ
dpc-1075	30	3	estrogen	estrogen	NOUN
dpc-1075	30	4	17α	17α	NOUN
dpc-1075	30	5	-	-	PUNCT
dpc-1075	30	6	estradiol	estradiol	PROPN
dpc-1075	30	7	has	have	AUX
dpc-1075	30	8	been	be	AUX
dpc-1075	30	9	used	use	VERB
dpc-1075	30	10	for	for	ADP
dpc-1075	30	11	many	many	ADJ
dpc-1075	30	12	years	year	NOUN
dpc-1075	30	13	as	as	ADP
dpc-1075	30	14	a	a	DET
dpc-1075	30	15	0.25	0.25	NUM
dpc-1075	30	16	-	-	PUNCT
dpc-1075	30	17	mg	mg	NOUN
dpc-1075	30	18	/	/	SYM
dpc-1075	30	19	ml	ml	NOUN
dpc-1075	30	20	topical	topical	ADJ
dpc-1075	30	21	alternative	alternative	NOUN
dpc-1075	30	22	for	for	ADP
dpc-1075	30	23	the	the	DET
dpc-1075	30	24	treatment	treatment	NOUN
dpc-1075	30	25	of	of	ADP
dpc-1075	30	26	both	both	DET
dpc-1075	30	27	male	male	ADJ
dpc-1075	30	28	androgenetic	androgenetic	ADJ
dpc-1075	30	29	alopecia	alopecia	NOUN
dpc-1075	30	30	and	and	CCONJ
dpc-1075	30	31	fphl	fphl	NOUN
dpc-1075	30	32	given	give	VERB
dpc-1075	30	33	the	the	DET
dpc-1075	30	34	absence	absence	NOUN
dpc-1075	30	35	of	of	ADP
dpc-1075	30	36	feminizing	feminize	VERB
dpc-1075	30	37	estrogenic	estrogenic	ADJ
dpc-1075	30	38	activity	activity	NOUN
dpc-1075	31	1	[	[	X
dpc-1075	31	2	11	11	NUM
dpc-1075	31	3	]	]	PUNCT
dpc-1075	31	4	and	and	CCONJ
dpc-1075	31	5	its	its	PRON
dpc-1075	31	6	ability	ability	NOUN
dpc-1075	31	7	to	to	PART
dpc-1075	31	8	weakly	weakly	ADV
dpc-1075	31	9	inhibit	inhibit	VERB
dpc-1075	31	10	5α	5α	ADJ
dpc-1075	31	11	-	-	PUNCT
dpc-1075	31	12	reductase	reductase	NOUN
dpc-1075	31	13	.	.	PUNCT
dpc-1075	32	1	the	the	DET
dpc-1075	32	2	objective	objective	NOUN
dpc-1075	32	3	of	of	ADP
dpc-1075	32	4	the	the	DET
dpc-1075	32	5	present	present	ADJ
dpc-1075	32	6	study	study	NOUN
dpc-1075	32	7	was	be	AUX
dpc-1075	32	8	to	to	PART
dpc-1075	32	9	compare	compare	VERB
dpc-1075	32	10	retrospectively	retrospectively	ADV
dpc-1075	32	11	the	the	DET
dpc-1075	32	12	efficacy	efficacy	NOUN
dpc-1075	32	13	of	of	ADP
dpc-1075	32	14	a	a	DET
dpc-1075	32	15	topical	topical	ADJ
dpc-1075	32	16	0.05	0.05	NUM
dpc-1075	32	17	%	%	NOUN
dpc-1075	32	18	17α	17α	NOUN
dpc-1075	32	19	-	-	PUNCT
dpc-1075	32	20	estradiol	estradiol	PROPN
dpc-1075	32	21	solution	solution	NOUN
dpc-1075	32	22	and	and	CCONJ
dpc-1075	32	23	a	a	DET
dpc-1075	32	24	0.5	0.5	NUM
dpc-1075	32	25	%	%	NOUN
dpc-1075	32	26	finasteride	finasteride	ADJ
dpc-1075	32	27	lotion	lotion	NOUN
dpc-1075	32	28	in	in	ADP
dpc-1075	32	29	the	the	DET
dpc-1075	32	30	treatment	treatment	NOUN
dpc-1075	32	31	of	of	ADP
dpc-1075	32	32	fphl	fphl	PROPN
dpc-1075	32	33	.	.	PUNCT
dpc-1075	33	1	methods	method	NOUN
dpc-1075	33	2	we	we	PRON
dpc-1075	33	3	performed	perform	VERB
dpc-1075	33	4	an	an	DET
dpc-1075	33	5	observational	observational	ADJ
dpc-1075	33	6	retrospective	retrospective	ADJ
dpc-1075	33	7	single	single	ADJ
dpc-1075	33	8	-	-	PUNCT
dpc-1075	33	9	blind	blind	ADJ
dpc-1075	33	10	study	study	NOUN
dpc-1075	33	11	of	of	ADP
dpc-1075	33	12	119	119	NUM
dpc-1075	33	13	female	female	ADJ
dpc-1075	33	14	postmenopausal	postmenopausal	NOUN
dpc-1075	33	15	patients	patient	NOUN
dpc-1075	33	16	affected	affect	VERB
dpc-1075	33	17	by	by	ADP
dpc-1075	33	18	fphl	fphl	PROPN
dpc-1075	33	19	.	.	PUNCT
dpc-1075	34	1	the	the	DET
dpc-1075	34	2	purpose	purpose	NOUN
dpc-1075	34	3	of	of	ADP
dpc-1075	34	4	this	this	DET
dpc-1075	34	5	study	study	NOUN
dpc-1075	34	6	was	be	AUX
dpc-1075	34	7	to	to	PART
dpc-1075	34	8	evaluate	evaluate	VERB
dpc-1075	34	9	and	and	CCONJ
dpc-1075	34	10	compare	compare	VERB
dpc-1075	34	11	the	the	DET
dpc-1075	34	12	efficacy	efficacy	NOUN
dpc-1075	34	13	of	of	ADP
dpc-1075	34	14	2	2	NUM
dpc-1075	34	15	different	different	ADJ
dpc-1075	34	16	fphl	fphl	NOUN
dpc-1075	34	17	treatments	treatment	NOUN
dpc-1075	34	18	:	:	PUNCT
dpc-1075	34	19	topical	topical	ADJ
dpc-1075	34	20	finasteride	finasteride	ADJ
dpc-1075	34	21	0.5	0.5	NUM
dpc-1075	34	22	%	%	NOUN
dpc-1075	34	23	and	and	CCONJ
dpc-1075	34	24	minoxidil	minoxidil	ADJ
dpc-1075	34	25	2	2	NUM
dpc-1075	34	26	%	%	NOUN
dpc-1075	34	27	lotion	lotion	NOUN
dpc-1075	34	28	(	(	PUNCT
dpc-1075	34	29	treatment	treatment	NOUN
dpc-1075	34	30	1	1	NUM
dpc-1075	34	31	)	)	PUNCT
dpc-1075	34	32	vs	vs	ADP
dpc-1075	34	33	17α	17α	NOUN
dpc-1075	34	34	-	-	PUNCT
dpc-1075	34	35	estradiol	estradiol	PROPN
dpc-1075	34	36	0.05	0.05	NUM
dpc-1075	34	37	%	%	NOUN
dpc-1075	34	38	and	and	CCONJ
dpc-1075	34	39	minoxidil	minoxidil	ADJ
dpc-1075	34	40	2	2	NUM
dpc-1075	34	41	%	%	NOUN
dpc-1075	34	42	formulation	formulation	NOUN
dpc-1075	34	43	(	(	PUNCT
dpc-1075	34	44	treatment	treatment	NOUN
dpc-1075	34	45	2	2	NUM
dpc-1075	34	46	)	)	PUNCT
dpc-1075	34	47	.	.	PUNCT
dpc-1075	35	1	introduction	introduction	NOUN
dpc-1075	35	2	female	female	ADJ
dpc-1075	35	3	pattern	pattern	NOUN
dpc-1075	35	4	hair	hair	NOUN
dpc-1075	35	5	loss	loss	NOUN
dpc-1075	35	6	(	(	PUNCT
dpc-1075	35	7	fphl	fphl	PROPN
dpc-1075	35	8	)	)	PUNCT
dpc-1075	35	9	,	,	PUNCT
dpc-1075	35	10	once	once	ADV
dpc-1075	35	11	known	know	VERB
dpc-1075	35	12	as	as	ADP
dpc-1075	35	13	female	female	ADJ
dpc-1075	35	14	androgenetic	androgenetic	ADJ
dpc-1075	35	15	alopecia	alopecia	NOUN
dpc-1075	35	16	,	,	PUNCT
dpc-1075	35	17	is	be	AUX
dpc-1075	35	18	a	a	DET
dpc-1075	35	19	common	common	ADJ
dpc-1075	35	20	form	form	NOUN
dpc-1075	35	21	of	of	ADP
dpc-1075	35	22	nonscarring	nonscarre	VERB
dpc-1075	35	23	scalp	scalp	NOUN
dpc-1075	35	24	hair	hair	NOUN
dpc-1075	35	25	loss	loss	NOUN
dpc-1075	35	26	in	in	ADP
dpc-1075	35	27	women	woman	NOUN
dpc-1075	35	28	occurring	occur	VERB
dpc-1075	35	29	in	in	ADP
dpc-1075	35	30	38	38	NUM
dpc-1075	35	31	%	%	NOUN
dpc-1075	35	32	of	of	ADP
dpc-1075	35	33	women	woman	NOUN
dpc-1075	35	34	between	between	ADP
dpc-1075	35	35	the	the	DET
dpc-1075	35	36	ages	age	NOUN
dpc-1075	35	37	of	of	ADP
dpc-1075	35	38	50	50	NUM
dpc-1075	35	39	and	and	CCONJ
dpc-1075	35	40	70	70	NUM
dpc-1075	35	41	years	year	NOUN
dpc-1075	35	42	[	[	X
dpc-1075	35	43	1,2	1,2	NUM
dpc-1075	35	44	]	]	PUNCT
dpc-1075	35	45	.	.	PUNCT
dpc-1075	36	1	it	it	PRON
dpc-1075	36	2	is	be	AUX
dpc-1075	36	3	characterized	characterize	VERB
dpc-1075	36	4	by	by	ADP
dpc-1075	36	5	a	a	DET
dpc-1075	36	6	progressive	progressive	ADJ
dpc-1075	36	7	miniaturization	miniaturization	NOUN
dpc-1075	36	8	of	of	ADP
dpc-1075	36	9	hair	hair	NOUN
dpc-1075	36	10	follicles	follicle	NOUN
dpc-1075	36	11	especially	especially	ADV
dpc-1075	36	12	localized	localize	VERB
dpc-1075	36	13	in	in	ADP
dpc-1075	36	14	the	the	DET
dpc-1075	36	15	frontal	frontal	ADJ
dpc-1075	36	16	,	,	PUNCT
dpc-1075	36	17	central	central	ADJ
dpc-1075	36	18	,	,	PUNCT
dpc-1075	36	19	and	and	CCONJ
dpc-1075	36	20	parietal	parietal	ADJ
dpc-1075	36	21	regions	region	NOUN
dpc-1075	36	22	of	of	ADP
dpc-1075	36	23	the	the	DET
dpc-1075	36	24	scalp	scalp	NOUN
dpc-1075	36	25	[	[	X
dpc-1075	36	26	3	3	NUM
dpc-1075	36	27	]	]	PUNCT
dpc-1075	36	28	.	.	PUNCT
dpc-1075	37	1	the	the	DET
dpc-1075	37	2	pathophysiology	pathophysiology	NOUN
dpc-1075	37	3	of	of	ADP
dpc-1075	37	4	fphl	fphl	PROPN
dpc-1075	37	5	is	be	AUX
dpc-1075	37	6	still	still	ADV
dpc-1075	37	7	not	not	PART
dpc-1075	37	8	completely	completely	ADV
dpc-1075	37	9	clear	clear	ADJ
dpc-1075	37	10	.	.	PUNCT
dpc-1075	38	1	even	even	ADV
dpc-1075	38	2	though	though	SCONJ
dpc-1075	38	3	genetic	genetic	ADJ
dpc-1075	38	4	and	and	CCONJ
dpc-1075	38	5	hormonal	hormonal	ADJ
dpc-1075	38	6	factors	factor	NOUN
dpc-1075	38	7	are	be	AUX
dpc-1075	38	8	considered	consider	VERB
dpc-1075	38	9	involved	involve	VERB
dpc-1075	38	10	as	as	ADP
dpc-1075	38	11	in	in	ADP
dpc-1075	38	12	the	the	DET
dpc-1075	38	13	more	more	ADV
dpc-1075	38	14	common	common	ADJ
dpc-1075	38	15	male	male	ADJ
dpc-1075	38	16	form	form	NOUN
dpc-1075	38	17	[	[	X
dpc-1075	38	18	4	4	NUM
dpc-1075	38	19	]	]	PUNCT
dpc-1075	38	20	,	,	PUNCT
dpc-1075	38	21	its	its	PRON
dpc-1075	38	22	link	link	NOUN
dpc-1075	38	23	to	to	ADP
dpc-1075	38	24	androgen	androgen	NOUN
dpc-1075	38	25	hormones	hormone	NOUN
dpc-1075	38	26	is	be	AUX
dpc-1075	38	27	less	less	ADV
dpc-1075	38	28	clear	clear	ADJ
dpc-1075	38	29	as	as	SCONJ
dpc-1075	38	30	it	it	PRON
dpc-1075	38	31	has	have	AUX
dpc-1075	38	32	been	be	AUX
dpc-1075	38	33	shown	show	VERB
dpc-1075	38	34	to	to	PART
dpc-1075	38	35	appear	appear	VERB
dpc-1075	38	36	in	in	ADP
dpc-1075	38	37	females	female	NOUN
dpc-1075	38	38	affected	affect	VERB
dpc-1075	38	39	by	by	ADP
dpc-1075	38	40	complete	complete	ADJ
dpc-1075	38	41	androgen	androgen	NOUN
dpc-1075	38	42	insensitivity	insensitivity	NOUN
dpc-1075	38	43	syndrome	syndrome	NOUN
dpc-1075	38	44	[	[	X
dpc-1075	38	45	5	5	NUM
dpc-1075	38	46	]	]	PUNCT
dpc-1075	38	47	.	.	PUNCT
dpc-1075	39	1	the	the	DET
dpc-1075	39	2	2	2	NUM
dpc-1075	39	3	drugs	drug	NOUN
dpc-1075	39	4	approved	approve	VERB
dpc-1075	39	5	by	by	ADP
dpc-1075	39	6	the	the	DET
dpc-1075	39	7	us	us	PROPN
dpc-1075	39	8	food	food	NOUN
dpc-1075	39	9	and	and	CCONJ
dpc-1075	39	10	drug	drug	PROPN
dpc-1075	39	11	administration	administration	PROPN
dpc-1075	39	12	(	(	PUNCT
dpc-1075	39	13	fda	fda	PROPN
dpc-1075	39	14	)	)	PUNCT
dpc-1075	39	15	and	and	CCONJ
dpc-1075	39	16	european	european	ADJ
dpc-1075	39	17	medicines	medicine	NOUN
dpc-1075	39	18	agency	agency	NOUN
dpc-1075	39	19	for	for	ADP
dpc-1075	39	20	the	the	DET
dpc-1075	39	21	treatment	treatment	NOUN
dpc-1075	39	22	of	of	ADP
dpc-1075	39	23	male	male	ADJ
dpc-1075	39	24	androgenetic	androgenetic	ADJ
dpc-1075	39	25	alopecia	alopecia	NOUN
dpc-1075	39	26	are	be	AUX
dpc-1075	39	27	topical	topical	ADJ
dpc-1075	39	28	2	2	NUM
dpc-1075	39	29	%	%	NOUN
dpc-1075	39	30	and	and	CCONJ
dpc-1075	39	31	5	5	NUM
dpc-1075	39	32	%	%	NOUN
dpc-1075	39	33	minoxidil	minoxidil	NOUN
dpc-1075	39	34	and	and	CCONJ
dpc-1075	39	35	oral	oral	ADJ
dpc-1075	39	36	finasteride	finasteride	ADJ
dpc-1075	39	37	(	(	PUNCT
dpc-1075	39	38	1	1	NUM
dpc-1075	39	39	mg	mg	NOUN
dpc-1075	39	40	/	/	SYM
dpc-1075	39	41	day	day	NOUN
dpc-1075	39	42	)	)	PUNCT
dpc-1075	40	1	[	[	X
dpc-1075	40	2	6	6	NUM
dpc-1075	40	3	]	]	PUNCT
dpc-1075	40	4	.	.	PUNCT
dpc-1075	41	1	currently	currently	ADV
dpc-1075	41	2	,	,	PUNCT
dpc-1075	41	3	minoxidil	minoxidil	ADJ
dpc-1075	41	4	solution	solution	NOUN
dpc-1075	41	5	is	be	AUX
dpc-1075	41	6	the	the	DET
dpc-1075	41	7	only	only	ADJ
dpc-1075	41	8	fda	fda	PROPN
dpc-1075	41	9	-	-	PUNCT
dpc-1075	41	10	approved	approve	VERB
dpc-1075	41	11	therapeutic	therapeutic	ADJ
dpc-1075	41	12	option	option	NOUN
dpc-1075	41	13	for	for	ADP
dpc-1075	41	14	fphl	fphl	NOUN
dpc-1075	41	15	.	.	PUNCT
dpc-1075	42	1	finasteride	finasteride	PROPN
dpc-1075	42	2	is	be	AUX
dpc-1075	42	3	a	a	DET
dpc-1075	42	4	selective	selective	ADJ
dpc-1075	42	5	type	type	NOUN
dpc-1075	42	6	ii	ii	NOUN
dpc-1075	42	7	5α	5α	ADJ
dpc-1075	42	8	-	-	PUNCT
dpc-1075	42	9	reductase	reductase	NOUN
dpc-1075	42	10	inhibitor	inhibitor	NOUN
dpc-1075	42	11	,	,	PUNCT
dpc-1075	42	12	the	the	DET
dpc-1075	42	13	enzyme	enzyme	NOUN
dpc-1075	42	14	responsible	responsible	ADJ
dpc-1075	42	15	for	for	ADP
dpc-1075	42	16	the	the	DET
dpc-1075	42	17	conversion	conversion	NOUN
dpc-1075	42	18	of	of	ADP
dpc-1075	42	19	testosterone	testosterone	NOUN
dpc-1075	42	20	(	(	PUNCT
dpc-1075	42	21	t	t	NOUN
dpc-1075	42	22	)	)	PUNCT
dpc-1075	42	23	to	to	ADP
dpc-1075	42	24	its	its	PRON
dpc-1075	42	25	more	more	ADV
dpc-1075	42	26	active	active	ADJ
dpc-1075	42	27	form	form	NOUN
dpc-1075	42	28	dihydrotestosterone	dihydrotestosterone	NOUN
dpc-1075	42	29	(	(	PUNCT
dpc-1075	42	30	dht	dht	NOUN
dpc-1075	42	31	)	)	PUNCT
dpc-1075	42	32	.	.	PUNCT
dpc-1075	43	1	it	it	PRON
dpc-1075	43	2	has	have	AUX
dpc-1075	43	3	been	be	AUX
dpc-1075	43	4	considered	consider	VERB
dpc-1075	43	5	a	a	DET
dpc-1075	43	6	treatment	treatment	NOUN
dpc-1075	43	7	option	option	NOUN
dpc-1075	43	8	also	also	ADV
dpc-1075	43	9	in	in	ADP
dpc-1075	43	10	women	woman	NOUN
dpc-1075	43	11	even	even	ADV
dpc-1075	43	12	though	though	SCONJ
dpc-1075	43	13	its	its	PRON
dpc-1075	43	14	teratogenic	teratogenic	ADJ
dpc-1075	43	15	effects	effect	NOUN
dpc-1075	43	16	tend	tend	VERB
dpc-1075	43	17	to	to	PART
dpc-1075	43	18	limit	limit	VERB
dpc-1075	43	19	its	its	PRON
dpc-1075	43	20	prescription	prescription	NOUN
dpc-1075	43	21	.	.	PUNCT
dpc-1075	44	1	reports	report	NOUN
dpc-1075	44	2	of	of	ADP
dpc-1075	44	3	its	its	PRON
dpc-1075	44	4	efficacy	efficacy	NOUN
dpc-1075	44	5	in	in	ADP
dpc-1075	44	6	women	woman	NOUN
dpc-1075	44	7	are	be	AUX
dpc-1075	44	8	contradictory	contradictory	ADJ
dpc-1075	44	9	,	,	PUNCT
dpc-1075	44	10	with	with	ADP
dpc-1075	44	11	less	less	ADV
dpc-1075	44	12	consistent	consistent	ADJ
dpc-1075	44	13	results	result	NOUN
dpc-1075	44	14	than	than	ADP
dpc-1075	44	15	in	in	ADP
dpc-1075	44	16	men	man	NOUN
dpc-1075	44	17	[	[	X
dpc-1075	44	18	7,8	7,8	NUM
dpc-1075	44	19	]	]	PUNCT
dpc-1075	44	20	.	.	PUNCT
dpc-1075	45	1	recently	recently	ADV
dpc-1075	45	2	,	,	PUNCT
dpc-1075	45	3	topical	topical	ADJ
dpc-1075	45	4	formulations	formulation	NOUN
dpc-1075	45	5	have	have	AUX
dpc-1075	45	6	been	be	AUX
dpc-1075	45	7	evaluated	evaluate	VERB
dpc-1075	45	8	to	to	PART
dpc-1075	45	9	limit	limit	VERB
dpc-1075	45	10	the	the	DET
dpc-1075	45	11	side	side	ADJ
dpc-1075	45	12	effect	effect	NOUN
dpc-1075	45	13	profile	profile	NOUN
dpc-1075	45	14	of	of	ADP
dpc-1075	45	15	the	the	DET
dpc-1075	45	16	drug	drug	NOUN
dpc-1075	45	17	[	[	X
dpc-1075	45	18	9	9	NUM
dpc-1075	45	19	]	]	PUNCT
dpc-1075	45	20	.	.	PUNCT
dpc-1075	46	1	other	other	ADJ
dpc-1075	46	2	commonly	commonly	ADV
dpc-1075	46	3	used	use	VERB
dpc-1075	46	4	therapies	therapy	NOUN
dpc-1075	46	5	in	in	ADP
dpc-1075	46	6	fphl	fphl	PROPN
dpc-1075	46	7	are	be	AUX
dpc-1075	46	8	cyproterone	cyproterone	NOUN
dpc-1075	46	9	acetate	acetate	NOUN
dpc-1075	46	10	,	,	PUNCT
dpc-1075	46	11	spironolactone	spironolactone	NOUN
dpc-1075	46	12	,	,	PUNCT
dpc-1075	46	13	flutamide	flutamide	NOUN
dpc-1075	46	14	,	,	PUNCT
dpc-1075	46	15	topical	topical	ADJ
dpc-1075	46	16	17α	17α	NOUN
dpc-1075	46	17	-	-	PUNCT
dpc-1075	46	18	estradiol	estradiol	PROPN
dpc-1075	46	19	,	,	PUNCT
dpc-1075	46	20	greater	great	ADJ
dpc-1075	46	21	than	than	ADP
dpc-1075	46	22	that	that	PRON
dpc-1075	46	23	of	of	ADP
dpc-1075	46	24	17α	17α	NOUN
dpc-1075	46	25	-	-	PUNCT
dpc-1075	46	26	estradiol	estradiol	PROPN
dpc-1075	46	27	solution	solution	NOUN
dpc-1075	46	28	,	,	PUNCT
dpc-1075	46	29	both	both	CCONJ
dpc-1075	46	30	at	at	ADP
dpc-1075	46	31	the	the	DET
dpc-1075	46	32	6	6	NUM
dpc-1075	46	33	-	-	PUNCT
dpc-1075	46	34	month	month	NOUN
dpc-1075	46	35	(	(	PUNCT
dpc-1075	46	36	p	p	X
dpc-1075	46	37	<	<	X
dpc-1075	46	38	0.05	0.05	NUM
dpc-1075	46	39	)	)	PUNCT
dpc-1075	46	40	and	and	CCONJ
dpc-1075	46	41	at	at	ADP
dpc-1075	46	42	the	the	DET
dpc-1075	46	43	12to	12to	ADJ
dpc-1075	46	44	18	18	NUM
dpc-1075	46	45	-	-	PUNCT
dpc-1075	46	46	month	month	NOUN
dpc-1075	46	47	follow	follow	NOUN
dpc-1075	46	48	-	-	PUNCT
dpc-1075	46	49	up	up	NOUN
dpc-1075	46	50	(	(	PUNCT
dpc-1075	46	51	p	p	X
dpc-1075	46	52	<	<	X
dpc-1075	46	53	0.005	0.005	NUM
dpc-1075	46	54	)	)	PUNCT
dpc-1075	46	55	.	.	PUNCT
dpc-1075	47	1	in	in	ADP
dpc-1075	47	2	general	general	ADJ
dpc-1075	47	3	,	,	PUNCT
dpc-1075	47	4	the	the	DET
dpc-1075	47	5	highest	high	ADJ
dpc-1075	47	6	improvement	improvement	NOUN
dpc-1075	47	7	was	be	AUX
dpc-1075	47	8	observed	observe	VERB
dpc-1075	47	9	after	after	ADP
dpc-1075	47	10	12	12	NUM
dpc-1075	47	11	-	-	SYM
dpc-1075	47	12	18	18	NUM
dpc-1075	47	13	months	month	NOUN
dpc-1075	47	14	of	of	ADP
dpc-1075	47	15	treatment	treatment	NOUN
dpc-1075	47	16	with	with	ADP
dpc-1075	47	17	topical	topical	ADJ
dpc-1075	47	18	finasteride	finasteride	ADJ
dpc-1075	47	19	therapy	therapy	NOUN
dpc-1075	47	20	.	.	PUNCT
dpc-1075	48	1	conclusions	conclusion	NOUN
dpc-1075	48	2	:	:	PUNCT
dpc-1075	48	3	topical	topical	ADJ
dpc-1075	48	4	finasteride	finasteride	ADJ
dpc-1075	48	5	0.5	0.5	NUM
dpc-1075	48	6	%	%	NOUN
dpc-1075	48	7	in	in	ADP
dpc-1075	48	8	combination	combination	NOUN
dpc-1075	48	9	with	with	ADP
dpc-1075	48	10	minoxidil	minoxidil	NOUN
dpc-1075	48	11	2	2	NUM
dpc-1075	48	12	%	%	NOUN
dpc-1075	48	13	could	could	AUX
dpc-1075	48	14	represent	represent	VERB
dpc-1075	48	15	a	a	DET
dpc-1075	48	16	valid	valid	ADJ
dpc-1075	48	17	therapeutic	therapeutic	ADJ
dpc-1075	48	18	option	option	NOUN
dpc-1075	48	19	for	for	ADP
dpc-1075	48	20	the	the	DET
dpc-1075	48	21	treatment	treatment	NOUN
dpc-1075	48	22	of	of	ADP
dpc-1075	48	23	postmenopausal	postmenopausal	ADJ
dpc-1075	48	24	fphl	fphl	PROPN
dpc-1075	48	25	,	,	PUNCT
dpc-1075	48	26	showing	show	VERB
dpc-1075	48	27	higher	high	ADJ
dpc-1075	48	28	efficacy	efficacy	NOUN
dpc-1075	48	29	than	than	ADP
dpc-1075	48	30	topical	topical	ADJ
dpc-1075	48	31	17α	17α	NOUN
dpc-1075	48	32	-	-	NOUN
dpc-1075	48	33	estradiol	estradiol	PROPN
dpc-1075	48	34	with	with	ADP
dpc-1075	48	35	minoxidil	minoxidil	ADJ
dpc-1075	48	36	2	2	NUM
dpc-1075	48	37	%	%	NOUN
dpc-1075	48	38	both	both	PRON
dpc-1075	48	39	at	at	ADP
dpc-1075	48	40	6	6	NUM
dpc-1075	48	41	-	-	PUNCT
dpc-1075	48	42	month	month	NOUN
dpc-1075	48	43	and	and	CCONJ
dpc-1075	48	44	12to	12to	ADJ
dpc-1075	48	45	18	18	NUM
dpc-1075	48	46	-	-	PUNCT
dpc-1075	48	47	month	month	NOUN
dpc-1075	48	48	follow	follow	NOUN
dpc-1075	48	49	-	-	PUNCT
dpc-1075	48	50	up	up	NOUN
dpc-1075	48	51	.	.	PUNCT
dpc-1075	49	1	abstract	abstract	ADJ
dpc-1075	49	2	table	table	NOUN
dpc-1075	49	3	1	1	NUM
dpc-1075	49	4	.	.	X
dpc-1075	49	5	inclusion	inclusion	NOUN
dpc-1075	49	6	and	and	CCONJ
dpc-1075	49	7	exclusion	exclusion	NOUN
dpc-1075	49	8	criteria	criterion	NOUN
dpc-1075	49	9	for	for	ADP
dpc-1075	49	10	the	the	DET
dpc-1075	49	11	study	study	NOUN
dpc-1075	49	12	inclusion	inclusion	NOUN
dpc-1075	49	13	criteria	criterion	NOUN
dpc-1075	49	14	:	:	PUNCT
dpc-1075	49	15	•	•	NUM
dpc-1075	49	16	postmenopausal	postmenopausal	ADJ
dpc-1075	49	17	patients	patient	NOUN
dpc-1075	49	18	•	•	ADP
dpc-1075	50	1	female	female	ADJ
dpc-1075	50	2	pattern	pattern	NOUN
dpc-1075	50	3	hair	hair	NOUN
dpc-1075	50	4	loss	loss	NOUN
dpc-1075	50	5	•	•	NOUN
dpc-1075	50	6	type	type	NOUN
dpc-1075	50	7	i	i	PROPN
dpc-1075	50	8	-	-	PUNCT
dpc-1075	50	9	ii	ii	PROPN
dpc-1075	50	10	-	-	PUNCT
dpc-1075	50	11	iii	iii	NOUN
dpc-1075	50	12	of	of	ADP
dpc-1075	50	13	ludwig	ludwig	PROPN
dpc-1075	50	14	classification	classification	NOUN
dpc-1075	50	15	•	•	NOUN
dpc-1075	50	16	no	no	DET
dpc-1075	50	17	other	other	ADJ
dpc-1075	50	18	concomitant	concomitant	ADJ
dpc-1075	50	19	treatments	treatment	NOUN
dpc-1075	50	20	,	,	PUNCT
dpc-1075	50	21	including	include	VERB
dpc-1075	50	22	hormonal	hormonal	ADJ
dpc-1075	50	23	replacement	replacement	NOUN
dpc-1075	50	24	therapy	therapy	NOUN
dpc-1075	50	25	exclusion	exclusion	NOUN
dpc-1075	50	26	criteria	criterion	NOUN
dpc-1075	50	27	:	:	PUNCT
dpc-1075	50	28	•	•	NUM
dpc-1075	50	29	concomitant	concomitant	ADJ
dpc-1075	50	30	treatments	treatment	NOUN
dpc-1075	50	31	of	of	ADP
dpc-1075	50	32	the	the	DET
dpc-1075	50	33	scalp	scalp	NOUN
dpc-1075	50	34	•	•	ADP
dpc-1075	50	35	associated	associate	VERB
dpc-1075	50	36	systemic	systemic	ADJ
dpc-1075	50	37	diseases	disease	NOUN
dpc-1075	50	38	and/or	and/or	CCONJ
dpc-1075	50	39	systemic	systemic	ADJ
dpc-1075	50	40	therapies	therapy	NOUN
dpc-1075	50	41	which	which	PRON
dpc-1075	50	42	could	could	AUX
dpc-1075	50	43	influence	influence	VERB
dpc-1075	50	44	hair	hair	NOUN
dpc-1075	50	45	growth	growth	NOUN
dpc-1075	50	46	(	(	PUNCT
dpc-1075	50	47	such	such	ADJ
dpc-1075	50	48	as	as	ADP
dpc-1075	50	49	oncological	oncological	ADJ
dpc-1075	50	50	patients	patient	NOUN
dpc-1075	50	51	undergoing	undergo	VERB
dpc-1075	50	52	chemotherapy	chemotherapy	NOUN
dpc-1075	50	53	)	)	PUNCT
dpc-1075	50	54	•	•	ADP
dpc-1075	50	55	concomitant	concomitant	ADJ
dpc-1075	50	56	scalp	scalp	NOUN
dpc-1075	50	57	diseases	disease	NOUN
dpc-1075	50	58	(	(	PUNCT
dpc-1075	50	59	such	such	ADJ
dpc-1075	50	60	as	as	ADP
dpc-1075	50	61	lichen	lichen	NOUN
dpc-1075	50	62	planopilaris	planopilaris	NOUN
dpc-1075	50	63	,	,	PUNCT
dpc-1075	50	64	alopecia	alopecia	NOUN
dpc-1075	50	65	areata	areata	NOUN
dpc-1075	50	66	,	,	PUNCT
dpc-1075	50	67	frontal	frontal	ADJ
dpc-1075	50	68	fibrosing	fibrose	VERB
dpc-1075	50	69	alopecia	alopecia	NOUN
dpc-1075	50	70	,	,	PUNCT
dpc-1075	50	71	telogen	telogen	NOUN
dpc-1075	50	72	effluvium	effluvium	NOUN
dpc-1075	50	73	)	)	PUNCT
dpc-1075	50	74	research	research	NOUN
dpc-1075	50	75	|	|	ADV
dpc-1075	50	76	dermatol	dermatol	NOUN
dpc-1075	50	77	pract	pract	NOUN
dpc-1075	50	78	concept	concept	NOUN
dpc-1075	50	79	2020;10(2):e2020039	2020;10(2):e2020039	NUM
dpc-1075	50	80	3	3	NUM
dpc-1075	50	81	excluded	exclude	VERB
dpc-1075	50	82	these	these	DET
dpc-1075	50	83	patients	patient	NOUN
dpc-1075	50	84	from	from	ADP
dpc-1075	50	85	further	further	ADJ
dpc-1075	50	86	analyses	analysis	NOUN
dpc-1075	50	87	.	.	PUNCT
dpc-1075	51	1	the	the	DET
dpc-1075	51	2	following	follow	VERB
dpc-1075	51	3	results	result	NOUN
dpc-1075	51	4	apply	apply	VERB
dpc-1075	51	5	only	only	ADV
dpc-1075	51	6	to	to	ADP
dpc-1075	51	7	patients	patient	NOUN
dpc-1075	51	8	who	who	PRON
dpc-1075	51	9	showed	show	VERB
dpc-1075	51	10	improvement	improvement	NOUN
dpc-1075	51	11	following	follow	VERB
dpc-1075	51	12	treatment	treatment	NOUN
dpc-1075	51	13	(	(	PUNCT
dpc-1075	51	14	n	n	NOUN
dpc-1075	51	15	=	=	SYM
dpc-1075	51	16	112	112	NUM
dpc-1075	51	17	)	)	PUNCT
dpc-1075	51	18	.	.	PUNCT
dpc-1075	52	1	we	we	PRON
dpc-1075	52	2	tested	test	VERB
dpc-1075	52	3	whether	whether	SCONJ
dpc-1075	52	4	the	the	DET
dpc-1075	52	5	2	2	NUM
dpc-1075	52	6	treatments	treatment	NOUN
dpc-1075	52	7	led	lead	VERB
dpc-1075	52	8	to	to	ADP
dpc-1075	52	9	improvements	improvement	NOUN
dpc-1075	52	10	of	of	ADP
dpc-1075	52	11	different	different	ADJ
dpc-1075	52	12	entity	entity	NOUN
dpc-1075	52	13	by	by	ADP
dpc-1075	52	14	comparing	compare	VERB
dpc-1075	52	15	the	the	DET
dpc-1075	52	16	mean	mean	ADJ
dpc-1075	52	17	ratings	rating	NOUN
dpc-1075	52	18	on	on	ADP
dpc-1075	52	19	the	the	DET
dpc-1075	52	20	7	7	NUM
dpc-1075	52	21	-	-	PUNCT
dpc-1075	52	22	point	point	NOUN
dpc-1075	52	23	scale	scale	NOUN
dpc-1075	52	24	.	.	PUNCT
dpc-1075	53	1	the	the	DET
dpc-1075	53	2	improvement	improvement	NOUN
dpc-1075	53	3	was	be	AUX
dpc-1075	53	4	statistically	statistically	ADV
dpc-1075	53	5	significant	significant	ADJ
dpc-1075	53	6	from	from	ADP
dpc-1075	53	7	6	6	NUM
dpc-1075	53	8	months	month	NOUN
dpc-1075	53	9	to	to	ADP
dpc-1075	53	10	12	12	NUM
dpc-1075	53	11	-	-	SYM
dpc-1075	53	12	18	18	NUM
dpc-1075	53	13	months	month	NOUN
dpc-1075	53	14	,	,	PUNCT
dpc-1075	53	15	both	both	PRON
dpc-1075	53	16	for	for	ADP
dpc-1075	53	17	finasteride	finasteride	ADJ
dpc-1075	53	18	(	(	PUNCT
dpc-1075	53	19	p	p	X
dpc-1075	53	20	<	<	X
dpc-1075	53	21	0.005	0.005	NUM
dpc-1075	53	22	)	)	PUNCT
dpc-1075	53	23	and	and	CCONJ
dpc-1075	53	24	17α	17α	NOUN
dpc-1075	53	25	-	-	PUNCT
dpc-1075	53	26	estradiol	estradiol	PROPN
dpc-1075	53	27	(	(	PUNCT
dpc-1075	53	28	p	p	X
dpc-1075	53	29	<	<	X
dpc-1075	53	30	0.05	0.05	NUM
dpc-1075	53	31	)	)	PUNCT
dpc-1075	53	32	galenic	galenic	ADJ
dpc-1075	53	33	−1	−1	NOUN
dpc-1075	53	34	on	on	ADP
dpc-1075	53	35	the	the	DET
dpc-1075	53	36	7	7	NUM
dpc-1075	53	37	-	-	PUNCT
dpc-1075	53	38	point	point	NOUN
dpc-1075	53	39	scale	scale	NOUN
dpc-1075	53	40	)	)	PUNCT
dpc-1075	53	41	.	.	PUNCT
dpc-1075	54	1	in	in	SCONJ
dpc-1075	54	2	the	the	DET
dpc-1075	54	3	group	group	NOUN
dpc-1075	54	4	to	to	PART
dpc-1075	54	5	which	which	PRON
dpc-1075	54	6	treatment	treatment	NOUN
dpc-1075	54	7	2	2	NUM
dpc-1075	54	8	(	(	PUNCT
dpc-1075	54	9	17α	17α	NOUN
dpc-1075	54	10	-	-	PUNCT
dpc-1075	54	11	estradiol	estradiol	NOUN
dpc-1075	54	12	)	)	PUNCT
dpc-1075	54	13	was	be	AUX
dpc-1075	54	14	prescribed	prescribe	VERB
dpc-1075	54	15	,	,	PUNCT
dpc-1075	54	16	64	64	NUM
dpc-1075	54	17	out	out	ADP
dpc-1075	54	18	of	of	ADP
dpc-1075	54	19	69	69	NUM
dpc-1075	54	20	patients	patient	NOUN
dpc-1075	54	21	(	(	PUNCT
dpc-1075	54	22	92.7	92.7	NUM
dpc-1075	54	23	%	%	NOUN
dpc-1075	54	24	)	)	PUNCT
dpc-1075	54	25	showed	show	VERB
dpc-1075	54	26	improvement	improvement	NOUN
dpc-1075	54	27	.	.	PUNCT
dpc-1075	55	1	four	four	NUM
dpc-1075	55	2	out	out	ADP
dpc-1075	55	3	of	of	ADP
dpc-1075	55	4	69	69	NUM
dpc-1075	55	5	patients	patient	NOUN
dpc-1075	55	6	worsened	worsen	VERB
dpc-1075	55	7	after	after	ADP
dpc-1075	55	8	12	12	NUM
dpc-1075	55	9	-	-	SYM
dpc-1075	55	10	18	18	NUM
dpc-1075	55	11	months	month	NOUN
dpc-1075	55	12	(	(	PUNCT
dpc-1075	55	13	average	average	ADJ
dpc-1075	55	14	rating	rating	NOUN
dpc-1075	55	15	of	of	ADP
dpc-1075	55	16	−1	−1	NOUN
dpc-1075	55	17	in	in	ADP
dpc-1075	55	18	all	all	DET
dpc-1075	55	19	cases	case	NOUN
dpc-1075	55	20	)	)	PUNCT
dpc-1075	55	21	,	,	PUNCT
dpc-1075	55	22	while	while	SCONJ
dpc-1075	55	23	1	1	NUM
dpc-1075	55	24	patient	patient	NOUN
dpc-1075	55	25	had	have	VERB
dpc-1075	55	26	worse	bad	ADJ
dpc-1075	55	27	scores	score	NOUN
dpc-1075	55	28	already	already	ADV
dpc-1075	55	29	at	at	ADP
dpc-1075	55	30	6	6	NUM
dpc-1075	55	31	months	month	NOUN
dpc-1075	55	32	(	(	PUNCT
dpc-1075	55	33	rated	rate	VERB
dpc-1075	55	34	−2	−2	NOUN
dpc-1075	55	35	after	after	ADP
dpc-1075	55	36	6	6	NUM
dpc-1075	55	37	months	month	NOUN
dpc-1075	55	38	and	and	CCONJ
dpc-1075	55	39	−1	−1	NOUN
dpc-1075	55	40	after	after	ADP
dpc-1075	55	41	12	12	NUM
dpc-1075	55	42	-	-	SYM
dpc-1075	55	43	18	18	NUM
dpc-1075	55	44	months	month	NOUN
dpc-1075	55	45	)	)	PUNCT
dpc-1075	55	46	.	.	PUNCT
dpc-1075	56	1	given	give	VERB
dpc-1075	56	2	the	the	DET
dpc-1075	56	3	small	small	ADJ
dpc-1075	56	4	number	number	NOUN
dpc-1075	56	5	of	of	ADP
dpc-1075	56	6	patients	patient	NOUN
dpc-1075	56	7	who	who	PRON
dpc-1075	56	8	showed	show	VERB
dpc-1075	56	9	a	a	DET
dpc-1075	56	10	worsening	worsening	NOUN
dpc-1075	56	11	of	of	ADP
dpc-1075	56	12	their	their	PRON
dpc-1075	56	13	condition	condition	NOUN
dpc-1075	56	14	following	follow	VERB
dpc-1075	56	15	either	either	DET
dpc-1075	56	16	treatment	treatment	NOUN
dpc-1075	56	17	,	,	PUNCT
dpc-1075	56	18	we	we	PRON
dpc-1075	56	19	region	region	NOUN
dpc-1075	56	20	.	.	PUNCT
dpc-1075	57	1	follow	follow	VERB
dpc-1075	57	2	-	-	PUNCT
dpc-1075	57	3	up	up	ADP
dpc-1075	57	4	visits	visit	NOUN
dpc-1075	57	5	occurred	occur	VERB
dpc-1075	57	6	after	after	ADP
dpc-1075	57	7	6	6	NUM
dpc-1075	57	8	and	and	CCONJ
dpc-1075	57	9	12	12	NUM
dpc-1075	57	10	-	-	SYM
dpc-1075	57	11	18	18	NUM
dpc-1075	57	12	months	month	NOUN
dpc-1075	57	13	.	.	PUNCT
dpc-1075	58	1	at	at	ADP
dpc-1075	58	2	the	the	DET
dpc-1075	58	3	time	time	NOUN
dpc-1075	58	4	of	of	ADP
dpc-1075	58	5	the	the	DET
dpc-1075	58	6	diagnosis	diagnosis	NOUN
dpc-1075	58	7	,	,	PUNCT
dpc-1075	58	8	and	and	CCONJ
dpc-1075	58	9	at	at	ADP
dpc-1075	58	10	each	each	PRON
dpc-1075	58	11	of	of	ADP
dpc-1075	58	12	the	the	DET
dpc-1075	58	13	follow	follow	NOUN
dpc-1075	58	14	-	-	PUNCT
dpc-1075	58	15	up	up	ADP
dpc-1075	58	16	visits	visit	NOUN
dpc-1075	58	17	,	,	PUNCT
dpc-1075	58	18	pictures	picture	NOUN
dpc-1075	58	19	of	of	ADP
dpc-1075	58	20	the	the	DET
dpc-1075	58	21	frontal	frontal	ADJ
dpc-1075	58	22	and	and	CCONJ
dpc-1075	58	23	vertex	vertex	NOUN
dpc-1075	58	24	scalp	scalp	NOUN
dpc-1075	58	25	regions	region	NOUN
dpc-1075	58	26	were	be	AUX
dpc-1075	58	27	systematically	systematically	ADV
dpc-1075	58	28	taken	take	VERB
dpc-1075	58	29	using	use	VERB
dpc-1075	58	30	a	a	DET
dpc-1075	58	31	fotofinder	fotofinder	NOUN
dpc-1075	58	32	video	video	NOUN
dpc-1075	58	33	dermatoscope	dermatoscope	NOUN
dpc-1075	58	34	(	(	PUNCT
dpc-1075	58	35	medicam	medicam	PROPN
dpc-1075	58	36	800	800	NUM
dpc-1075	58	37	)	)	PUNCT
dpc-1075	58	38	.	.	PUNCT
dpc-1075	59	1	the	the	DET
dpc-1075	59	2	instrument	instrument	NOUN
dpc-1075	59	3	was	be	AUX
dpc-1075	59	4	placed	place	VERB
dpc-1075	59	5	on	on	ADP
dpc-1075	59	6	the	the	DET
dpc-1075	59	7	rotating	rotate	VERB
dpc-1075	59	8	arm	arm	NOUN
dpc-1075	59	9	of	of	ADP
dpc-1075	59	10	a	a	DET
dpc-1075	59	11	head	head	NOUN
dpc-1075	59	12	-	-	PUNCT
dpc-1075	59	13	positioning	positioning	NOUN
dpc-1075	59	14	device	device	NOUN
dpc-1075	59	15	(	(	PUNCT
dpc-1075	59	16	canfield	canfield	PROPN
dpc-1075	59	17	scientific	scientific	PROPN
dpc-1075	59	18	)	)	PUNCT
dpc-1075	59	19	,	,	PUNCT
dpc-1075	59	20	permitting	permit	VERB
dpc-1075	59	21	a	a	DET
dpc-1075	59	22	standardized	standardized	ADJ
dpc-1075	59	23	photograph	photograph	NOUN
dpc-1075	59	24	collection	collection	NOUN
dpc-1075	59	25	.	.	PUNCT
dpc-1075	60	1	to	to	PART
dpc-1075	60	2	assess	assess	VERB
dpc-1075	60	3	the	the	DET
dpc-1075	60	4	improvement	improvement	NOUN
dpc-1075	60	5	at	at	ADP
dpc-1075	60	6	different	different	ADJ
dpc-1075	60	7	time	time	NOUN
dpc-1075	60	8	intervals	interval	NOUN
dpc-1075	60	9	,	,	PUNCT
dpc-1075	60	10	3	3	NUM
dpc-1075	60	11	operators	operator	NOUN
dpc-1075	60	12	blind	blind	ADJ
dpc-1075	60	13	to	to	ADP
dpc-1075	60	14	the	the	DET
dpc-1075	60	15	prescribed	prescribed	ADJ
dpc-1075	60	16	treatment	treatment	NOUN
dpc-1075	60	17	evaluated	evaluate	VERB
dpc-1075	60	18	photographs	photograph	NOUN
dpc-1075	60	19	of	of	ADP
dpc-1075	60	20	the	the	DET
dpc-1075	60	21	affected	affect	VERB
dpc-1075	60	22	areas	area	NOUN
dpc-1075	60	23	for	for	ADP
dpc-1075	60	24	each	each	DET
dpc-1075	60	25	patient	patient	NOUN
dpc-1075	60	26	at	at	ADP
dpc-1075	60	27	baseline	baseline	NOUN
dpc-1075	60	28	,	,	PUNCT
dpc-1075	60	29	at	at	ADP
dpc-1075	60	30	6	6	NUM
dpc-1075	60	31	months	month	NOUN
dpc-1075	60	32	,	,	PUNCT
dpc-1075	60	33	and	and	CCONJ
dpc-1075	60	34	at	at	ADP
dpc-1075	60	35	12	12	NUM
dpc-1075	60	36	-	-	SYM
dpc-1075	60	37	18	18	NUM
dpc-1075	60	38	months	month	NOUN
dpc-1075	60	39	from	from	ADP
dpc-1075	60	40	diagnosis	diagnosis	NOUN
dpc-1075	60	41	.	.	PUNCT
dpc-1075	61	1	for	for	ADP
dpc-1075	61	2	the	the	DET
dpc-1075	61	3	evaluation	evaluation	NOUN
dpc-1075	61	4	,	,	PUNCT
dpc-1075	61	5	a	a	DET
dpc-1075	61	6	7	7	NUM
dpc-1075	61	7	-	-	PUNCT
dpc-1075	61	8	point	point	NOUN
dpc-1075	61	9	improvement	improvement	NOUN
dpc-1075	61	10	scale	scale	NOUN
dpc-1075	61	11	was	be	AUX
dpc-1075	61	12	used	use	VERB
dpc-1075	61	13	.	.	PUNCT
dpc-1075	62	1	this	this	PRON
dpc-1075	62	2	is	be	AUX
dpc-1075	62	3	a	a	DET
dpc-1075	62	4	standardized	standardized	ADJ
dpc-1075	62	5	quantitative	quantitative	ADJ
dpc-1075	62	6	score	score	NOUN
dpc-1075	62	7	for	for	ADP
dpc-1075	62	8	measuring	measure	VERB
dpc-1075	62	9	the	the	DET
dpc-1075	62	10	hair	hair	NOUN
dpc-1075	62	11	growth	growth	NOUN
dpc-1075	62	12	and	and	CCONJ
dpc-1075	62	13	clinical	clinical	ADJ
dpc-1075	62	14	response	response	NOUN
dpc-1075	62	15	:	:	PUNCT
dpc-1075	62	16	−3	−3	NOUN
dpc-1075	62	17	 	 	SPACE
dpc-1075	62	18	=	=	PUNCT
dpc-1075	62	19	greatly	greatly	ADV
dpc-1075	62	20	decreased	decrease	VERB
dpc-1075	62	21	,	,	PUNCT
dpc-1075	62	22	−2	−2	X
dpc-1075	62	23	=	=	PRON
dpc-1075	62	24	moderately	moderately	ADV
dpc-1075	62	25	decreased	decrease	VERB
dpc-1075	62	26	,	,	PUNCT
dpc-1075	62	27	−1	−1	NOUN
dpc-1075	62	28	=	=	PUNCT
dpc-1075	62	29	slightly	slightly	ADV
dpc-1075	62	30	decreased	decrease	VERB
dpc-1075	62	31	,	,	PUNCT
dpc-1075	62	32	0	0	PUNCT
dpc-1075	63	1	=	=	SYM
dpc-1075	63	2	no	no	DET
dpc-1075	63	3	change	change	NOUN
dpc-1075	63	4	,	,	PUNCT
dpc-1075	63	5	+1	+1	PROPN
dpc-1075	63	6	=	=	PUNCT
dpc-1075	63	7	slightly	slightly	ADV
dpc-1075	63	8	increased	increase	VERB
dpc-1075	63	9	,	,	PUNCT
dpc-1075	63	10	+2	+2	PROPN
dpc-1075	63	11	=	=	PUNCT
dpc-1075	63	12	moderately	moderately	ADV
dpc-1075	63	13	increased	increase	VERB
dpc-1075	63	14	,	,	PUNCT
dpc-1075	63	15	and	and	CCONJ
dpc-1075	63	16	+3	+3	PROPN
dpc-1075	63	17	=	=	PUNCT
dpc-1075	63	18	greatly	greatly	ADV
dpc-1075	63	19	increased	increase	VERB
dpc-1075	63	20	.	.	PUNCT
dpc-1075	64	1	all	all	DET
dpc-1075	64	2	operators	operator	NOUN
dpc-1075	64	3	rated	rate	VERB
dpc-1075	64	4	photographs	photograph	NOUN
dpc-1075	64	5	for	for	ADP
dpc-1075	64	6	all	all	DET
dpc-1075	64	7	participants	participant	NOUN
dpc-1075	64	8	at	at	ADP
dpc-1075	64	9	all	all	DET
dpc-1075	64	10	time	time	NOUN
dpc-1075	64	11	points	point	NOUN
dpc-1075	64	12	,	,	PUNCT
dpc-1075	64	13	and	and	CCONJ
dpc-1075	64	14	the	the	DET
dpc-1075	64	15	score	score	NOUN
dpc-1075	64	16	was	be	AUX
dpc-1075	64	17	then	then	ADV
dpc-1075	64	18	averaged	average	VERB
dpc-1075	64	19	.	.	PUNCT
dpc-1075	65	1	statistical	statistical	ADJ
dpc-1075	65	2	analyses	analysis	NOUN
dpc-1075	65	3	one	one	NUM
dpc-1075	65	4	-	-	PUNCT
dpc-1075	65	5	way	way	NOUN
dpc-1075	65	6	analysis	analysis	NOUN
dpc-1075	65	7	of	of	ADP
dpc-1075	65	8	variance	variance	NOUN
dpc-1075	65	9	and	and	CCONJ
dpc-1075	65	10	unpaired	unpaired	ADJ
dpc-1075	65	11	student	student	NOUN
dpc-1075	65	12	t	t	NOUN
dpc-1075	65	13	tests	test	NOUN
dpc-1075	65	14	were	be	AUX
dpc-1075	65	15	performed	perform	VERB
dpc-1075	65	16	using	use	VERB
dpc-1075	65	17	spss	spss	PROPN
dpc-1075	65	18	software	software	NOUN
dpc-1075	65	19	v19	v19	PROPN
dpc-1075	65	20	(	(	PUNCT
dpc-1075	65	21	ibm	ibm	PROPN
dpc-1075	65	22	,	,	PUNCT
dpc-1075	65	23	armonk	armonk	PROPN
dpc-1075	65	24	,	,	PUNCT
dpc-1075	65	25	ny	ny	PROPN
dpc-1075	65	26	,	,	PUNCT
dpc-1075	65	27	usa	usa	PROPN
dpc-1075	65	28	)	)	PUNCT
dpc-1075	65	29	and	and	CCONJ
dpc-1075	65	30	graphpad	graphpad	NOUN
dpc-1075	65	31	prism	prism	NOUN
dpc-1075	65	32	v6	v6	PROPN
dpc-1075	65	33	(	(	PUNCT
dpc-1075	65	34	graphpad	graphpad	NOUN
dpc-1075	65	35	software	software	NOUN
dpc-1075	65	36	,	,	PUNCT
dpc-1075	65	37	san	san	PROPN
dpc-1075	65	38	diego	diego	PROPN
dpc-1075	65	39	,	,	PUNCT
dpc-1075	65	40	ca	ca	PROPN
dpc-1075	65	41	,	,	PUNCT
dpc-1075	65	42	usa	usa	PROPN
dpc-1075	65	43	)	)	PUNCT
dpc-1075	65	44	.	.	PUNCT
dpc-1075	66	1	confidence	confidence	NOUN
dpc-1075	66	2	interval	interval	NOUN
dpc-1075	66	3	was	be	AUX
dpc-1075	66	4	set	set	VERB
dpc-1075	66	5	to	to	ADP
dpc-1075	66	6	95	95	NUM
dpc-1075	66	7	%	%	NOUN
dpc-1075	66	8	assuming	assume	VERB
dpc-1075	66	9	statistically	statistically	ADV
dpc-1075	66	10	significant	significant	ADJ
dpc-1075	66	11	p	p	ADJ
dpc-1075	66	12	values	value	NOUN
dpc-1075	66	13	≤	≤	NOUN
dpc-1075	66	14	0.05	0.05	NUM
dpc-1075	66	15	.	.	PUNCT
dpc-1075	67	1	results	result	NOUN
dpc-1075	67	2	in	in	ADP
dpc-1075	67	3	our	our	PRON
dpc-1075	67	4	sample	sample	NOUN
dpc-1075	67	5	of	of	ADP
dpc-1075	67	6	119	119	NUM
dpc-1075	67	7	patients	patient	NOUN
dpc-1075	67	8	,	,	PUNCT
dpc-1075	67	9	hair	hair	NOUN
dpc-1075	67	10	loss	loss	NOUN
dpc-1075	67	11	improvement	improvement	NOUN
dpc-1075	67	12	was	be	AUX
dpc-1075	67	13	observed	observe	VERB
dpc-1075	67	14	in	in	ADP
dpc-1075	67	15	112	112	NUM
dpc-1075	67	16	women	woman	NOUN
dpc-1075	67	17	,	,	PUNCT
dpc-1075	67	18	while	while	SCONJ
dpc-1075	67	19	worsening	worsen	VERB
dpc-1075	67	20	was	be	AUX
dpc-1075	67	21	noticed	notice	VERB
dpc-1075	67	22	in	in	ADP
dpc-1075	67	23	7	7	NUM
dpc-1075	67	24	patients	patient	NOUN
dpc-1075	67	25	.	.	PUNCT
dpc-1075	68	1	specifically	specifically	ADV
dpc-1075	68	2	,	,	PUNCT
dpc-1075	68	3	in	in	ADP
dpc-1075	68	4	the	the	DET
dpc-1075	68	5	group	group	NOUN
dpc-1075	68	6	to	to	PART
dpc-1075	68	7	which	which	PRON
dpc-1075	68	8	treatment	treatment	NOUN
dpc-1075	68	9	1	1	NUM
dpc-1075	68	10	(	(	PUNCT
dpc-1075	68	11	topical	topical	ADJ
dpc-1075	68	12	finasteride	finasteride	NOUN
dpc-1075	68	13	)	)	PUNCT
dpc-1075	68	14	was	be	AUX
dpc-1075	68	15	prescribed	prescribe	VERB
dpc-1075	68	16	,	,	PUNCT
dpc-1075	68	17	48	48	NUM
dpc-1075	68	18	out	out	ADP
dpc-1075	68	19	of	of	ADP
dpc-1075	68	20	50	50	NUM
dpc-1075	68	21	patients	patient	NOUN
dpc-1075	68	22	(	(	PUNCT
dpc-1075	68	23	96	96	NUM
dpc-1075	68	24	%	%	NOUN
dpc-1075	68	25	)	)	PUNCT
dpc-1075	68	26	showed	show	VERB
dpc-1075	68	27	improvement	improvement	NOUN
dpc-1075	68	28	,	,	PUNCT
dpc-1075	68	29	while	while	SCONJ
dpc-1075	68	30	2	2	NUM
dpc-1075	68	31	out	out	ADP
dpc-1075	68	32	of	of	ADP
dpc-1075	68	33	50	50	NUM
dpc-1075	68	34	showed	show	VERB
dpc-1075	68	35	an	an	DET
dpc-1075	68	36	increase	increase	NOUN
dpc-1075	68	37	of	of	ADP
dpc-1075	68	38	hair	hair	NOUN
dpc-1075	68	39	loss	loss	NOUN
dpc-1075	68	40	after	after	ADP
dpc-1075	68	41	6	6	NUM
dpc-1075	68	42	months	month	NOUN
dpc-1075	68	43	(	(	PUNCT
dpc-1075	68	44	both	both	PRON
dpc-1075	68	45	of	of	ADP
dpc-1075	68	46	these	these	DET
dpc-1075	68	47	patients	patient	NOUN
dpc-1075	68	48	’	'	PUNCT
dpc-1075	68	49	photographs	photograph	NOUN
dpc-1075	68	50	had	have	VERB
dpc-1075	68	51	an	an	DET
dpc-1075	68	52	average	average	ADJ
dpc-1075	68	53	rating	rating	NOUN
dpc-1075	68	54	of	of	ADP
dpc-1075	68	55	figure	figure	NOUN
dpc-1075	68	56	1	1	NUM
dpc-1075	68	57	.	.	PUNCT
dpc-1075	69	1	scalp	scalp	NOUN
dpc-1075	69	2	photographs	photograph	NOUN
dpc-1075	69	3	and	and	CCONJ
dpc-1075	69	4	trichoscopy	trichoscopy	NOUN
dpc-1075	69	5	of	of	ADP
dpc-1075	69	6	a	a	DET
dpc-1075	69	7	patient	patient	NOUN
dpc-1075	69	8	undergoing	undergo	VERB
dpc-1075	69	9	topical	topical	ADJ
dpc-1075	69	10	treatment	treatment	NOUN
dpc-1075	69	11	with	with	ADP
dpc-1075	69	12	finasteride	finasteride	ADJ
dpc-1075	69	13	lotion	lotion	NOUN
dpc-1075	69	14	,	,	PUNCT
dpc-1075	69	15	at	at	ADP
dpc-1075	69	16	baseline	baseline	PROPN
dpc-1075	69	17	(	(	PUNCT
dpc-1075	69	18	a	a	DET
dpc-1075	69	19	,	,	PUNCT
dpc-1075	69	20	c	c	NOUN
dpc-1075	69	21	)	)	PUNCT
dpc-1075	69	22	and	and	CCONJ
dpc-1075	69	23	after	after	ADP
dpc-1075	69	24	6	6	NUM
dpc-1075	69	25	months	month	NOUN
dpc-1075	69	26	of	of	ADP
dpc-1075	69	27	therapy	therapy	NOUN
dpc-1075	69	28	(	(	PUNCT
dpc-1075	69	29	b	b	NOUN
dpc-1075	69	30	,	,	PUNCT
dpc-1075	69	31	d	d	NOUN
dpc-1075	69	32	)	)	PUNCT
dpc-1075	69	33	.	.	PUNCT
dpc-1075	70	1	figure	figure	NOUN
dpc-1075	70	2	2	2	NUM
dpc-1075	70	3	.	.	NOUN
dpc-1075	70	4	macroscopic	macroscopic	ADJ
dpc-1075	70	5	and	and	CCONJ
dpc-1075	70	6	trichoscopy	trichoscopy	NOUN
dpc-1075	70	7	pictures	picture	NOUN
dpc-1075	70	8	of	of	ADP
dpc-1075	70	9	a	a	DET
dpc-1075	70	10	patient	patient	NOUN
dpc-1075	70	11	under	under	ADP
dpc-1075	70	12	treatment	treatment	NOUN
dpc-1075	70	13	with	with	ADP
dpc-1075	70	14	17α	17α	NOUN
dpc-1075	70	15	-	-	PUNCT
dpc-1075	70	16	estradiol	estradiol	PROPN
dpc-1075	70	17	topical	topical	ADJ
dpc-1075	70	18	lotion	lotion	NOUN
dpc-1075	70	19	,	,	PUNCT
dpc-1075	70	20	at	at	ADP
dpc-1075	70	21	baseline	baseline	PROPN
dpc-1075	70	22	(	(	PUNCT
dpc-1075	70	23	a	a	DET
dpc-1075	70	24	,	,	PUNCT
dpc-1075	70	25	c	c	NOUN
dpc-1075	70	26	)	)	PUNCT
dpc-1075	70	27	and	and	CCONJ
dpc-1075	70	28	after	after	ADP
dpc-1075	70	29	6	6	NUM
dpc-1075	70	30	months	month	NOUN
dpc-1075	70	31	of	of	ADP
dpc-1075	70	32	therapy	therapy	NOUN
dpc-1075	70	33	(	(	PUNCT
dpc-1075	70	34	b	b	NOUN
dpc-1075	70	35	,	,	PUNCT
dpc-1075	70	36	d	d	NOUN
dpc-1075	70	37	)	)	PUNCT
dpc-1075	70	38	.	.	PUNCT
dpc-1075	71	1	4	4	NUM
dpc-1075	71	2	research	research	NOUN
dpc-1075	71	3	|	|	ADV
dpc-1075	71	4	dermatol	dermatol	ADJ
dpc-1075	71	5	pract	pract	NOUN
dpc-1075	71	6	concept	concept	NOUN
dpc-1075	71	7	2020;10(2):e2020039	2020;10(2):e2020039	NUM
dpc-1075	71	8	formulations	formulation	NOUN
dpc-1075	71	9	(	(	PUNCT
dpc-1075	71	10	figures	figure	NOUN
dpc-1075	71	11	1	1	NUM
dpc-1075	71	12	-	-	SYM
dpc-1075	71	13	3	3	NUM
dpc-1075	71	14	)	)	PUNCT
dpc-1075	71	15	.	.	PUNCT
dpc-1075	72	1	more	more	ADV
dpc-1075	72	2	important	important	ADJ
dpc-1075	72	3	,	,	PUNCT
dpc-1075	72	4	the	the	DET
dpc-1075	72	5	efficacy	efficacy	NOUN
dpc-1075	72	6	of	of	ADP
dpc-1075	72	7	topical	topical	ADJ
dpc-1075	72	8	finasteride	finasteride	NOUN
dpc-1075	72	9	(	(	PUNCT
dpc-1075	72	10	treatment	treatment	NOUN
dpc-1075	72	11	1	1	NUM
dpc-1075	72	12	)	)	PUNCT
dpc-1075	72	13	was	be	AUX
dpc-1075	72	14	significantly	significantly	ADV
dpc-1075	72	15	greater	great	ADJ
dpc-1075	72	16	than	than	ADP
dpc-1075	72	17	that	that	PRON
dpc-1075	72	18	of	of	ADP
dpc-1075	72	19	the	the	DET
dpc-1075	72	20	17α	17α	NOUN
dpc-1075	72	21	-	-	PUNCT
dpc-1075	72	22	estradiol	estradiol	PROPN
dpc-1075	72	23	solution	solution	NOUN
dpc-1075	72	24	(	(	PUNCT
dpc-1075	72	25	treatment	treatment	NOUN
dpc-1075	72	26	2	2	NUM
dpc-1075	72	27	)	)	PUNCT
dpc-1075	72	28	,	,	PUNCT
dpc-1075	72	29	both	both	CCONJ
dpc-1075	72	30	at	at	ADP
dpc-1075	72	31	the	the	DET
dpc-1075	72	32	6	6	NUM
dpc-1075	72	33	-	-	PUNCT
dpc-1075	72	34	month	month	NOUN
dpc-1075	72	35	(	(	PUNCT
dpc-1075	72	36	p	p	X
dpc-1075	72	37	<	<	X
dpc-1075	72	38	0.05	0.05	NUM
dpc-1075	72	39	)	)	PUNCT
dpc-1075	72	40	and	and	CCONJ
dpc-1075	72	41	at	at	ADP
dpc-1075	72	42	the	the	DET
dpc-1075	72	43	12to	12to	ADJ
dpc-1075	72	44	18	18	NUM
dpc-1075	72	45	-	-	PUNCT
dpc-1075	72	46	month	month	NOUN
dpc-1075	72	47	follow	follow	NOUN
dpc-1075	72	48	-	-	PUNCT
dpc-1075	72	49	up	up	NOUN
dpc-1075	72	50	(	(	PUNCT
dpc-1075	72	51	p	p	X
dpc-1075	72	52	<	<	X
dpc-1075	72	53	0.005	0.005	NUM
dpc-1075	72	54	)	)	PUNCT
dpc-1075	72	55	(	(	PUNCT
dpc-1075	72	56	figure	figure	VERB
dpc-1075	72	57	4	4	NUM
dpc-1075	72	58	)	)	PUNCT
dpc-1075	72	59	.	.	PUNCT
dpc-1075	73	1	in	in	ADP
dpc-1075	73	2	general	general	ADJ
dpc-1075	73	3	,	,	PUNCT
dpc-1075	73	4	the	the	DET
dpc-1075	73	5	highest	high	ADJ
dpc-1075	73	6	improvement	improvement	NOUN
dpc-1075	73	7	was	be	AUX
dpc-1075	73	8	observed	observe	VERB
dpc-1075	73	9	after	after	ADP
dpc-1075	73	10	12	12	NUM
dpc-1075	73	11	-	-	SYM
dpc-1075	73	12	18	18	NUM
dpc-1075	73	13	months	month	NOUN
dpc-1075	73	14	of	of	ADP
dpc-1075	73	15	treatment	treatment	NOUN
dpc-1075	73	16	with	with	ADP
dpc-1075	73	17	topical	topical	ADJ
dpc-1075	73	18	finasteride	finasteride	NOUN
dpc-1075	73	19	and	and	CCONJ
dpc-1075	73	20	minoxidil	minoxidil	NOUN
dpc-1075	73	21	therapy	therapy	NOUN
dpc-1075	73	22	(	(	PUNCT
dpc-1075	73	23	figure	figure	NOUN
dpc-1075	73	24	5	5	NUM
dpc-1075	73	25	)	)	PUNCT
dpc-1075	73	26	.	.	PUNCT
dpc-1075	74	1	discussion	discussion	NOUN
dpc-1075	74	2	in	in	ADP
dpc-1075	74	3	our	our	PRON
dpc-1075	74	4	work	work	NOUN
dpc-1075	74	5	,	,	PUNCT
dpc-1075	74	6	we	we	PRON
dpc-1075	74	7	compared	compare	VERB
dpc-1075	74	8	2	2	NUM
dpc-1075	74	9	galenic	galenic	NOUN
dpc-1075	74	10	formulations	formulation	NOUN
dpc-1075	74	11	for	for	ADP
dpc-1075	74	12	the	the	DET
dpc-1075	74	13	treatment	treatment	NOUN
dpc-1075	74	14	of	of	ADP
dpc-1075	74	15	fphl	fphl	NOUN
dpc-1075	74	16	.	.	PUNCT
dpc-1075	75	1	the	the	DET
dpc-1075	75	2	first	first	ADJ
dpc-1075	75	3	100	100	NUM
dpc-1075	75	4	-	-	PUNCT
dpc-1075	75	5	ml	ml	NOUN
dpc-1075	75	6	solution	solution	NOUN
dpc-1075	75	7	contained	contain	VERB
dpc-1075	75	8	17α	17α	NOUN
dpc-1075	75	9	-	-	PUNCT
dpc-1075	75	10	estradiol	estradiol	PROPN
dpc-1075	75	11	0.05	0.05	NUM
dpc-1075	75	12	%	%	NOUN
dpc-1075	75	13	,	,	PUNCT
dpc-1075	75	14	minoxidil	minoxidil	NOUN
dpc-1075	75	15	2	2	NUM
dpc-1075	75	16	%	%	NOUN
dpc-1075	75	17	,	,	PUNCT
dpc-1075	75	18	hydrocortisone	hydrocortisone	PROPN
dpc-1075	75	19	butyrate	butyrate	NOUN
dpc-1075	75	20	0.08	0.08	NUM
dpc-1075	75	21	%	%	NOUN
dpc-1075	75	22	,	,	PUNCT
dpc-1075	75	23	and	and	CCONJ
dpc-1075	75	24	cyclosilicone	cyclosilicone	NOUN
dpc-1075	75	25	pentamer	pentamer	NOUN
dpc-1075	75	26	16	16	NUM
dpc-1075	75	27	%	%	NOUN
dpc-1075	75	28	in	in	ADP
dpc-1075	75	29	alcohol	alcohol	NOUN
dpc-1075	75	30	96	96	NUM
dpc-1075	75	31	°	°	NOUN
dpc-1075	75	32	81.87	81.87	NUM
dpc-1075	75	33	%	%	NOUN
dpc-1075	75	34	.	.	PUNCT
dpc-1075	76	1	the	the	DET
dpc-1075	76	2	second	second	ADJ
dpc-1075	76	3	100	100	NUM
dpc-1075	76	4	-	-	PUNCT
dpc-1075	76	5	ml	ml	NOUN
dpc-1075	76	6	formulation	formulation	NOUN
dpc-1075	76	7	was	be	AUX
dpc-1075	76	8	composed	compose	VERB
dpc-1075	76	9	of	of	ADP
dpc-1075	76	10	finasteride	finasteride	ADJ
dpc-1075	76	11	0.5	0.5	NUM
dpc-1075	76	12	%	%	NOUN
dpc-1075	76	13	,	,	PUNCT
dpc-1075	76	14	minoxidil	minoxidil	NOUN
dpc-1075	76	15	2	2	NUM
dpc-1075	76	16	%	%	NOUN
dpc-1075	76	17	,	,	PUNCT
dpc-1075	76	18	hydrocortisone	hydrocortisone	PROPN
dpc-1075	76	19	butyrate	butyrate	NOUN
dpc-1075	76	20	0.08	0.08	NUM
dpc-1075	76	21	%	%	NOUN
dpc-1075	76	22	,	,	PUNCT
dpc-1075	76	23	and	and	CCONJ
dpc-1075	77	1	cyclosilicone	cyclosilicone	NOUN
dpc-1075	77	2	pentamer	pentamer	NOUN
dpc-1075	77	3	16	16	NUM
dpc-1075	77	4	%	%	NOUN
dpc-1075	77	5	in	in	ADP
dpc-1075	77	6	alcohol	alcohol	NOUN
dpc-1075	77	7	96	96	NUM
dpc-1075	77	8	°	°	NUM
dpc-1075	77	9	81.4	81.4	NUM
dpc-1075	77	10	%	%	NOUN
dpc-1075	77	11	.	.	PUNCT
dpc-1075	78	1	hydrocortisone	hydrocortisone	PROPN
dpc-1075	78	2	butyrate	butyrate	PROPN
dpc-1075	78	3	is	be	AUX
dpc-1075	78	4	a	a	DET
dpc-1075	78	5	class	class	NOUN
dpc-1075	78	6	ii	ii	NOUN
dpc-1075	78	7	steroid	steroid	NOUN
dpc-1075	78	8	that	that	PRON
dpc-1075	78	9	blocks	block	VERB
dpc-1075	78	10	the	the	DET
dpc-1075	78	11	inflammatory	inflammatory	ADJ
dpc-1075	78	12	process	process	NOUN
dpc-1075	78	13	induced	induce	VERB
dpc-1075	78	14	by	by	ADP
dpc-1075	78	15	lymphocytic	lymphocytic	ADJ
dpc-1075	78	16	peri	peri	NOUN
dpc-1075	78	17	-	-	PUNCT
dpc-1075	78	18	infundibular	infundibular	ADJ
dpc-1075	78	19	and	and	CCONJ
dpc-1075	78	20	peristhmic	peristhmic	ADJ
dpc-1075	78	21	infiltrate	infiltrate	NOUN
dpc-1075	79	1	[	[	X
dpc-1075	79	2	12,13	12,13	NUM
dpc-1075	79	3	]	]	PUNCT
dpc-1075	79	4	.	.	PUNCT
dpc-1075	80	1	minoxidil	minoxidil	PROPN
dpc-1075	80	2	is	be	AUX
dpc-1075	80	3	a	a	DET
dpc-1075	80	4	piperidinopyrimidine	piperidinopyrimidine	NOUN
dpc-1075	80	5	derivative	derivative	NOUN
dpc-1075	80	6	and	and	CCONJ
dpc-1075	80	7	its	its	PRON
dpc-1075	80	8	action	action	NOUN
dpc-1075	80	9	is	be	AUX
dpc-1075	80	10	believed	believe	VERB
dpc-1075	80	11	to	to	PART
dpc-1075	80	12	be	be	AUX
dpc-1075	80	13	due	due	ADJ
dpc-1075	80	14	to	to	ADP
dpc-1075	80	15	its	its	PRON
dpc-1075	80	16	vasodilator	vasodilator	NOUN
dpc-1075	80	17	properties	property	NOUN
dpc-1075	80	18	.	.	PUNCT
dpc-1075	81	1	this	this	PRON
dpc-1075	81	2	is	be	AUX
dpc-1075	81	3	realized	realize	VERB
dpc-1075	81	4	through	through	ADP
dpc-1075	81	5	the	the	DET
dpc-1075	81	6	opening	opening	NOUN
dpc-1075	81	7	of	of	ADP
dpc-1075	81	8	potassium	potassium	NOUN
dpc-1075	81	9	channels	channel	NOUN
dpc-1075	81	10	localized	localize	VERB
dpc-1075	81	11	on	on	ADP
dpc-1075	81	12	the	the	DET
dpc-1075	81	13	smooth	smooth	ADJ
dpc-1075	81	14	muscular	muscular	ADJ
dpc-1075	81	15	cells	cell	NOUN
dpc-1075	81	16	of	of	ADP
dpc-1075	81	17	the	the	DET
dpc-1075	81	18	peripheral	peripheral	ADJ
dpc-1075	81	19	artery	artery	NOUN
dpc-1075	81	20	[	[	X
dpc-1075	81	21	14	14	NUM
dpc-1075	81	22	]	]	PUNCT
dpc-1075	81	23	.	.	PUNCT
dpc-1075	82	1	approved	approve	VERB
dpc-1075	82	2	in	in	ADP
dpc-1075	82	3	1979	1979	NUM
dpc-1075	82	4	for	for	ADP
dpc-1075	82	5	hypertension	hypertension	NOUN
dpc-1075	82	6	,	,	PUNCT
dpc-1075	82	7	it	it	PRON
dpc-1075	82	8	is	be	AUX
dpc-1075	82	9	largely	largely	ADV
dpc-1075	82	10	used	use	VERB
dpc-1075	82	11	as	as	ADP
dpc-1075	82	12	a	a	DET
dpc-1075	82	13	topical	topical	ADJ
dpc-1075	82	14	product	product	NOUN
dpc-1075	82	15	for	for	ADP
dpc-1075	82	16	alopecia	alopecia	NOUN
dpc-1075	82	17	owing	owe	VERB
dpc-1075	82	18	to	to	ADP
dpc-1075	82	19	its	its	PRON
dpc-1075	82	20	common	common	ADJ
dpc-1075	82	21	adverse	adverse	ADJ
dpc-1075	82	22	effect	effect	NOUN
dpc-1075	82	23	of	of	ADP
dpc-1075	82	24	inducing	induce	VERB
dpc-1075	82	25	hair	hair	NOUN
dpc-1075	82	26	growth	growth	NOUN
dpc-1075	82	27	.	.	PUNCT
dpc-1075	83	1	minoxidil	minoxidil	PROPN
dpc-1075	83	2	modifies	modify	VERB
dpc-1075	83	3	the	the	DET
dpc-1075	83	4	hair	hair	NOUN
dpc-1075	83	5	cycle	cycle	NOUN
dpc-1075	83	6	,	,	PUNCT
dpc-1075	83	7	shortening	shorten	VERB
dpc-1075	83	8	the	the	DET
dpc-1075	83	9	telogen	telogen	NOUN
dpc-1075	83	10	phase	phase	NOUN
dpc-1075	83	11	or	or	CCONJ
dpc-1075	83	12	prolonging	prolong	VERB
dpc-1075	83	13	the	the	DET
dpc-1075	83	14	anagen	anagen	NOUN
dpc-1075	83	15	phase	phase	NOUN
dpc-1075	83	16	[	[	X
dpc-1075	83	17	12	12	NUM
dpc-1075	83	18	]	]	PUNCT
dpc-1075	83	19	.	.	PUNCT
dpc-1075	84	1	it	it	PRON
dpc-1075	84	2	directly	directly	ADV
dpc-1075	84	3	stimulates	stimulate	VERB
dpc-1075	84	4	the	the	DET
dpc-1075	84	5	dermal	dermal	ADJ
dpc-1075	84	6	papilla	papilla	NOUN
dpc-1075	84	7	or	or	CCONJ
dpc-1075	84	8	the	the	DET
dpc-1075	84	9	follicular	follicular	ADJ
dpc-1075	84	10	hair	hair	NOUN
dpc-1075	84	11	matrix	matrix	NOUN
dpc-1075	84	12	cells	cell	NOUN
dpc-1075	84	13	,	,	PUNCT
dpc-1075	84	14	causing	cause	VERB
dpc-1075	84	15	an	an	DET
dpc-1075	84	16	increase	increase	NOUN
dpc-1075	84	17	of	of	ADP
dpc-1075	84	18	vascular	vascular	ADJ
dpc-1075	84	19	endothelial	endothelial	ADJ
dpc-1075	84	20	growth	growth	NOUN
dpc-1075	84	21	factor	factor	NOUN
dpc-1075	84	22	and	and	CCONJ
dpc-1075	84	23	consequently	consequently	ADV
dpc-1075	84	24	angiogenesis	angiogenesis	NOUN
dpc-1075	84	25	[	[	X
dpc-1075	84	26	12,15	12,15	NUM
dpc-1075	84	27	]	]	X
dpc-1075	84	28	.	.	PUNCT
dpc-1075	85	1	furthermore	furthermore	ADV
dpc-1075	85	2	,	,	PUNCT
dpc-1075	85	3	it	it	PRON
dpc-1075	85	4	has	have	AUX
dpc-1075	85	5	been	be	AUX
dpc-1075	85	6	hypothesized	hypothesize	VERB
dpc-1075	85	7	that	that	SCONJ
dpc-1075	85	8	it	it	PRON
dpc-1075	85	9	activates	activate	VERB
dpc-1075	85	10	the	the	DET
dpc-1075	85	11	prostaglandin	prostaglandin	NOUN
dpc-1075	85	12	endoperoxide	endoperoxide	ADJ
dpc-1075	85	13	synthetase	synthetase	NOUN
dpc-1075	85	14	enzyme	enzyme	NOUN
dpc-1075	85	15	type	type	NOUN
dpc-1075	85	16	 	 	SPACE
dpc-1075	85	17	i	i	PROPN
dpc-1075	85	18	,	,	PUNCT
dpc-1075	85	19	which	which	PRON
dpc-1075	85	20	induces	induce	VERB
dpc-1075	85	21	hair	hair	NOUN
dpc-1075	85	22	growth	growth	NOUN
dpc-1075	86	1	[	[	X
dpc-1075	86	2	16	16	NUM
dpc-1075	86	3	]	]	PUNCT
dpc-1075	86	4	.	.	PUNCT
dpc-1075	87	1	figure	figure	NOUN
dpc-1075	87	2	3	3	NUM
dpc-1075	87	3	.	.	PUNCT
dpc-1075	88	1	using	use	VERB
dpc-1075	88	2	the	the	DET
dpc-1075	88	3	7	7	NUM
dpc-1075	88	4	-	-	PUNCT
dpc-1075	88	5	point	point	NOUN
dpc-1075	88	6	scale	scale	NOUN
dpc-1075	88	7	,	,	PUNCT
dpc-1075	88	8	the	the	DET
dpc-1075	88	9	improvement	improvement	NOUN
dpc-1075	88	10	was	be	AUX
dpc-1075	88	11	statistically	statistically	ADV
dpc-1075	88	12	significant	significant	ADJ
dpc-1075	88	13	from	from	ADP
dpc-1075	88	14	6	6	NUM
dpc-1075	88	15	months	month	NOUN
dpc-1075	88	16	to	to	ADP
dpc-1075	88	17	12	12	NUM
dpc-1075	88	18	-	-	SYM
dpc-1075	88	19	18	18	NUM
dpc-1075	88	20	months	month	NOUN
dpc-1075	88	21	,	,	PUNCT
dpc-1075	88	22	both	both	PRON
dpc-1075	88	23	for	for	ADP
dpc-1075	88	24	finasteride	finasteride	ADJ
dpc-1075	88	25	(	(	PUNCT
dpc-1075	88	26	p	p	X
dpc-1075	88	27	<	<	X
dpc-1075	88	28	0.0027	0.0027	NUM
dpc-1075	88	29	)	)	PUNCT
dpc-1075	88	30	and	and	CCONJ
dpc-1075	88	31	17α	17α	NOUN
dpc-1075	88	32	-	-	PUNCT
dpc-1075	88	33	estradiol	estradiol	PROPN
dpc-1075	88	34	(	(	PUNCT
dpc-1075	88	35	p	p	X
dpc-1075	88	36	<	<	X
dpc-1075	88	37	0.0205	0.0205	NUM
dpc-1075	88	38	)	)	PUNCT
dpc-1075	88	39	.	.	PUNCT
dpc-1075	89	1	est	est	X
dpc-1075	89	2	=	=	SYM
dpc-1075	89	3	17α	17α	NOUN
dpc-1075	89	4	-	-	PUNCT
dpc-1075	89	5	estradiol	estradiol	PROPN
dpc-1075	89	6	;	;	PUNCT
dpc-1075	89	7	fin	fin	NOUN
dpc-1075	89	8	=	=	PUNCT
dpc-1075	89	9	finasteride	finasteride	ADV
dpc-1075	89	10	;	;	PUNCT
dpc-1075	89	11	fphl	fphl	NOUN
dpc-1075	89	12	=	=	SYM
dpc-1075	89	13	female	female	ADJ
dpc-1075	89	14	pattern	pattern	NOUN
dpc-1075	89	15	hair	hair	NOUN
dpc-1075	89	16	loss	loss	NOUN
dpc-1075	89	17	;	;	PUNCT
dpc-1075	89	18	0	0	X
dpc-1075	89	19	=	=	SYM
dpc-1075	89	20	no	no	DET
dpc-1075	89	21	change	change	NOUN
dpc-1075	89	22	;	;	PUNCT
dpc-1075	89	23	1	1	NUM
dpc-1075	89	24	=	=	NUM
dpc-1075	89	25	slightly	slightly	ADV
dpc-1075	89	26	increased	increase	VERB
dpc-1075	89	27	;	;	PUNCT
dpc-1075	89	28	2	2	X
dpc-1075	89	29	=	=	PRON
dpc-1075	89	30	moderately	moderately	ADV
dpc-1075	89	31	increased	increase	VERB
dpc-1075	89	32	;	;	PUNCT
dpc-1075	89	33	3	3	NUM
dpc-1075	89	34	=	=	NUM
dpc-1075	89	35	greatly	greatly	ADV
dpc-1075	89	36	increased	increase	VERB
dpc-1075	89	37	.	.	PUNCT
dpc-1075	90	1	figure	figure	NOUN
dpc-1075	90	2	4	4	NUM
dpc-1075	90	3	.	.	PUNCT
dpc-1075	91	1	greater	great	ADJ
dpc-1075	91	2	efficacy	efficacy	NOUN
dpc-1075	91	3	of	of	ADP
dpc-1075	91	4	topical	topical	ADJ
dpc-1075	91	5	finasteride	finasteride	NOUN
dpc-1075	91	6	than	than	ADP
dpc-1075	91	7	17α	17α	NOUN
dpc-1075	91	8	-	-	PUNCT
dpc-1075	91	9	estradiol	estradiol	PROPN
dpc-1075	91	10	solution	solution	NOUN
dpc-1075	91	11	,	,	PUNCT
dpc-1075	91	12	both	both	PRON
dpc-1075	91	13	at	at	ADP
dpc-1075	91	14	6	6	NUM
dpc-1075	91	15	months	month	NOUN
dpc-1075	91	16	(	(	PUNCT
dpc-1075	91	17	p	p	X
dpc-1075	91	18	<	<	X
dpc-1075	91	19	0.0368	0.0368	NUM
dpc-1075	91	20	)	)	PUNCT
dpc-1075	91	21	and	and	CCONJ
dpc-1075	91	22	at	at	ADP
dpc-1075	91	23	12	12	NUM
dpc-1075	91	24	-	-	SYM
dpc-1075	91	25	18	18	NUM
dpc-1075	91	26	months	month	NOUN
dpc-1075	91	27	follow	follow	VERB
dpc-1075	91	28	-	-	PUNCT
dpc-1075	91	29	up	up	NOUN
dpc-1075	91	30	(	(	PUNCT
dpc-1075	91	31	p	p	X
dpc-1075	91	32	<	<	X
dpc-1075	91	33	0.0042	0.0042	NUM
dpc-1075	91	34	)	)	PUNCT
dpc-1075	91	35	.	.	PUNCT
dpc-1075	92	1	est	est	PROPN
dpc-1075	92	2	=	=	SYM
dpc-1075	92	3	17α	17α	NOUN
dpc-1075	92	4	-	-	PUNCT
dpc-1075	92	5	estradiol	estradiol	PROPN
dpc-1075	92	6	;	;	PUNCT
dpc-1075	92	7	fin	fin	NOUN
dpc-1075	92	8	=	=	PUNCT
dpc-1075	92	9	finasteride	finasteride	ADV
dpc-1075	92	10	;	;	PUNCT
dpc-1075	92	11	0	0	X
dpc-1075	92	12	=	=	SYM
dpc-1075	92	13	no	no	DET
dpc-1075	92	14	change	change	NOUN
dpc-1075	92	15	;	;	PUNCT
dpc-1075	92	16	1	1	NUM
dpc-1075	92	17	=	=	NUM
dpc-1075	92	18	slightly	slightly	ADV
dpc-1075	92	19	increased	increase	VERB
dpc-1075	92	20	;	;	PUNCT
dpc-1075	92	21	2	2	X
dpc-1075	92	22	=	=	PRON
dpc-1075	92	23	moderately	moderately	ADV
dpc-1075	92	24	increased	increase	VERB
dpc-1075	92	25	;	;	PUNCT
dpc-1075	92	26	3	3	NUM
dpc-1075	92	27	=	=	NUM
dpc-1075	92	28	greatly	greatly	ADV
dpc-1075	92	29	increased	increase	VERB
dpc-1075	92	30	.	.	PUNCT
dpc-1075	93	1	figure	figure	NOUN
dpc-1075	93	2	5	5	NUM
dpc-1075	93	3	.	.	PUNCT
dpc-1075	94	1	the	the	DET
dpc-1075	94	2	highest	high	ADJ
dpc-1075	94	3	improvement	improvement	NOUN
dpc-1075	94	4	is	be	AUX
dpc-1075	94	5	observed	observe	VERB
dpc-1075	94	6	after	after	ADP
dpc-1075	94	7	12	12	NUM
dpc-1075	94	8	to	to	PART
dpc-1075	94	9	18	18	NUM
dpc-1075	94	10	months	month	NOUN
dpc-1075	94	11	of	of	ADP
dpc-1075	94	12	treatment	treatment	NOUN
dpc-1075	94	13	with	with	ADP
dpc-1075	94	14	topical	topical	ADJ
dpc-1075	94	15	finasteride	finasteride	NOUN
dpc-1075	94	16	and	and	CCONJ
dpc-1075	94	17	minoxidil	minoxidil	ADJ
dpc-1075	94	18	therapy	therapy	NOUN
dpc-1075	94	19	.	.	PUNCT
dpc-1075	95	1	currently	currently	ADV
dpc-1075	95	2	,	,	PUNCT
dpc-1075	95	3	minoxidil	minoxidil	PROPN
dpc-1075	95	4	is	be	AUX
dpc-1075	95	5	the	the	DET
dpc-1075	95	6	only	only	ADJ
dpc-1075	95	7	fda	fda	PROPN
dpc-1075	95	8	-	-	PUNCT
dpc-1075	95	9	approved	approve	VERB
dpc-1075	95	10	therapeutic	therapeutic	ADJ
dpc-1075	95	11	option	option	NOUN
dpc-1075	95	12	for	for	ADP
dpc-1075	95	13	fphl	fphl	NOUN
dpc-1075	96	1	[	[	X
dpc-1075	96	2	17	17	NUM
dpc-1075	96	3	]	]	PUNCT
dpc-1075	96	4	.	.	PUNCT
dpc-1075	97	1	the	the	DET
dpc-1075	97	2	2	2	NUM
dpc-1075	97	3	%	%	NOUN
dpc-1075	97	4	concentration	concentration	NOUN
dpc-1075	97	5	was	be	AUX
dpc-1075	97	6	approved	approve	VERB
dpc-1075	97	7	in	in	ADP
dpc-1075	97	8	1991	1991	NUM
dpc-1075	97	9	,	,	PUNCT
dpc-1075	97	10	and	and	CCONJ
dpc-1075	97	11	5	5	NUM
dpc-1075	97	12	%	%	NOUN
dpc-1075	97	13	minoxidil	minoxidil	NOUN
dpc-1075	97	14	was	be	AUX
dpc-1075	97	15	approved	approve	VERB
dpc-1075	97	16	in	in	ADP
dpc-1075	97	17	2014	2014	NUM
dpc-1075	98	1	[	[	X
dpc-1075	98	2	18	18	NUM
dpc-1075	98	3	]	]	PUNCT
dpc-1075	98	4	.	.	PUNCT
dpc-1075	99	1	systemic	systemic	ADJ
dpc-1075	99	2	finasteride	finasteride	NOUN
dpc-1075	99	3	inhibits	inhibit	VERB
dpc-1075	99	4	the	the	DET
dpc-1075	99	5	type	type	NOUN
dpc-1075	99	6	ii	ii	PROPN
dpc-1075	99	7	5α	5α	ADJ
dpc-1075	99	8	-	-	PUNCT
dpc-1075	99	9	reductase	reductase	NOUN
dpc-1075	99	10	,	,	PUNCT
dpc-1075	99	11	which	which	PRON
dpc-1075	99	12	normally	normally	ADV
dpc-1075	99	13	catalyzes	catalyze	VERB
dpc-1075	99	14	the	the	DET
dpc-1075	99	15	conversion	conversion	NOUN
dpc-1075	99	16	of	of	ADP
dpc-1075	99	17	testosterone	testosterone	NOUN
dpc-1075	99	18	(	(	PUNCT
dpc-1075	99	19	t	t	NOUN
dpc-1075	99	20	)	)	PUNCT
dpc-1075	99	21	to	to	ADP
dpc-1075	99	22	dihydrotestosterone	dihydrotestosterone	NOUN
dpc-1075	99	23	(	(	PUNCT
dpc-1075	99	24	dht	dht	NOUN
dpc-1075	99	25	)	)	PUNCT
dpc-1075	99	26	,	,	PUNCT
dpc-1075	99	27	the	the	DET
dpc-1075	99	28	more	more	ADV
dpc-1075	99	29	active	active	ADJ
dpc-1075	99	30	form	form	NOUN
dpc-1075	99	31	of	of	ADP
dpc-1075	99	32	t.	t.	PROPN
dpc-1075	99	33	finasteride	finasteride	PROPN
dpc-1075	99	34	is	be	AUX
dpc-1075	99	35	research	research	NOUN
dpc-1075	100	1	|	|	ADV
dpc-1075	100	2	dermatol	dermatol	ADJ
dpc-1075	100	3	pract	pract	NOUN
dpc-1075	100	4	concept	concept	NOUN
dpc-1075	100	5	2020;10(2):e2020039	2020;10(2):e2020039	NUM
dpc-1075	100	6	5	5	NUM
dpc-1075	100	7	pausal	pausal	NOUN
dpc-1075	100	8	fphl	fphl	NOUN
dpc-1075	100	9	,	,	PUNCT
dpc-1075	100	10	showing	show	VERB
dpc-1075	100	11	higher	high	ADJ
dpc-1075	100	12	efficacy	efficacy	NOUN
dpc-1075	100	13	than	than	ADP
dpc-1075	100	14	topical	topical	ADJ
dpc-1075	100	15	formulation	formulation	NOUN
dpc-1075	100	16	containing	contain	VERB
dpc-1075	100	17	17α	17α	NOUN
dpc-1075	100	18	-	-	PUNCT
dpc-1075	100	19	estradiol	estradiol	PROPN
dpc-1075	100	20	0.05	0.05	NUM
dpc-1075	100	21	%	%	NOUN
dpc-1075	100	22	in	in	ADP
dpc-1075	100	23	combination	combination	NOUN
dpc-1075	100	24	with	with	ADP
dpc-1075	100	25	minoxidil	minoxidil	NOUN
dpc-1075	100	26	2	2	NUM
dpc-1075	100	27	%	%	NOUN
dpc-1075	100	28	and	and	CCONJ
dpc-1075	100	29	hydrocortisone	hydrocortisone	NOUN
dpc-1075	100	30	butyrate	butyrate	NOUN
dpc-1075	100	31	0.08	0.08	NUM
dpc-1075	100	32	%	%	NOUN
dpc-1075	100	33	,	,	PUNCT
dpc-1075	100	34	both	both	CCONJ
dpc-1075	100	35	at	at	ADP
dpc-1075	100	36	6	6	NUM
dpc-1075	100	37	-	-	PUNCT
dpc-1075	100	38	month	month	NOUN
dpc-1075	100	39	and	and	CCONJ
dpc-1075	100	40	12to	12to	ADJ
dpc-1075	100	41	18	18	NUM
dpc-1075	100	42	-	-	PUNCT
dpc-1075	100	43	month	month	NOUN
dpc-1075	100	44	follow	follow	NOUN
dpc-1075	100	45	-	-	PUNCT
dpc-1075	100	46	up	up	NOUN
dpc-1075	100	47	.	.	PUNCT
dpc-1075	101	1	references	reference	NOUN
dpc-1075	101	2	1	1	NUM
dpc-1075	101	3	.	.	PUNCT
dpc-1075	101	4	birch	birch	PROPN
dpc-1075	101	5	mp	mp	PROPN
dpc-1075	101	6	,	,	PUNCT
dpc-1075	101	7	messenger	messenger	PROPN
dpc-1075	101	8	jf	jf	PROPN
dpc-1075	101	9	,	,	PUNCT
dpc-1075	101	10	messenger	messenger	PROPN
dpc-1075	101	11	ag	ag	PROPN
dpc-1075	101	12	.	.	PROPN
dpc-1075	101	13	hair	hair	PROPN
dpc-1075	101	14	density	density	PROPN
dpc-1075	101	15	,	,	PUNCT
dpc-1075	101	16	hair	hair	NOUN
dpc-1075	101	17	diameter	diameter	NOUN
dpc-1075	101	18	and	and	CCONJ
dpc-1075	101	19	the	the	DET
dpc-1075	101	20	prevalence	prevalence	NOUN
dpc-1075	101	21	of	of	ADP
dpc-1075	101	22	female	female	ADJ
dpc-1075	101	23	pattern	pattern	NOUN
dpc-1075	101	24	hair	hair	NOUN
dpc-1075	101	25	loss	loss	NOUN
dpc-1075	101	26	.	.	PUNCT
dpc-1075	102	1	br	br	PROPN
dpc-1075	102	2	j	j	PROPN
dpc-1075	102	3	dermatol	dermatol	NOUN
dpc-1075	102	4	.	.	PUNCT
dpc-1075	103	1	2001;144(2):297	2001;144(2):297	NUM
dpc-1075	103	2	-	-	SYM
dpc-1075	103	3	304	304	NUM
dpc-1075	103	4	.	.	NOUN
dpc-1075	104	1	2	2	NUM
dpc-1075	104	2	.	.	X
dpc-1075	104	3	price	price	NOUN
dpc-1075	104	4	vh	vh	PROPN
dpc-1075	104	5	.	.	PUNCT
dpc-1075	105	1	androgenetic	androgenetic	ADJ
dpc-1075	105	2	alopecia	alopecia	NOUN
dpc-1075	105	3	in	in	ADP
dpc-1075	105	4	women	woman	NOUN
dpc-1075	105	5	.	.	PUNCT
dpc-1075	106	1	j	j	PROPN
dpc-1075	106	2	investig	investig	NOUN
dpc-1075	106	3	dermatol	dermatol	NOUN
dpc-1075	106	4	symp	symp	NOUN
dpc-1075	106	5	proc	proc	NOUN
dpc-1075	106	6	.	.	PUNCT
dpc-1075	107	1	2003;8(1):24	2003;8(1):24	NUM
dpc-1075	107	2	-	-	SYM
dpc-1075	107	3	27	27	NUM
dpc-1075	107	4	.	.	PUNCT
dpc-1075	108	1	3	3	X
dpc-1075	108	2	.	.	X
dpc-1075	109	1	olsen	olsen	PROPN
dpc-1075	109	2	ea	ea	PROPN
dpc-1075	109	3	.	.	PUNCT
dpc-1075	109	4	female	female	ADJ
dpc-1075	109	5	pattern	pattern	NOUN
dpc-1075	109	6	hair	hair	NOUN
dpc-1075	109	7	loss	loss	NOUN
dpc-1075	109	8	and	and	CCONJ
dpc-1075	109	9	its	its	PRON
dpc-1075	109	10	relationship	relationship	NOUN
dpc-1075	109	11	to	to	ADP
dpc-1075	109	12	permanent	permanent	ADJ
dpc-1075	109	13	/	/	SYM
dpc-1075	109	14	cicatricial	cicatricial	ADJ
dpc-1075	109	15	alopecia	alopecia	NOUN
dpc-1075	109	16	:	:	PUNCT
dpc-1075	109	17	a	a	DET
dpc-1075	109	18	new	new	ADJ
dpc-1075	109	19	perspective	perspective	NOUN
dpc-1075	109	20	.	.	PUNCT
dpc-1075	110	1	j	j	PROPN
dpc-1075	110	2	investig	investig	NOUN
dpc-1075	110	3	dermatol	dermatol	NOUN
dpc-1075	110	4	symp	symp	NOUN
dpc-1075	110	5	proc	proc	NOUN
dpc-1075	110	6	.	.	PUNCT
dpc-1075	111	1	2005;10(3);217221	2005;10(3);217221	NUM
dpc-1075	111	2	.	.	PUNCT
dpc-1075	112	1	4	4	X
dpc-1075	112	2	.	.	X
dpc-1075	112	3	messenger	messenger	PROPN
dpc-1075	112	4	ag	ag	PROPN
dpc-1075	112	5	.	.	PROPN
dpc-1075	112	6	hair	hair	NOUN
dpc-1075	112	7	through	through	ADP
dpc-1075	112	8	the	the	DET
dpc-1075	112	9	female	female	ADJ
dpc-1075	112	10	life	life	NOUN
dpc-1075	112	11	cycle	cycle	NOUN
dpc-1075	112	12	.	.	PUNCT
dpc-1075	113	1	br	br	PROPN
dpc-1075	113	2	j	j	PROPN
dpc-1075	113	3	dermatol	dermatol	NOUN
dpc-1075	113	4	.	.	PUNCT
dpc-1075	114	1	2011;165	2011;165	NUM
dpc-1075	114	2	(	(	PUNCT
dpc-1075	114	3	suppl	suppl	PROPN
dpc-1075	114	4	3):2	3):2	NUM
dpc-1075	114	5	-	-	SYM
dpc-1075	114	6	6	6	NUM
dpc-1075	114	7	.	.	NOUN
dpc-1075	114	8	5	5	NUM
dpc-1075	114	9	.	.	X
dpc-1075	114	10	cousen	cousen	PROPN
dpc-1075	114	11	p	p	NOUN
dpc-1075	114	12	,	,	PUNCT
dpc-1075	114	13	messenger	messenger	NOUN
dpc-1075	114	14	a.	a.	NOUN
dpc-1075	114	15	female	female	ADJ
dpc-1075	114	16	pattern	pattern	NOUN
dpc-1075	114	17	hair	hair	NOUN
dpc-1075	114	18	loss	loss	NOUN
dpc-1075	114	19	in	in	ADP
dpc-1075	114	20	complete	complete	ADJ
dpc-1075	114	21	androgen	androgen	NOUN
dpc-1075	114	22	insensitivity	insensitivity	NOUN
dpc-1075	114	23	syndrome	syndrome	NOUN
dpc-1075	114	24	.	.	PUNCT
dpc-1075	115	1	br	br	PROPN
dpc-1075	115	2	j	j	PROPN
dpc-1075	115	3	dermatol	dermatol	NOUN
dpc-1075	115	4	.	.	PUNCT
dpc-1075	116	1	2010;162(5):1135	2010;162(5):1135	NUM
dpc-1075	116	2	-	-	SYM
dpc-1075	116	3	1137	1137	NUM
dpc-1075	116	4	.	.	PUNCT
dpc-1075	117	1	6	6	NUM
dpc-1075	117	2	.	.	X
dpc-1075	117	3	rossi	rossi	PROPN
dpc-1075	117	4	a	a	PRON
dpc-1075	117	5	,	,	PUNCT
dpc-1075	117	6	anzalone	anzalone	PROPN
dpc-1075	117	7	a	a	NOUN
dpc-1075	117	8	,	,	PUNCT
dpc-1075	117	9	fortuna	fortuna	PROPN
dpc-1075	117	10	mc	mc	PROPN
dpc-1075	117	11	,	,	PUNCT
dpc-1075	117	12	et	et	PROPN
dpc-1075	117	13	al	al	PROPN
dpc-1075	117	14	.	.	PUNCT
dpc-1075	118	1	multi	multi	NOUN
dpc-1075	118	2	-	-	NOUN
dpc-1075	118	3	therapies	therapy	NOUN
dpc-1075	118	4	in	in	ADP
dpc-1075	118	5	androgenetic	androgenetic	ADJ
dpc-1075	118	6	alopecia	alopecia	NOUN
dpc-1075	118	7	:	:	PUNCT
dpc-1075	118	8	review	review	NOUN
dpc-1075	118	9	and	and	CCONJ
dpc-1075	118	10	clinical	clinical	ADJ
dpc-1075	118	11	experiences	experience	NOUN
dpc-1075	118	12	.	.	PUNCT
dpc-1075	119	1	dermatol	dermatol	NOUN
dpc-1075	119	2	ther	ther	ADV
dpc-1075	119	3	.	.	PUNCT
dpc-1075	120	1	2016;29(6):424	2016;29(6):424	NUM
dpc-1075	120	2	-	-	SYM
dpc-1075	120	3	432	432	NUM
dpc-1075	120	4	.	.	PUNCT
dpc-1075	121	1	7	7	X
dpc-1075	121	2	.	.	NUM
dpc-1075	121	3	iorizzo	iorizzo	VERB
dpc-1075	121	4	m	m	PROPN
dpc-1075	121	5	,	,	PUNCT
dpc-1075	121	6	vincenzi	vincenzi	PROPN
dpc-1075	121	7	c	c	PROPN
dpc-1075	121	8	,	,	PUNCT
dpc-1075	121	9	voudouris	voudouris	PROPN
dpc-1075	121	10	s	s	PROPN
dpc-1075	121	11	,	,	PUNCT
dpc-1075	121	12	piraccini	piraccini	PROPN
dpc-1075	121	13	bm	bm	PROPN
dpc-1075	121	14	,	,	PUNCT
dpc-1075	121	15	tosti	tosti	PROPN
dpc-1075	121	16	a.	a.	PROPN
dpc-1075	121	17	finasteride	finasteride	PROPN
dpc-1075	121	18	treatment	treatment	NOUN
dpc-1075	121	19	of	of	ADP
dpc-1075	121	20	female	female	ADJ
dpc-1075	121	21	pattern	pattern	NOUN
dpc-1075	121	22	hair	hair	NOUN
dpc-1075	121	23	loss	loss	NOUN
dpc-1075	121	24	.	.	PUNCT
dpc-1075	122	1	arch	arch	ADJ
dpc-1075	122	2	dermatol	dermatol	NOUN
dpc-1075	122	3	.	.	PUNCT
dpc-1075	123	1	2006;142(3):298	2006;142(3):298	NUM
dpc-1075	123	2	-	-	SYM
dpc-1075	123	3	302	302	NUM
dpc-1075	123	4	.	.	NOUN
dpc-1075	124	1	8	8	NUM
dpc-1075	124	2	.	.	X
dpc-1075	125	1	olszewska	olszewska	PROPN
dpc-1075	125	2	m	m	PROPN
dpc-1075	125	3	,	,	PUNCT
dpc-1075	125	4	rudnicka	rudnicka	PROPN
dpc-1075	125	5	l.	l.	PROPN
dpc-1075	125	6	effective	effective	ADJ
dpc-1075	125	7	treatment	treatment	NOUN
dpc-1075	125	8	of	of	ADP
dpc-1075	125	9	female	female	ADJ
dpc-1075	125	10	androgenic	androgenic	ADJ
dpc-1075	125	11	alopecia	alopecia	NOUN
dpc-1075	125	12	with	with	ADP
dpc-1075	125	13	dutasteride	dutasteride	PROPN
dpc-1075	125	14	.	.	PUNCT
dpc-1075	126	1	j	j	PROPN
dpc-1075	126	2	drugs	drug	NOUN
dpc-1075	126	3	dermatol	dermatol	NOUN
dpc-1075	126	4	.	.	PUNCT
dpc-1075	127	1	2005;4(5):637	2005;4(5):637	NUM
dpc-1075	127	2	-	-	SYM
dpc-1075	127	3	640	640	NUM
dpc-1075	127	4	.	.	PUNCT
dpc-1075	128	1	9	9	NUM
dpc-1075	128	2	.	.	X
dpc-1075	128	3	lee	lee	PROPN
dpc-1075	128	4	sw	sw	PROPN
dpc-1075	128	5	,	,	PUNCT
dpc-1075	128	6	juhasz	juhasz	PROPN
dpc-1075	128	7	m	m	PROPN
dpc-1075	128	8	,	,	PUNCT
dpc-1075	128	9	mobasher	mobasher	NOUN
dpc-1075	128	10	p	p	NOUN
dpc-1075	128	11	,	,	PUNCT
dpc-1075	128	12	ekelem	ekelem	NOUN
dpc-1075	128	13	c	c	NOUN
dpc-1075	128	14	,	,	PUNCT
dpc-1075	128	15	mesinkovska	mesinkovska	PROPN
dpc-1075	128	16	na	na	PROPN
dpc-1075	128	17	.	.	PUNCT
dpc-1075	129	1	a	a	DET
dpc-1075	129	2	systematic	systematic	ADJ
dpc-1075	129	3	review	review	NOUN
dpc-1075	129	4	of	of	ADP
dpc-1075	129	5	topical	topical	ADJ
dpc-1075	129	6	finasteride	finasteride	NOUN
dpc-1075	129	7	in	in	ADP
dpc-1075	129	8	the	the	DET
dpc-1075	129	9	treatment	treatment	NOUN
dpc-1075	129	10	of	of	ADP
dpc-1075	129	11	androgenetic	androgenetic	ADJ
dpc-1075	129	12	alopecia	alopecia	NOUN
dpc-1075	129	13	in	in	ADP
dpc-1075	129	14	men	man	NOUN
dpc-1075	129	15	and	and	CCONJ
dpc-1075	129	16	women	woman	NOUN
dpc-1075	129	17	.	.	PUNCT
dpc-1075	130	1	j	j	PROPN
dpc-1075	130	2	drugs	drug	NOUN
dpc-1075	130	3	dermatol	dermatol	NOUN
dpc-1075	130	4	.	.	PUNCT
dpc-1075	131	1	2018;17(4):457463	2018;17(4):457463	NUM
dpc-1075	131	2	.	.	PUNCT
dpc-1075	132	1	10	10	NUM
dpc-1075	132	2	.	.	PUNCT
dpc-1075	133	1	choe	choe	PROPN
dpc-1075	133	2	sj	sj	PROPN
dpc-1075	133	3	,	,	PUNCT
dpc-1075	133	4	lee	lee	PROPN
dpc-1075	133	5	s	s	PROPN
dpc-1075	133	6	,	,	PUNCT
dpc-1075	133	7	choi	choi	PROPN
dpc-1075	133	8	j	j	PROPN
dpc-1075	133	9	,	,	PUNCT
dpc-1075	133	10	lee	lee	PROPN
dpc-1075	133	11	ws	ws	PROPN
dpc-1075	133	12	.	.	PUNCT
dpc-1075	134	1	therapeutic	therapeutic	ADJ
dpc-1075	134	2	efficacy	efficacy	NOUN
dpc-1075	134	3	of	of	ADP
dpc-1075	134	4	a	a	DET
dpc-1075	134	5	combination	combination	NOUN
dpc-1075	134	6	therapy	therapy	NOUN
dpc-1075	134	7	of	of	ADP
dpc-1075	134	8	topical	topical	ADJ
dpc-1075	134	9	17alpha	17alpha	PROPN
dpc-1075	134	10	-	-	PUNCT
dpc-1075	134	11	estradiol	estradiol	PROPN
dpc-1075	134	12	and	and	CCONJ
dpc-1075	134	13	topical	topical	ADJ
dpc-1075	134	14	minoxidil	minoxidil	NOUN
dpc-1075	134	15	on	on	ADP
dpc-1075	134	16	female	female	ADJ
dpc-1075	134	17	pattern	pattern	NOUN
dpc-1075	134	18	hair	hair	NOUN
dpc-1075	134	19	loss	loss	NOUN
dpc-1075	134	20	:	:	PUNCT
dpc-1075	134	21	a	a	DET
dpc-1075	134	22	noncomparative	noncomparative	ADJ
dpc-1075	134	23	,	,	PUNCT
dpc-1075	134	24	retrospective	retrospective	ADJ
dpc-1075	134	25	evaluation	evaluation	NOUN
dpc-1075	134	26	.	.	PUNCT
dpc-1075	135	1	ann	ann	PROPN
dpc-1075	135	2	dermatol	dermatol	NOUN
dpc-1075	135	3	.	.	PUNCT
dpc-1075	136	1	2017;29(3):276282	2017;29(3):276282	NUM
dpc-1075	136	2	.	.	PUNCT
dpc-1075	137	1	11	11	NUM
dpc-1075	137	2	.	.	PUNCT
dpc-1075	138	1	moos	moos	PROPN
dpc-1075	138	2	wh	wh	PROPN
dpc-1075	138	3	,	,	PUNCT
dpc-1075	138	4	dykens	dyken	VERB
dpc-1075	138	5	ja	ja	PROPN
dpc-1075	138	6	,	,	PUNCT
dpc-1075	138	7	howell	howell	PROPN
dpc-1075	138	8	n.	n.	PROPN
dpc-1075	138	9	17α	17α	NOUN
dpc-1075	138	10	-	-	PUNCT
dpc-1075	138	11	estradiol	estradiol	PROPN
dpc-1075	138	12	:	:	PUNCT
dpc-1075	138	13	a	a	DET
dpc-1075	138	14	less	less	ADV
dpc-1075	138	15	-	-	PUNCT
dpc-1075	138	16	feminizing	feminizing	NOUN
dpc-1075	138	17	estrogen	estrogen	NOUN
dpc-1075	138	18	.	.	PUNCT
dpc-1075	139	1	drug	drug	NOUN
dpc-1075	139	2	dev	dev	PROPN
dpc-1075	139	3	res	re	NOUN
dpc-1075	139	4	.	.	PUNCT
dpc-1075	140	1	2008;69(4):177	2008;69(4):177	NUM
dpc-1075	140	2	-	-	SYM
dpc-1075	140	3	184	184	NUM
dpc-1075	140	4	.	.	NOUN
dpc-1075	140	5	12	12	NUM
dpc-1075	140	6	.	.	PUNCT
dpc-1075	141	1	rossi	rossi	PROPN
dpc-1075	141	2	a	a	PRON
dpc-1075	141	3	,	,	PUNCT
dpc-1075	141	4	iorio	iorio	NOUN
dpc-1075	141	5	a	a	PRON
dpc-1075	141	6	,	,	PUNCT
dpc-1075	141	7	scarnò	scarnò	PROPN
dpc-1075	141	8	m	m	PROPN
dpc-1075	141	9	,	,	PUNCT
dpc-1075	141	10	et	et	PROPN
dpc-1075	141	11	al	al	PROPN
dpc-1075	141	12	.	.	PUNCT
dpc-1075	141	13	use	use	NOUN
dpc-1075	141	14	of	of	ADP
dpc-1075	141	15	topical	topical	ADJ
dpc-1075	141	16	minoxidil	minoxidil	NOUN
dpc-1075	141	17	,	,	PUNCT
dpc-1075	141	18	17α	17α	NOUN
dpc-1075	141	19	-	-	PUNCT
dpc-1075	141	20	estradiol	estradiol	PROPN
dpc-1075	141	21	and	and	CCONJ
dpc-1075	141	22	hydrocortisone	hydrocortisone	PROPN
dpc-1075	141	23	butyrate	butyrate	NOUN
dpc-1075	141	24	in	in	ADP
dpc-1075	141	25	frontal	frontal	ADJ
dpc-1075	141	26	fibrosing	fibrose	VERB
dpc-1075	141	27	parable	parable	ADJ
dpc-1075	141	28	with	with	ADP
dpc-1075	141	29	the	the	DET
dpc-1075	141	30	improvement	improvement	NOUN
dpc-1075	141	31	of	of	ADP
dpc-1075	141	32	17α	17α	NOUN
dpc-1075	141	33	-	-	PUNCT
dpc-1075	141	34	estradiol	estradiol	NOUN
dpc-1075	141	35	-	-	PUNCT
dpc-1075	141	36	treated	treat	VERB
dpc-1075	141	37	patients	patient	NOUN
dpc-1075	141	38	at	at	ADP
dpc-1075	141	39	12	12	NUM
dpc-1075	141	40	-	-	SYM
dpc-1075	141	41	18	18	NUM
dpc-1075	141	42	months	month	NOUN
dpc-1075	141	43	.	.	PUNCT
dpc-1075	142	1	indeed	indeed	ADV
dpc-1075	142	2	,	,	PUNCT
dpc-1075	142	3	topical	topical	ADJ
dpc-1075	142	4	17α	17α	NOUN
dpc-1075	142	5	-	-	PUNCT
dpc-1075	142	6	estradiol	estradiol	PROPN
dpc-1075	142	7	therapy	therapy	NOUN
dpc-1075	142	8	required	require	VERB
dpc-1075	142	9	more	more	ADJ
dpc-1075	142	10	time	time	NOUN
dpc-1075	142	11	to	to	PART
dpc-1075	142	12	achieve	achieve	VERB
dpc-1075	142	13	the	the	DET
dpc-1075	142	14	same	same	ADJ
dpc-1075	142	15	results	result	NOUN
dpc-1075	142	16	of	of	ADP
dpc-1075	142	17	finasteride	finasteride	ADJ
dpc-1075	142	18	.	.	PUNCT
dpc-1075	143	1	the	the	DET
dpc-1075	143	2	greater	great	ADJ
dpc-1075	143	3	rapidity	rapidity	NOUN
dpc-1075	143	4	and	and	CCONJ
dpc-1075	143	5	higher	high	ADJ
dpc-1075	143	6	efficacy	efficacy	NOUN
dpc-1075	143	7	of	of	ADP
dpc-1075	143	8	finasteride	finasteride	NOUN
dpc-1075	143	9	could	could	AUX
dpc-1075	143	10	be	be	AUX
dpc-1075	143	11	explained	explain	VERB
dpc-1075	143	12	with	with	ADP
dpc-1075	143	13	2	2	NUM
dpc-1075	143	14	observations	observation	NOUN
dpc-1075	143	15	.	.	PUNCT
dpc-1075	144	1	first	first	ADV
dpc-1075	144	2	,	,	PUNCT
dpc-1075	144	3	finasteride	finasteride	ADJ
dpc-1075	144	4	induces	induce	VERB
dpc-1075	144	5	a	a	DET
dpc-1075	144	6	stronger	strong	ADJ
dpc-1075	144	7	block	block	NOUN
dpc-1075	144	8	of	of	ADP
dpc-1075	144	9	type	type	NOUN
dpc-1075	144	10	ii	ii	PROPN
dpc-1075	144	11	5α	5α	ADJ
dpc-1075	144	12	-	-	PUNCT
dpc-1075	144	13	reductase	reductase	NOUN
dpc-1075	144	14	,	,	PUNCT
dpc-1075	144	15	if	if	SCONJ
dpc-1075	144	16	compared	compare	VERB
dpc-1075	144	17	with	with	ADP
dpc-1075	144	18	the	the	DET
dpc-1075	144	19	weak	weak	ADJ
dpc-1075	144	20	inhibition	inhibition	NOUN
dpc-1075	144	21	of	of	ADP
dpc-1075	144	22	17α	17α	NOUN
dpc-1075	144	23	-	-	PUNCT
dpc-1075	144	24	estradiol	estradiol	NOUN
dpc-1075	144	25	.	.	PUNCT
dpc-1075	145	1	moreover	moreover	ADV
dpc-1075	145	2	,	,	PUNCT
dpc-1075	145	3	the	the	DET
dpc-1075	145	4	inhibition	inhibition	NOUN
dpc-1075	145	5	of	of	ADP
dpc-1075	145	6	type	type	NOUN
dpc-1075	145	7	ii	ii	PROPN
dpc-1075	145	8	5α	5α	ADJ
dpc-1075	145	9	-	-	PUNCT
dpc-1075	145	10	reductase	reductase	NOUN
dpc-1075	145	11	induced	induce	VERB
dpc-1075	145	12	by	by	ADP
dpc-1075	145	13	finasteride	finasteride	ADJ
dpc-1075	145	14	could	could	AUX
dpc-1075	145	15	cause	cause	VERB
dpc-1075	145	16	a	a	DET
dpc-1075	145	17	t	t	NOUN
dpc-1075	145	18	escape	escape	NOUN
dpc-1075	145	19	,	,	PUNCT
dpc-1075	145	20	which	which	PRON
dpc-1075	145	21	in	in	ADP
dpc-1075	145	22	turn	turn	NOUN
dpc-1075	145	23	stimulates	stimulate	VERB
dpc-1075	145	24	the	the	DET
dpc-1075	145	25	aromatases	aromatase	NOUN
dpc-1075	145	26	,	,	PUNCT
dpc-1075	145	27	increasing	increase	VERB
dpc-1075	145	28	estradiol	estradiol	PROPN
dpc-1075	145	29	conversion	conversion	NOUN
dpc-1075	145	30	and	and	CCONJ
dpc-1075	145	31	guaranteeing	guarantee	VERB
dpc-1075	145	32	an	an	DET
dpc-1075	145	33	adjunctive	adjunctive	ADJ
dpc-1075	145	34	activity	activity	NOUN
dpc-1075	145	35	similar	similar	ADJ
dpc-1075	145	36	to	to	ADP
dpc-1075	145	37	that	that	PRON
dpc-1075	145	38	of	of	ADP
dpc-1075	145	39	17α	17α	NOUN
dpc-1075	145	40	-	-	PUNCT
dpc-1075	145	41	estradiol	estradiol	NOUN
dpc-1075	145	42	.	.	PUNCT
dpc-1075	146	1	as	as	SCONJ
dpc-1075	146	2	we	we	PRON
dpc-1075	146	3	have	have	AUX
dpc-1075	146	4	shown	show	VERB
dpc-1075	146	5	,	,	PUNCT
dpc-1075	146	6	both	both	DET
dpc-1075	146	7	therapies	therapy	NOUN
dpc-1075	146	8	produced	produce	VERB
dpc-1075	146	9	an	an	DET
dpc-1075	146	10	improvement	improvement	NOUN
dpc-1075	146	11	that	that	PRON
dpc-1075	146	12	was	be	AUX
dpc-1075	146	13	already	already	ADV
dpc-1075	146	14	visible	visible	ADJ
dpc-1075	146	15	at	at	ADP
dpc-1075	146	16	6	6	NUM
dpc-1075	146	17	months	month	NOUN
dpc-1075	146	18	and	and	CCONJ
dpc-1075	146	19	especially	especially	ADV
dpc-1075	146	20	after	after	ADP
dpc-1075	146	21	12	12	NUM
dpc-1075	146	22	-	-	SYM
dpc-1075	146	23	18	18	NUM
dpc-1075	146	24	months	month	NOUN
dpc-1075	146	25	.	.	PUNCT
dpc-1075	147	1	indeed	indeed	ADV
dpc-1075	147	2	,	,	PUNCT
dpc-1075	147	3	the	the	DET
dpc-1075	147	4	treatment	treatment	NOUN
dpc-1075	147	5	should	should	AUX
dpc-1075	147	6	be	be	AUX
dpc-1075	147	7	always	always	ADV
dpc-1075	147	8	continued	continue	VERB
dpc-1075	147	9	for	for	ADP
dpc-1075	147	10	long	long	ADJ
dpc-1075	147	11	periods	period	NOUN
dpc-1075	147	12	to	to	PART
dpc-1075	147	13	achieve	achieve	VERB
dpc-1075	147	14	better	well	ADJ
dpc-1075	147	15	results	result	NOUN
dpc-1075	147	16	.	.	PUNCT
dpc-1075	148	1	concerning	concern	VERB
dpc-1075	148	2	topical	topical	ADJ
dpc-1075	148	3	finasteride	finasteride	ADJ
dpc-1075	148	4	’s	’s	PART
dpc-1075	148	5	side	side	NOUN
dpc-1075	148	6	effects	effect	NOUN
dpc-1075	148	7	,	,	PUNCT
dpc-1075	148	8	a	a	DET
dpc-1075	148	9	systemic	systemic	ADJ
dpc-1075	148	10	absorption	absorption	NOUN
dpc-1075	148	11	is	be	AUX
dpc-1075	148	12	possible	possible	ADJ
dpc-1075	148	13	,	,	PUNCT
dpc-1075	148	14	as	as	SCONJ
dpc-1075	148	15	described	describe	VERB
dpc-1075	148	16	by	by	ADP
dpc-1075	148	17	caserini	caserini	NOUN
dpc-1075	148	18	et	et	PROPN
dpc-1075	148	19	al	al	PROPN
dpc-1075	149	1	[	[	X
dpc-1075	149	2	22	22	NUM
dpc-1075	149	3	]	]	PUNCT
dpc-1075	149	4	.	.	PUNCT
dpc-1075	150	1	also	also	ADV
dpc-1075	150	2	,	,	PUNCT
dpc-1075	150	3	suchonwanit	suchonwanit	PROPN
dpc-1075	150	4	et	et	PROPN
dpc-1075	150	5	al	al	PROPN
dpc-1075	150	6	demonstrated	demonstrate	VERB
dpc-1075	150	7	a	a	DET
dpc-1075	150	8	lower	low	ADJ
dpc-1075	150	9	serum	serum	NOUN
dpc-1075	150	10	level	level	NOUN
dpc-1075	150	11	of	of	ADP
dpc-1075	150	12	dth	dth	NOUN
dpc-1075	150	13	in	in	ADP
dpc-1075	150	14	postmenopausal	postmenopausal	ADJ
dpc-1075	150	15	women	woman	NOUN
dpc-1075	150	16	treated	treat	VERB
dpc-1075	150	17	with	with	ADP
dpc-1075	150	18	it	it	PRON
dpc-1075	150	19	.	.	PUNCT
dpc-1075	151	1	indeed	indeed	ADV
dpc-1075	151	2	,	,	PUNCT
dpc-1075	151	3	topical	topical	ADJ
dpc-1075	151	4	finasteride	finasteride	NOUN
dpc-1075	151	5	should	should	AUX
dpc-1075	151	6	be	be	AUX
dpc-1075	151	7	used	use	VERB
dpc-1075	151	8	only	only	ADV
dpc-1075	151	9	in	in	ADP
dpc-1075	151	10	postmenopausal	postmenopausal	ADJ
dpc-1075	151	11	women	woman	NOUN
dpc-1075	151	12	.	.	PUNCT
dpc-1075	152	1	a	a	DET
dpc-1075	152	2	limit	limit	NOUN
dpc-1075	152	3	of	of	ADP
dpc-1075	152	4	our	our	PRON
dpc-1075	152	5	study	study	NOUN
dpc-1075	152	6	was	be	AUX
dpc-1075	152	7	the	the	DET
dpc-1075	152	8	absence	absence	NOUN
dpc-1075	152	9	of	of	ADP
dpc-1075	152	10	a	a	DET
dpc-1075	152	11	control	control	NOUN
dpc-1075	152	12	group	group	NOUN
dpc-1075	152	13	.	.	PUNCT
dpc-1075	153	1	another	another	DET
dpc-1075	153	2	limit	limit	NOUN
dpc-1075	153	3	was	be	AUX
dpc-1075	153	4	the	the	DET
dpc-1075	153	5	lack	lack	NOUN
dpc-1075	153	6	of	of	ADP
dpc-1075	153	7	hair	hair	NOUN
dpc-1075	153	8	analysis	analysis	NOUN
dpc-1075	153	9	besides	besides	SCONJ
dpc-1075	153	10	global	global	ADJ
dpc-1075	153	11	photographs	photograph	NOUN
dpc-1075	153	12	.	.	PUNCT
dpc-1075	154	1	we	we	PRON
dpc-1075	154	2	did	do	AUX
dpc-1075	154	3	not	not	PART
dpc-1075	154	4	perform	perform	VERB
dpc-1075	154	5	a	a	DET
dpc-1075	154	6	computerized	computerized	ADJ
dpc-1075	154	7	quantitative	quantitative	ADJ
dpc-1075	154	8	measure	measure	NOUN
dpc-1075	154	9	(	(	PUNCT
dpc-1075	154	10	trichoscale	trichoscale	NOUN
dpc-1075	154	11	)	)	PUNCT
dpc-1075	154	12	because	because	SCONJ
dpc-1075	154	13	most	most	ADJ
dpc-1075	154	14	of	of	ADP
dpc-1075	154	15	our	our	PRON
dpc-1075	154	16	female	female	ADJ
dpc-1075	154	17	patients	patient	NOUN
dpc-1075	154	18	refused	refuse	VERB
dpc-1075	154	19	to	to	PART
dpc-1075	154	20	realize	realize	VERB
dpc-1075	154	21	a	a	DET
dpc-1075	154	22	circumscribed	circumscribed	ADJ
dpc-1075	154	23	shaved	shave	VERB
dpc-1075	154	24	area	area	NOUN
dpc-1075	154	25	on	on	ADP
dpc-1075	154	26	the	the	DET
dpc-1075	154	27	scalp	scalp	NOUN
dpc-1075	154	28	with	with	ADP
dpc-1075	154	29	tattoos	tattoo	NOUN
dpc-1075	154	30	.	.	PUNCT
dpc-1075	155	1	another	another	DET
dpc-1075	155	2	limit	limit	NOUN
dpc-1075	155	3	was	be	AUX
dpc-1075	155	4	the	the	DET
dpc-1075	155	5	subjective	subjective	ADJ
dpc-1075	155	6	assessment	assessment	NOUN
dpc-1075	155	7	of	of	ADP
dpc-1075	155	8	patients	patient	NOUN
dpc-1075	155	9	,	,	PUNCT
dpc-1075	155	10	even	even	ADV
dpc-1075	155	11	though	though	SCONJ
dpc-1075	155	12	all	all	DET
dpc-1075	155	13	observers	observer	NOUN
dpc-1075	155	14	were	be	AUX
dpc-1075	155	15	blind	blind	ADJ
dpc-1075	155	16	to	to	ADP
dpc-1075	155	17	the	the	DET
dpc-1075	155	18	therapies	therapy	NOUN
dpc-1075	155	19	.	.	PUNCT
dpc-1075	156	1	regardless	regardless	ADV
dpc-1075	156	2	,	,	PUNCT
dpc-1075	156	3	the	the	DET
dpc-1075	156	4	use	use	NOUN
dpc-1075	156	5	of	of	ADP
dpc-1075	156	6	the	the	DET
dpc-1075	156	7	7	7	NUM
dpc-1075	156	8	-	-	PUNCT
dpc-1075	156	9	point	point	NOUN
dpc-1075	156	10	scale	scale	NOUN
dpc-1075	156	11	allowed	allow	VERB
dpc-1075	156	12	us	we	PRON
dpc-1075	156	13	to	to	PART
dpc-1075	156	14	perform	perform	VERB
dpc-1075	156	15	a	a	DET
dpc-1075	156	16	valid	valid	ADJ
dpc-1075	156	17	statistical	statistical	ADJ
dpc-1075	156	18	analysis	analysis	NOUN
dpc-1075	156	19	.	.	PUNCT
dpc-1075	157	1	conclusions	conclusion	NOUN
dpc-1075	157	2	based	base	VERB
dpc-1075	157	3	on	on	ADP
dpc-1075	157	4	our	our	PRON
dpc-1075	157	5	results	result	NOUN
dpc-1075	157	6	,	,	PUNCT
dpc-1075	157	7	topical	topical	ADJ
dpc-1075	157	8	finasteride	finasteride	ADJ
dpc-1075	157	9	0.5	0.5	NUM
dpc-1075	157	10	%	%	NOUN
dpc-1075	157	11	in	in	ADP
dpc-1075	157	12	combination	combination	NOUN
dpc-1075	157	13	with	with	ADP
dpc-1075	157	14	minoxidil	minoxidil	NOUN
dpc-1075	157	15	2	2	NUM
dpc-1075	157	16	%	%	NOUN
dpc-1075	157	17	and	and	CCONJ
dpc-1075	157	18	hydrocortisone	hydrocortisone	NOUN
dpc-1075	157	19	butyrate	butyrate	NOUN
dpc-1075	157	20	0.08	0.08	NUM
dpc-1075	157	21	%	%	NOUN
dpc-1075	157	22	could	could	AUX
dpc-1075	157	23	represent	represent	VERB
dpc-1075	157	24	a	a	DET
dpc-1075	157	25	valid	valid	ADJ
dpc-1075	157	26	therapeutic	therapeutic	ADJ
dpc-1075	157	27	option	option	NOUN
dpc-1075	157	28	for	for	ADP
dpc-1075	157	29	the	the	DET
dpc-1075	157	30	treatment	treatment	NOUN
dpc-1075	157	31	of	of	ADP
dpc-1075	157	32	postmenonot	postmenonot	PROPN
dpc-1075	157	33	fda	fda	PROPN
dpc-1075	157	34	-	-	PUNCT
dpc-1075	157	35	approved	approve	VERB
dpc-1075	157	36	for	for	ADP
dpc-1075	157	37	the	the	DET
dpc-1075	157	38	female	female	ADJ
dpc-1075	157	39	population	population	NOUN
dpc-1075	157	40	.	.	PUNCT
dpc-1075	158	1	studies	study	NOUN
dpc-1075	158	2	are	be	AUX
dpc-1075	158	3	limited	limited	ADJ
dpc-1075	158	4	and	and	CCONJ
dpc-1075	158	5	variable	variable	ADJ
dpc-1075	158	6	dosages	dosage	NOUN
dpc-1075	158	7	of	of	ADP
dpc-1075	158	8	oral	oral	ADJ
dpc-1075	158	9	finasteride	finasteride	NOUN
dpc-1075	158	10	have	have	AUX
dpc-1075	158	11	been	be	AUX
dpc-1075	158	12	tested	test	VERB
dpc-1075	158	13	in	in	ADP
dpc-1075	158	14	female	female	ADJ
dpc-1075	158	15	patients	patient	NOUN
dpc-1075	158	16	(	(	PUNCT
dpc-1075	158	17	1	1	NUM
dpc-1075	158	18	-	-	SYM
dpc-1075	158	19	5	5	NUM
dpc-1075	158	20	mg	mg	PROPN
dpc-1075	158	21	/	/	SYM
dpc-1075	158	22	day	day	NOUN
dpc-1075	158	23	)	)	PUNCT
dpc-1075	158	24	with	with	ADP
dpc-1075	158	25	conflicting	conflicting	ADJ
dpc-1075	158	26	results	result	NOUN
dpc-1075	158	27	[	[	X
dpc-1075	158	28	19	19	NUM
dpc-1075	158	29	]	]	PUNCT
dpc-1075	158	30	.	.	PUNCT
dpc-1075	159	1	therefore	therefore	ADV
dpc-1075	159	2	,	,	PUNCT
dpc-1075	159	3	further	far	ADV
dpc-1075	159	4	randomized	randomized	ADJ
dpc-1075	159	5	studies	study	NOUN
dpc-1075	159	6	are	be	AUX
dpc-1075	159	7	still	still	ADV
dpc-1075	159	8	necessary	necessary	ADJ
dpc-1075	159	9	to	to	PART
dpc-1075	159	10	determine	determine	VERB
dpc-1075	159	11	the	the	DET
dpc-1075	159	12	efficacy	efficacy	NOUN
dpc-1075	159	13	and	and	CCONJ
dpc-1075	159	14	optimal	optimal	ADJ
dpc-1075	159	15	dosage	dosage	NOUN
dpc-1075	159	16	of	of	ADP
dpc-1075	159	17	this	this	DET
dpc-1075	159	18	drug	drug	NOUN
dpc-1075	159	19	.	.	PUNCT
dpc-1075	160	1	moreover	moreover	ADV
dpc-1075	160	2	,	,	PUNCT
dpc-1075	160	3	systemic	systemic	ADJ
dpc-1075	160	4	finasteride	finasteride	NOUN
dpc-1075	160	5	is	be	AUX
dpc-1075	160	6	associated	associate	VERB
dpc-1075	160	7	with	with	ADP
dpc-1075	160	8	several	several	ADJ
dpc-1075	160	9	side	side	NOUN
dpc-1075	160	10	effects	effect	NOUN
dpc-1075	160	11	,	,	PUNCT
dpc-1075	160	12	especially	especially	ADV
dpc-1075	160	13	sexual	sexual	ADJ
dpc-1075	160	14	alterations	alteration	NOUN
dpc-1075	160	15	,	,	PUNCT
dpc-1075	160	16	and	and	CCONJ
dpc-1075	160	17	its	its	PRON
dpc-1075	160	18	assumption	assumption	NOUN
dpc-1075	160	19	is	be	AUX
dpc-1075	160	20	contraindicated	contraindicate	VERB
dpc-1075	160	21	during	during	ADP
dpc-1075	160	22	pregnancy	pregnancy	NOUN
dpc-1075	160	23	and	and	CCONJ
dpc-1075	160	24	breast	breast	NOUN
dpc-1075	160	25	-	-	PUNCT
dpc-1075	160	26	feeding	feeding	NOUN
dpc-1075	160	27	because	because	SCONJ
dpc-1075	160	28	of	of	ADP
dpc-1075	160	29	the	the	DET
dpc-1075	160	30	risk	risk	NOUN
dpc-1075	160	31	of	of	ADP
dpc-1075	160	32	feminization	feminization	NOUN
dpc-1075	160	33	of	of	ADP
dpc-1075	160	34	the	the	DET
dpc-1075	160	35	male	male	ADJ
dpc-1075	160	36	fetus	fetus	NOUN
dpc-1075	161	1	[	[	X
dpc-1075	161	2	18	18	NUM
dpc-1075	161	3	]	]	PUNCT
dpc-1075	161	4	.	.	PUNCT
dpc-1075	162	1	with	with	ADP
dpc-1075	162	2	the	the	DET
dpc-1075	162	3	aim	aim	NOUN
dpc-1075	162	4	of	of	ADP
dpc-1075	162	5	reducing	reduce	VERB
dpc-1075	162	6	oral	oral	ADJ
dpc-1075	162	7	finasteride	finasteride	ADJ
dpc-1075	162	8	side	side	NOUN
dpc-1075	162	9	effects	effect	NOUN
dpc-1075	162	10	,	,	PUNCT
dpc-1075	162	11	a	a	DET
dpc-1075	162	12	topical	topical	ADJ
dpc-1075	162	13	formulation	formulation	NOUN
dpc-1075	162	14	of	of	ADP
dpc-1075	162	15	this	this	DET
dpc-1075	162	16	drug	drug	NOUN
dpc-1075	162	17	was	be	AUX
dpc-1075	162	18	introduced	introduce	VERB
dpc-1075	162	19	years	year	NOUN
dpc-1075	162	20	ago	ago	ADV
dpc-1075	162	21	,	,	PUNCT
dpc-1075	162	22	with	with	ADP
dpc-1075	162	23	promising	promising	ADJ
dpc-1075	162	24	results	result	NOUN
dpc-1075	162	25	in	in	ADP
dpc-1075	162	26	male	male	ADJ
dpc-1075	162	27	patients	patient	NOUN
dpc-1075	162	28	.	.	PUNCT
dpc-1075	163	1	recently	recently	ADV
dpc-1075	163	2	,	,	PUNCT
dpc-1075	163	3	suchonwanit	suchonwanit	NOUN
dpc-1075	163	4	et	et	NOUN
dpc-1075	163	5	al	al	PROPN
dpc-1075	164	1	[	[	X
dpc-1075	164	2	20	20	NUM
dpc-1075	164	3	]	]	PUNCT
dpc-1075	164	4	studied	study	VERB
dpc-1075	164	5	and	and	CCONJ
dpc-1075	164	6	compared	compare	VERB
dpc-1075	164	7	for	for	ADP
dpc-1075	164	8	the	the	DET
dpc-1075	164	9	first	first	ADJ
dpc-1075	164	10	time	time	NOUN
dpc-1075	164	11	the	the	DET
dpc-1075	164	12	efficacy	efficacy	NOUN
dpc-1075	164	13	of	of	ADP
dpc-1075	164	14	topical	topical	ADJ
dpc-1075	164	15	0.25	0.25	NUM
dpc-1075	164	16	%	%	NOUN
dpc-1075	164	17	finasteride	finasteride	ADV
dpc-1075	164	18	combined	combine	VERB
dpc-1075	164	19	with	with	ADP
dpc-1075	164	20	3	3	NUM
dpc-1075	164	21	%	%	NOUN
dpc-1075	164	22	minoxidil	minoxidil	ADJ
dpc-1075	164	23	solution	solution	NOUN
dpc-1075	164	24	and	and	CCONJ
dpc-1075	164	25	3	3	NUM
dpc-1075	164	26	%	%	NOUN
dpc-1075	164	27	minoxidil	minoxidil	ADJ
dpc-1075	164	28	solution	solution	NOUN
dpc-1075	164	29	as	as	ADP
dpc-1075	164	30	monotherapy	monotherapy	NOUN
dpc-1075	164	31	in	in	ADP
dpc-1075	164	32	30	30	NUM
dpc-1075	164	33	fphl	fphl	PROPN
dpc-1075	164	34	postmenopausal	postmenopausal	ADJ
dpc-1075	164	35	patients	patient	NOUN
dpc-1075	164	36	.	.	PUNCT
dpc-1075	165	1	in	in	ADP
dpc-1075	165	2	their	their	PRON
dpc-1075	165	3	work	work	NOUN
dpc-1075	165	4	,	,	PUNCT
dpc-1075	165	5	the	the	DET
dpc-1075	165	6	finasteride/	finasteride/	NUM
dpc-1075	165	7	minoxidil	minoxidil	NOUN
dpc-1075	165	8	solution	solution	NOUN
dpc-1075	165	9	was	be	AUX
dpc-1075	165	10	significantly	significantly	ADV
dpc-1075	165	11	superior	superior	ADJ
dpc-1075	165	12	to	to	PART
dpc-1075	165	13	minoxidil	minoxidil	VERB
dpc-1075	165	14	in	in	ADP
dpc-1075	165	15	improvement	improvement	NOUN
dpc-1075	165	16	of	of	ADP
dpc-1075	165	17	hair	hair	NOUN
dpc-1075	165	18	diameter	diameter	NOUN
dpc-1075	165	19	.	.	PUNCT
dpc-1075	166	1	17α	17α	PROPN
dpc-1075	166	2	-	-	PUNCT
dpc-1075	166	3	estradiol	estradiol	PROPN
dpc-1075	166	4	solutions	solution	NOUN
dpc-1075	166	5	represent	represent	VERB
dpc-1075	166	6	another	another	DET
dpc-1075	166	7	therapeutic	therapeutic	ADJ
dpc-1075	166	8	option	option	NOUN
dpc-1075	166	9	for	for	ADP
dpc-1075	166	10	fphl	fphl	NOUN
dpc-1075	166	11	.	.	PUNCT
dpc-1075	167	1	this	this	PRON
dpc-1075	167	2	is	be	AUX
dpc-1075	167	3	a	a	DET
dpc-1075	167	4	stereoisomer	stereoisomer	NOUN
dpc-1075	167	5	of	of	ADP
dpc-1075	167	6	the	the	DET
dpc-1075	167	7	female	female	ADJ
dpc-1075	167	8	hormone	hormone	NOUN
dpc-1075	167	9	17β	17β	NUM
dpc-1075	167	10	-	-	PUNCT
dpc-1075	167	11	estradiol	estradiol	PROPN
dpc-1075	167	12	,	,	PUNCT
dpc-1075	167	13	which	which	PRON
dpc-1075	167	14	weakly	weakly	ADV
dpc-1075	167	15	inhibits	inhibit	VERB
dpc-1075	167	16	5α	5α	ADJ
dpc-1075	167	17	-	-	PUNCT
dpc-1075	167	18	reductase	reductase	NOUN
dpc-1075	167	19	.	.	PUNCT
dpc-1075	168	1	furthermore	furthermore	ADV
dpc-1075	168	2	,	,	PUNCT
dpc-1075	168	3	it	it	PRON
dpc-1075	168	4	suppresses	suppress	VERB
dpc-1075	168	5	the	the	DET
dpc-1075	168	6	17β	17β	NUM
dpc-1075	168	7	-	-	PUNCT
dpc-1075	168	8	dehydrogenase	dehydrogenase	NOUN
dpc-1075	168	9	,	,	PUNCT
dpc-1075	168	10	causing	cause	VERB
dpc-1075	168	11	a	a	DET
dpc-1075	168	12	reductive	reductive	ADJ
dpc-1075	168	13	conversion	conversion	NOUN
dpc-1075	168	14	of	of	ADP
dpc-1075	168	15	androstenedione	androstenedione	NOUN
dpc-1075	168	16	to	to	ADP
dpc-1075	168	17	t	t	PROPN
dpc-1075	168	18	,	,	PUNCT
dpc-1075	168	19	and	and	CCONJ
dpc-1075	168	20	it	it	PRON
dpc-1075	168	21	stimulates	stimulate	VERB
dpc-1075	168	22	the	the	DET
dpc-1075	168	23	aromatase	aromatase	NOUN
dpc-1075	168	24	,	,	PUNCT
dpc-1075	168	25	which	which	PRON
dpc-1075	168	26	induces	induce	VERB
dpc-1075	168	27	the	the	DET
dpc-1075	168	28	conversion	conversion	NOUN
dpc-1075	168	29	of	of	ADP
dpc-1075	168	30	t	t	PROPN
dpc-1075	168	31	to	to	PART
dpc-1075	168	32	estradiol	estradiol	PROPN
dpc-1075	168	33	[	[	X
dpc-1075	168	34	21	21	NUM
dpc-1075	168	35	]	]	PUNCT
dpc-1075	168	36	.	.	PUNCT
dpc-1075	169	1	in	in	ADP
dpc-1075	169	2	our	our	PRON
dpc-1075	169	3	work	work	NOUN
dpc-1075	169	4	,	,	PUNCT
dpc-1075	169	5	through	through	ADP
dpc-1075	169	6	global	global	ADJ
dpc-1075	169	7	photographs	photograph	NOUN
dpc-1075	169	8	and	and	CCONJ
dpc-1075	169	9	using	use	VERB
dpc-1075	169	10	the	the	DET
dpc-1075	169	11	7	7	NUM
dpc-1075	169	12	-	-	PUNCT
dpc-1075	169	13	point	point	NOUN
dpc-1075	169	14	rating	rating	NOUN
dpc-1075	169	15	scale	scale	NOUN
dpc-1075	169	16	,	,	PUNCT
dpc-1075	169	17	we	we	PRON
dpc-1075	169	18	observed	observe	VERB
dpc-1075	169	19	that	that	SCONJ
dpc-1075	169	20	both	both	DET
dpc-1075	169	21	galenic	galenic	PROPN
dpc-1075	169	22	formulations	formulation	NOUN
dpc-1075	169	23	determined	determine	VERB
dpc-1075	169	24	a	a	DET
dpc-1075	169	25	statistically	statistically	ADV
dpc-1075	169	26	significant	significant	ADJ
dpc-1075	169	27	improvement	improvement	NOUN
dpc-1075	169	28	of	of	ADP
dpc-1075	169	29	hair	hair	NOUN
dpc-1075	169	30	loss	loss	NOUN
dpc-1075	169	31	from	from	ADP
dpc-1075	169	32	6	6	NUM
dpc-1075	169	33	-	-	PUNCT
dpc-1075	169	34	month	month	NOUN
dpc-1075	169	35	follow	follow	NOUN
dpc-1075	169	36	-	-	PUNCT
dpc-1075	169	37	up	up	NOUN
dpc-1075	169	38	to	to	ADP
dpc-1075	169	39	12to	12to	NOUN
dpc-1075	169	40	18	18	NUM
dpc-1075	169	41	-	-	PUNCT
dpc-1075	169	42	month	month	NOUN
dpc-1075	169	43	follow	follow	NOUN
dpc-1075	169	44	-	-	PUNCT
dpc-1075	169	45	up	up	NOUN
dpc-1075	169	46	.	.	PUNCT
dpc-1075	170	1	more	more	ADV
dpc-1075	170	2	important	important	ADJ
dpc-1075	170	3	,	,	PUNCT
dpc-1075	170	4	0.5	0.5	NUM
dpc-1075	170	5	%	%	NOUN
dpc-1075	170	6	finasteride	finasteride	ADV
dpc-1075	170	7	showed	show	VERB
dpc-1075	170	8	higher	high	ADJ
dpc-1075	170	9	efficacy	efficacy	NOUN
dpc-1075	170	10	than	than	ADP
dpc-1075	170	11	0.05	0.05	NUM
dpc-1075	170	12	%	%	NOUN
dpc-1075	170	13	17α	17α	NOUN
dpc-1075	170	14	-	-	PUNCT
dpc-1075	170	15	estradiol	estradiol	PROPN
dpc-1075	170	16	lotion	lotion	NOUN
dpc-1075	170	17	,	,	PUNCT
dpc-1075	170	18	both	both	PRON
dpc-1075	170	19	at	at	ADP
dpc-1075	170	20	6	6	NUM
dpc-1075	170	21	and	and	CCONJ
dpc-1075	170	22	12	12	NUM
dpc-1075	170	23	-	-	SYM
dpc-1075	170	24	18	18	NUM
dpc-1075	170	25	months	month	NOUN
dpc-1075	170	26	.	.	PUNCT
dpc-1075	171	1	this	this	DET
dpc-1075	171	2	outcome	outcome	NOUN
dpc-1075	171	3	was	be	AUX
dpc-1075	171	4	statistically	statistically	ADV
dpc-1075	171	5	significant	significant	ADJ
dpc-1075	171	6	.	.	PUNCT
dpc-1075	172	1	i	i	PRON
dpc-1075	172	2	t	t	VERB
dpc-1075	173	1	i	i	PRON
dpc-1075	173	2	s	s	VERB
dpc-1075	173	3	i	i	PRON
dpc-1075	173	4	n	n	NOUN
dpc-1075	173	5	t	t	X
dpc-1075	173	6	e	e	NOUN
dpc-1075	173	7	r	r	NOUN
dpc-1075	173	8	e	e	PROPN
dpc-1075	173	9	s	s	PROPN
dpc-1075	173	10	t	t	X
dpc-1075	174	1	i	i	PRON
dpc-1075	174	2	ng	ng	INTJ
dpc-1075	175	1	tha	tha	INTJ
dpc-1075	176	1	t	t	NOUN
dpc-1075	176	2	f	f	NOUN
dpc-1075	177	1	i	i	PRON
dpc-1075	177	2	na	na	VERB
dpc-1075	177	3	s	s	VERB
dpc-1075	177	4	teride	teride	ADV
dpc-1075	177	5	-	-	PUNCT
dpc-1075	177	6	treated	treat	VERB
dpc-1075	177	7	patients	patient	NOUN
dpc-1075	177	8	had	have	VERB
dpc-1075	177	9	an	an	DET
dpc-1075	177	10	improvement	improvement	NOUN
dpc-1075	177	11	at	at	ADP
dpc-1075	177	12	6	6	NUM
dpc-1075	177	13	months	month	NOUN
dpc-1075	177	14	,	,	PUNCT
dpc-1075	177	15	which	which	PRON
dpc-1075	177	16	was	be	AUX
dpc-1075	177	17	com6	com6	PROPN
dpc-1075	177	18	research	research	NOUN
dpc-1075	177	19	|	|	ADV
dpc-1075	177	20	dermatol	dermatol	NOUN
dpc-1075	177	21	pract	pract	NOUN
dpc-1075	177	22	concept	concept	NOUN
dpc-1075	177	23	2020;10(2):e2020039	2020;10(2):e2020039	NUM
dpc-1075	177	24	of	of	ADP
dpc-1075	177	25	0.25	0.25	NUM
dpc-1075	177	26	%	%	NOUN
dpc-1075	177	27	finasteride	finasteride	ADV
dpc-1075	177	28	and	and	CCONJ
dpc-1075	177	29	3	3	NUM
dpc-1075	177	30	%	%	NOUN
dpc-1075	177	31	minoxidil	minoxidil	NOUN
dpc-1075	177	32	versus	versus	ADP
dpc-1075	177	33	3	3	NUM
dpc-1075	177	34	%	%	NOUN
dpc-1075	177	35	minoxidil	minoxidil	ADJ
dpc-1075	177	36	solution	solution	NOUN
dpc-1075	177	37	in	in	ADP
dpc-1075	177	38	female	female	ADJ
dpc-1075	177	39	pattern	pattern	NOUN
dpc-1075	177	40	hair	hair	NOUN
dpc-1075	177	41	loss	loss	NOUN
dpc-1075	177	42	:	:	PUNCT
dpc-1075	177	43	a	a	DET
dpc-1075	177	44	randomized	randomized	ADJ
dpc-1075	177	45	,	,	PUNCT
dpc-1075	177	46	double	double	ADJ
dpc-1075	177	47	-	-	PUNCT
dpc-1075	177	48	blind	blind	ADJ
dpc-1075	177	49	,	,	PUNCT
dpc-1075	177	50	controlled	control	VERB
dpc-1075	177	51	study	study	NOUN
dpc-1075	177	52	.	.	PUNCT
dpc-1075	178	1	am	be	AUX
dpc-1075	178	2	j	j	PROPN
dpc-1075	178	3	clin	clin	PROPN
dpc-1075	178	4	dermatol	dermatol	NOUN
dpc-1075	178	5	.	.	PUNCT
dpc-1075	179	1	2019;20(1):147	2019;20(1):147	NUM
dpc-1075	179	2	-	-	SYM
dpc-1075	179	3	153	153	NUM
dpc-1075	179	4	.	.	PUNCT
dpc-1075	179	5	21	21	NUM
dpc-1075	179	6	.	.	PUNCT
dpc-1075	180	1	kim	kim	PROPN
dpc-1075	180	2	jh	jh	PROPN
dpc-1075	180	3	,	,	PUNCT
dpc-1075	180	4	lee	lee	PROPN
dpc-1075	180	5	sy	sy	PROPN
dpc-1075	180	6	,	,	PUNCT
dpc-1075	180	7	lee	lee	PROPN
dpc-1075	180	8	hj	hj	PROPN
dpc-1075	180	9	,	,	PUNCT
dpc-1075	180	10	yoon	yoon	PROPN
dpc-1075	180	11	ny	ny	PROPN
dpc-1075	180	12	,	,	PUNCT
dpc-1075	180	13	lee	lee	PROPN
dpc-1075	180	14	ws	ws	PROPN
dpc-1075	180	15	.	.	PUNCT
dpc-1075	181	1	the	the	DET
dpc-1075	181	2	efficacy	efficacy	NOUN
dpc-1075	181	3	and	and	CCONJ
dpc-1075	181	4	safety	safety	NOUN
dpc-1075	181	5	of	of	ADP
dpc-1075	181	6	17α	17α	NOUN
dpc-1075	181	7	-	-	PUNCT
dpc-1075	181	8	estradiol	estradiol	PROPN
dpc-1075	181	9	(	(	PUNCT
dpc-1075	181	10	ell	ell	NOUN
dpc-1075	181	11	-	-	PUNCT
dpc-1075	181	12	cranell	cranell	NOUN
dpc-1075	181	13	®	®	NOUN
dpc-1075	181	14	alpha	alpha	NOUN
dpc-1075	181	15	0.025	0.025	NUM
dpc-1075	181	16	%	%	NOUN
dpc-1075	181	17	)	)	PUNCT
dpc-1075	181	18	solution	solution	NOUN
dpc-1075	181	19	on	on	ADP
dpc-1075	181	20	female	female	ADJ
dpc-1075	181	21	pattern	pattern	NOUN
dpc-1075	181	22	hair	hair	NOUN
dpc-1075	181	23	loss	loss	NOUN
dpc-1075	181	24	:	:	PUNCT
dpc-1075	181	25	single	single	ADJ
dpc-1075	181	26	center	center	NOUN
dpc-1075	181	27	,	,	PUNCT
dpc-1075	181	28	open	open	ADJ
dpc-1075	181	29	-	-	PUNCT
dpc-1075	181	30	label	label	NOUN
dpc-1075	181	31	,	,	PUNCT
dpc-1075	181	32	non	non	ADJ
dpc-1075	181	33	-	-	ADJ
dpc-1075	181	34	comparative	comparative	ADJ
dpc-1075	181	35	,	,	PUNCT
dpc-1075	181	36	phase	phase	NOUN
dpc-1075	181	37	iv	iv	NUM
dpc-1075	181	38	study	study	NOUN
dpc-1075	181	39	.	.	PUNCT
dpc-1075	182	1	ann	ann	PROPN
dpc-1075	182	2	dermatol	dermatol	NOUN
dpc-1075	182	3	.	.	PUNCT
dpc-1075	183	1	2012;24(3):295	2012;24(3):295	NUM
dpc-1075	183	2	-	-	SYM
dpc-1075	183	3	305	305	NUM
dpc-1075	183	4	.	.	PUNCT
dpc-1075	184	1	22	22	NUM
dpc-1075	184	2	.	.	PUNCT
dpc-1075	185	1	caserini	caserini	PROPN
dpc-1075	185	2	m	m	PROPN
dpc-1075	185	3	,	,	PUNCT
dpc-1075	185	4	radicioni	radicioni	PROPN
dpc-1075	185	5	m	m	PROPN
dpc-1075	185	6	,	,	PUNCT
dpc-1075	185	7	leuratti	leuratti	PROPN
dpc-1075	185	8	c	c	NUM
dpc-1075	185	9	,	,	PUNCT
dpc-1075	185	10	annoni	annoni	VERB
dpc-1075	185	11	o	o	PROPN
dpc-1075	185	12	,	,	PUNCT
dpc-1075	185	13	palmieri	palmieri	PROPN
dpc-1075	185	14	r.	r.	PROPN
dpc-1075	185	15	a	a	DET
dpc-1075	185	16	novel	novel	ADJ
dpc-1075	185	17	finasteride	finasteride	ADJ
dpc-1075	185	18	0.25	0.25	NUM
dpc-1075	185	19	%	%	NOUN
dpc-1075	185	20	topical	topical	ADJ
dpc-1075	185	21	solution	solution	NOUN
dpc-1075	185	22	for	for	ADP
dpc-1075	185	23	androgenetic	androgenetic	ADJ
dpc-1075	185	24	alopecia	alopecia	NOUN
dpc-1075	185	25	:	:	PUNCT
dpc-1075	185	26	pharmacokinetics	pharmacokinetic	NOUN
dpc-1075	185	27	and	and	CCONJ
dpc-1075	185	28	effects	effect	NOUN
dpc-1075	185	29	on	on	ADP
dpc-1075	185	30	plasma	plasma	NOUN
dpc-1075	185	31	androgen	androgen	NOUN
dpc-1075	185	32	levels	level	NOUN
dpc-1075	185	33	in	in	ADP
dpc-1075	185	34	healthy	healthy	ADJ
dpc-1075	185	35	male	male	NOUN
dpc-1075	185	36	volunteers	volunteer	NOUN
dpc-1075	185	37	.	.	PUNCT
dpc-1075	186	1	int	int	PROPN
dpc-1075	187	1	j	j	PROPN
dpc-1075	187	2	clin	clin	PROPN
dpc-1075	187	3	pharmacol	pharmacol	PROPN
dpc-1075	187	4	ther	ther	ADV
dpc-1075	187	5	.	.	PUNCT
dpc-1075	188	1	2014;52(10):842	2014;52(10):842	X
dpc-1075	188	2	-	-	SYM
dpc-1075	188	3	849	849	NUM
dpc-1075	188	4	.	.	PUNCT
dpc-1075	189	1	mechanism	mechanism	NOUN
dpc-1075	189	2	affecting	affect	VERB
dpc-1075	189	3	hair	hair	NOUN
dpc-1075	189	4	growth	growth	NOUN
dpc-1075	189	5	both	both	CCONJ
dpc-1075	189	6	in	in	ADP
dpc-1075	189	7	vitro	vitro	X
dpc-1075	189	8	and	and	CCONJ
dpc-1075	189	9	in	in	ADP
dpc-1075	189	10	vivo	vivo	NOUN
dpc-1075	189	11	.	.	PUNCT
dpc-1075	190	1	j	j	PROPN
dpc-1075	190	2	invest	invest	VERB
dpc-1075	190	3	dermatol	dermatol	NOUN
dpc-1075	190	4	.	.	PUNCT
dpc-1075	191	1	1992;98(3):315	1992;98(3):315	PROPN
dpc-1075	191	2	-	-	SYM
dpc-1075	191	3	319	319	NUM
dpc-1075	191	4	.	.	PUNCT
dpc-1075	191	5	17	17	NUM
dpc-1075	191	6	.	.	PUNCT
dpc-1075	192	1	rogers	rogers	PROPN
dpc-1075	192	2	ne	ne	PROPN
dpc-1075	192	3	,	,	PUNCT
dpc-1075	192	4	avram	avram	PROPN
dpc-1075	192	5	mr	mr	PROPN
dpc-1075	192	6	.	.	PROPN
dpc-1075	192	7	medical	medical	ADJ
dpc-1075	192	8	treatments	treatment	NOUN
dpc-1075	192	9	for	for	ADP
dpc-1075	192	10	male	male	ADJ
dpc-1075	192	11	and	and	CCONJ
dpc-1075	192	12	female	female	ADJ
dpc-1075	192	13	pattern	pattern	NOUN
dpc-1075	192	14	hair	hair	NOUN
dpc-1075	192	15	loss	loss	NOUN
dpc-1075	192	16	.	.	PUNCT
dpc-1075	193	1	j	j	PROPN
dpc-1075	193	2	am	be	AUX
dpc-1075	193	3	acad	acad	ADJ
dpc-1075	193	4	dermatol	dermatol	NOUN
dpc-1075	193	5	.	.	PUNCT
dpc-1075	194	1	2008;59(4):547	2008;59(4):547	NUM
dpc-1075	194	2	-	-	SYM
dpc-1075	194	3	566	566	NUM
dpc-1075	194	4	.	.	NOUN
dpc-1075	194	5	18	18	NUM
dpc-1075	194	6	.	.	PUNCT
dpc-1075	194	7	fabbrocini	fabbrocini	PROPN
dpc-1075	194	8	g	g	PROPN
dpc-1075	194	9	,	,	PUNCT
dpc-1075	194	10	cantelli	cantelli	PROPN
dpc-1075	194	11	m	m	PROPN
dpc-1075	194	12	,	,	PUNCT
dpc-1075	194	13	masara	masara	ADJ
dpc-1075	194	14	a	a	PRON
dpc-1075	194	15	,	,	PUNCT
dpc-1075	194	16	annunziata	annunziata	PROPN
dpc-1075	194	17	mc	mc	PROPN
dpc-1075	194	18	,	,	PUNCT
dpc-1075	194	19	marasca	marasca	PROPN
dpc-1075	194	20	c	c	PROPN
dpc-1075	194	21	,	,	PUNCT
dpc-1075	194	22	cacciapuoti	cacciapuoti	PROPN
dpc-1075	194	23	s.	s.	PROPN
dpc-1075	194	24	female	female	ADJ
dpc-1075	194	25	pattern	pattern	NOUN
dpc-1075	194	26	hair	hair	NOUN
dpc-1075	194	27	loss	loss	NOUN
dpc-1075	194	28	:	:	PUNCT
dpc-1075	194	29	a	a	DET
dpc-1075	194	30	clinical	clinical	ADJ
dpc-1075	194	31	,	,	PUNCT
dpc-1075	194	32	pathophysiologic	pathophysiologic	ADJ
dpc-1075	194	33	,	,	PUNCT
dpc-1075	194	34	and	and	CCONJ
dpc-1075	194	35	therapeutic	therapeutic	ADJ
dpc-1075	194	36	review	review	NOUN
dpc-1075	194	37	.	.	PUNCT
dpc-1075	195	1	int	int	PROPN
dpc-1075	195	2	j	j	PROPN
dpc-1075	195	3	womens	womens	PROPN
dpc-1075	195	4	dermatol	dermatol	NOUN
dpc-1075	195	5	.	.	PUNCT
dpc-1075	196	1	2018;4(4	2018;4(4	NUM
dpc-1075	196	2	):	):	PUNCT
dpc-1075	196	3	203	203	NUM
dpc-1075	196	4	-	-	SYM
dpc-1075	196	5	211	211	NUM
dpc-1075	196	6	.	.	PUNCT
dpc-1075	197	1	19	19	NUM
dpc-1075	197	2	.	.	X
dpc-1075	197	3	hu	hu	PROPN
dpc-1075	197	4	ac	ac	PROPN
dpc-1075	197	5	,	,	PUNCT
dpc-1075	197	6	chapman	chapman	PROPN
dpc-1075	197	7	lw	lw	PROPN
dpc-1075	197	8	,	,	PUNCT
dpc-1075	197	9	mesinkovska	mesinkovska	PROPN
dpc-1075	197	10	na	na	PROPN
dpc-1075	197	11	.	.	PUNCT
dpc-1075	198	1	the	the	DET
dpc-1075	198	2	efficacy	efficacy	NOUN
dpc-1075	198	3	and	and	CCONJ
dpc-1075	198	4	use	use	NOUN
dpc-1075	198	5	of	of	ADP
dpc-1075	198	6	finasteride	finasteride	ADJ
dpc-1075	198	7	in	in	ADP
dpc-1075	198	8	women	woman	NOUN
dpc-1075	198	9	:	:	PUNCT
dpc-1075	198	10	a	a	DET
dpc-1075	198	11	systematic	systematic	ADJ
dpc-1075	198	12	review	review	NOUN
dpc-1075	198	13	.	.	PUNCT
dpc-1075	199	1	int	int	NOUN
dpc-1075	199	2	j	j	PROPN
dpc-1075	199	3	dermatol	dermatol	NOUN
dpc-1075	199	4	.	.	PUNCT
dpc-1075	200	1	2019;58(7):759	2019;58(7):759	NUM
dpc-1075	200	2	-	-	PUNCT
dpc-1075	200	3	776	776	NUM
dpc-1075	200	4	.	.	NOUN
dpc-1075	200	5	20	20	NUM
dpc-1075	200	6	.	.	PUNCT
dpc-1075	201	1	suchonwanit	suchonwanit	PROPN
dpc-1075	201	2	p	p	NOUN
dpc-1075	201	3	,	,	PUNCT
dpc-1075	201	4	iamsumang	iamsumang	PROPN
dpc-1075	201	5	w	w	PROPN
dpc-1075	201	6	,	,	PUNCT
dpc-1075	201	7	rojhirunsakool	rojhirunsakool	PROPN
dpc-1075	201	8	s.	s.	PROPN
dpc-1075	201	9	efficacy	efficacy	PROPN
dpc-1075	201	10	of	of	ADP
dpc-1075	201	11	topical	topical	ADJ
dpc-1075	201	12	combination	combination	NOUN
dpc-1075	201	13	alopecia	alopecia	NOUN
dpc-1075	201	14	.	.	PUNCT
dpc-1075	202	1	eur	eur	PROPN
dpc-1075	202	2	j	j	PROPN
dpc-1075	202	3	inflamm	inflamm	PROPN
dpc-1075	202	4	.	.	PUNCT
dpc-1075	203	1	2014;12(2):399404	2014;12(2):399404	NUM
dpc-1075	203	2	.	.	PUNCT
dpc-1075	204	1	13	13	NUM
dpc-1075	204	2	.	.	X
dpc-1075	205	1	whiting	white	VERB
dpc-1075	205	2	da	da	PROPN
dpc-1075	205	3	.	.	PUNCT
dpc-1075	206	1	diagnostic	diagnostic	ADJ
dpc-1075	206	2	and	and	CCONJ
dpc-1075	206	3	predictive	predictive	ADJ
dpc-1075	206	4	value	value	NOUN
dpc-1075	206	5	of	of	ADP
dpc-1075	206	6	horizontal	horizontal	ADJ
dpc-1075	206	7	sections	section	NOUN
dpc-1075	206	8	of	of	ADP
dpc-1075	206	9	scalp	scalp	NOUN
dpc-1075	206	10	biopsy	biopsy	NOUN
dpc-1075	206	11	specimens	specimen	NOUN
dpc-1075	206	12	in	in	ADP
dpc-1075	206	13	male	male	ADJ
dpc-1075	206	14	pattern	pattern	NOUN
dpc-1075	206	15	androgenetic	androgenetic	ADJ
dpc-1075	206	16	alopecia	alopecia	NOUN
dpc-1075	206	17	.	.	PUNCT
dpc-1075	207	1	j	j	PROPN
dpc-1075	207	2	am	be	AUX
dpc-1075	207	3	acad	acad	ADJ
dpc-1075	207	4	dermatol	dermatol	NOUN
dpc-1075	207	5	.	.	PUNCT
dpc-1075	208	1	1993;28(5	1993;28(5	NUM
dpc-1075	208	2	pt	pt	PROPN
dpc-1075	208	3	1):755	1):755	NUM
dpc-1075	208	4	-	-	SYM
dpc-1075	208	5	763	763	NUM
dpc-1075	208	6	.	.	PUNCT
dpc-1075	209	1	14	14	NUM
dpc-1075	209	2	.	.	PUNCT
dpc-1075	209	3	rossi	rossi	PROPN
dpc-1075	209	4	a	a	PRON
dpc-1075	209	5	,	,	PUNCT
dpc-1075	209	6	cantisani	cantisani	NOUN
dpc-1075	209	7	c	c	PROPN
dpc-1075	209	8	,	,	PUNCT
dpc-1075	209	9	melis	melis	PROPN
dpc-1075	209	10	l	l	PROPN
dpc-1075	209	11	,	,	PUNCT
dpc-1075	209	12	iorio	iorio	VERB
dpc-1075	209	13	a	a	PRON
dpc-1075	209	14	,	,	PUNCT
dpc-1075	209	15	scali	scali	ADJ
dpc-1075	209	16	e	e	NOUN
dpc-1075	209	17	,	,	PUNCT
dpc-1075	209	18	calvieri	calvieri	PROPN
dpc-1075	209	19	s.	s.	PROPN
dpc-1075	209	20	minoxidil	minoxidil	PROPN
dpc-1075	209	21	use	use	NOUN
dpc-1075	209	22	in	in	ADP
dpc-1075	209	23	dermatology	dermatology	NOUN
dpc-1075	209	24	,	,	PUNCT
dpc-1075	209	25	side	side	NOUN
dpc-1075	209	26	effects	effect	NOUN
dpc-1075	209	27	and	and	CCONJ
dpc-1075	209	28	recent	recent	ADJ
dpc-1075	209	29	patents	patent	NOUN
dpc-1075	209	30	.	.	PUNCT
dpc-1075	210	1	recent	recent	ADJ
dpc-1075	210	2	pat	pat	PROPN
dpc-1075	210	3	inflamm	inflamm	PROPN
dpc-1075	210	4	allergy	allergy	PROPN
dpc-1075	210	5	drug	drug	PROPN
dpc-1075	210	6	discov	discov	PROPN
dpc-1075	210	7	.	.	PUNCT
dpc-1075	211	1	2012;6(2):130	2012;6(2):130	NUM
dpc-1075	211	2	-	-	SYM
dpc-1075	211	3	136	136	NUM
dpc-1075	211	4	.	.	PUNCT
dpc-1075	212	1	15	15	NUM
dpc-1075	212	2	.	.	PUNCT
dpc-1075	213	1	walsh	walsh	PROPN
dpc-1075	213	2	ds	ds	PROPN
dpc-1075	213	3	,	,	PUNCT
dpc-1075	213	4	dunn	dunn	PROPN
dpc-1075	213	5	cl	cl	PROPN
dpc-1075	213	6	,	,	PUNCT
dpc-1075	213	7	james	james	PROPN
dpc-1075	213	8	wd	wd	PROPN
dpc-1075	213	9	.	.	PUNCT
dpc-1075	213	10	improvement	improvement	NOUN
dpc-1075	213	11	in	in	ADP
dpc-1075	213	12	androgenetic	androgenetic	ADJ
dpc-1075	213	13	alopecia	alopecia	NOUN
dpc-1075	213	14	(	(	PUNCT
dpc-1075	213	15	stage	stage	NOUN
dpc-1075	213	16	v	v	NOUN
dpc-1075	213	17	)	)	PUNCT
dpc-1075	213	18	using	use	VERB
dpc-1075	213	19	topical	topical	ADJ
dpc-1075	213	20	minoxidil	minoxidil	NOUN
dpc-1075	213	21	in	in	ADP
dpc-1075	213	22	a	a	DET
dpc-1075	213	23	retinoid	retinoid	NOUN
dpc-1075	213	24	vehicle	vehicle	NOUN
dpc-1075	213	25	and	and	CCONJ
dpc-1075	213	26	oral	oral	ADJ
dpc-1075	213	27	finasteride	finasteride	ADV
dpc-1075	213	28	.	.	PUNCT
dpc-1075	214	1	arch	arch	ADJ
dpc-1075	214	2	dermatol	dermatol	NOUN
dpc-1075	214	3	.	.	PUNCT
dpc-1075	215	1	1995;131(12):1373	1995;131(12):1373	PROPN
dpc-1075	215	2	-	-	SYM
dpc-1075	215	3	1375	1375	NUM
dpc-1075	215	4	.	.	PUNCT
dpc-1075	216	1	16	16	NUM
dpc-1075	216	2	.	.	PUNCT
dpc-1075	217	1	buhl	buhl	PROPN
dpc-1075	217	2	ae	ae	PROPN
dpc-1075	217	3	,	,	PUNCT
dpc-1075	217	4	waldon	waldon	PROPN
dpc-1075	217	5	dj	dj	PROPN
dpc-1075	217	6	,	,	PUNCT
dpc-1075	217	7	conrad	conrad	PROPN
dpc-1075	217	8	sj	sj	PROPN
dpc-1075	217	9	,	,	PUNCT
dpc-1075	217	10	et	et	PROPN
dpc-1075	217	11	al	al	PROPN
dpc-1075	217	12	.	.	PROPN
dpc-1075	217	13	potassium	potassium	NOUN
dpc-1075	217	14	channel	channel	NOUN
dpc-1075	217	15	conductance	conductance	NOUN
dpc-1075	217	16	:	:	PUNCT
dpc-1075	217	17	a	a	PRON